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CHAPTER 1 
INTRODUCTION 
1.1 PREFACE 
Isozymes of 5o-reductase (E.C. 1.3.99.5) mediate in the wide variety of actions elicited 
by testosterone in androgen-target cells, and play a role in the catabolism and 
excretion of steroids in non-androgen target cells. Recent progress in the research on 
5o-reductase with current molecular biological techniques has elucidated many of the 
discrepancies in earlier reports on enzymatic activity measurements of 5o-reductase in 
rat and human tissues. However, our apprehension of the in vivo function of 5a-
reductase in normal and diseased tissue is still clouded by kinetic peculiarities of the 
isozymes. As the two now established isozymes catalyze the same reaction, 
quantification of their activities is difficult, even more so due to differences in opinion 
as to the best method of quantification. 
The introductory chapter addresses the crucial roles of 5o-reduction in the effectuation 
and regulation of testosterone action {section 1.2), and the role of isozymes of 5a-
reductase herein {section 1.3). In the ensuing sections, the literature on 5a-reductase, 
from gene structure {section 1.4) to protein structure {section 1.5) and to enzymatic 
activity {section 7.6) is discussed. Furthermore, data on the tissue-specific, cell-type-
specific, and intracellular localization of the isozymes are presented {section 1.7). 
Section 1.8 presents the scope of this thesis. 
1.2 ROLE OF 5CT-REDUCTASE IN ANDROGEN ACTION 
The constituting parts of all higher animal organisms (cells, tissues, organs) are 
integrated by a complex network of neuronal and endocrine signals. The complexity 
of this network can be illustrated by the wide variety of effects elicited by the most 
common male endocrine signal, the steroid hormone testosterone. 
This steroid is the principal androgen in the human male and is pivotal in all stages of 
development, from the embryo, foetus and neonate to the sexually mature adult [128]. 
It is secreted by the testes and circulates in the bloodstream, either free or bound to 
specific binding proteins [223, 224]. In particular, the поп-protein bound fraction of 
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steroids (approximately 1-2% in the case of testosterone) is thought to elicit effects on 
the different cells of the body (free hormone hypothesis) [171]. From the bloodstream, 
testosterone can ubiquitously diffuse across plasma cell membranes. Remarkably, the 
effects of this very hormone range from development of the urogenital tract, male type 
hair-growth, deepening of the voice, increase in musculature to male behaviour and 
sexual attraction. Furthermore, it exerts mitogenic and haematogenic effects [138]. 
An important element in providing the desired specificity for the indiscriminately 
distributed testosterone is the androgen receptor [23], member of the steroid/thyroid 
hormone/retinoic acid receptor family [158]. Cells in an organism that display this 
receptor are able to interact with testosterone. After binding, the hormone-steroid 
receptor complex binds to hormone response elements in the DNA of the cell, 
resulting in the switching on, or off, of the appropriate genes within that specific cell-
type [159]. However, the androgen receptor can be found in almost every organ in 
the human body, with the notable exception of the spleen [123]. In the disorder of 
androgen insensitivity syndrome (AIS), there is a complete lack of, or structural change 
in this androgen receptor [168]. Patients with the complete form of AIS, though 
genetically male (XY genotype), have female external genitalia, a blunt-ended vagina, 
absent uterus, abdominal or inguinal testes and defective sexual hair growth [18, 45, 
63]. In these patients, testosterone has been unable to initiate the development of 
Wolffian ducts into vasa deferentia, seminal vesicles, ejaculatory ducts and 
epididymides. Female internal structures, however, are absent because of the activity 
of Mullerian inhibitory factor produced by the testes. This disorder stipulates the 
prerequisite of testosterone action in male sexual development and its wide range of 
possible effects. 
Another important factor determining the physiological effects of testosterone is the 
local metabolism of this steroid in the target cells [197]. Two of the major pathways in 
the metabolism of testosterone are aromatization and 5a-reduction, resulting in the 
formation of estrogens and dihydrotestosterone (DHT) respectively. For instance, the 
effect of testosterone on male sexual behaviour and sexual orientation is mediated by 
its aromatization to 17ß-estradiol in specific parts of the central nervous system, and 
subsequent binding to the estrogen receptor [138, 144]. The effect of testosterone on 
male pattern hair growth results from its 5o-reduction to DHT in the hair follicles 
[166]. Remarkably, testosterone and DHT bind to the same (androgen) receptor. The 
mechanism by which one receptor can differentiate between these two ligands is still 
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not known. Testosterone does have a 3-fold lower affinity for the androgen receptor 
than DHT [209] and high concentrations of testosterone might be able to mimic DHT 
binding to the androgen receptor [62]. 
The crucial role of DHT in androgen action has been greatly exemplified by studies of 
male patients with pseudohermaphroditism who partially or completely lack the 
enzyme 5a-reductase [48, 229]. The disorder was attributed to the lack of peripheral 
conversion of testosterone to DHT [87, 220], enabling distinction between the effects 
of testosterone and DHT per se on androgen target cells. In contrast to patients with 
the complete form of AIS, male pseudohermaphrodites with 5a-reductase deficiency 
exhibit normal male internal genitalia derived from Wolffian ducts (vasa deferenza, 
seminal vesicles, ejaculatory ducts and epididymides) [48, 220, 229]. The androgenic 
effects of testosterone on these tissues are completed before 5o-reductase is present 
[192]. At puberty normal male musculature develops, but the external genitalia are 
ambiguous. The prostate is atrophic [86]. In addition, these patients appear to have 
less baldness and acne. The normal androgenization of the internal genitalia and male 
musculature can thus be ascribed to the androgenic action of testosterone, whereas 
the lack of DHT is responsible for the ambiguity of the external genitalia and atrophy 
of the prostate. So, both testosterone and DHT have distinctive roles in male sex 
determination [64]. 
Thus, if a cell expresses only the androgen receptor and no 5a-reductase, the 
androgenic effects are elicited by testosterone itself (as is the case in muscle tissue). If 
a cell does contain 5a-reductase, the androgenic effects of testosterone are mediated 
by DHT (as in the prostate). Furthermore, if 5o-reductase and other metabolizing 
enzymes are expressed, the metabolism and subsequent excretion of testosterone is 
facilitated (as in the liver) (figure 1.1). Therefore, androgen target tissues are imparted 
with the enzymatic machinery for producing the appropriate metabolites of 
testosterone as (and when) required. In doing so, the cell itself can modify the effect 
of testosterone. 
The enzyme 5a-reductase has been implicated in several diseases and disorders, 
including benign prostatic hyperplasia (BPH) [191, 228], male pattern baldness [13], 
hirsutism [95, 106, 186], acne [175] and prostatic cancer [21, 54, 68]. Some of these 
relationships are, however, disputed [165]. With the isolation of the genes for this 
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Figure 1.1: Graphical representation of the role of 5o-reductase in androgen 
action. The non-protein bound fraction of testosterone (T) can readily diffuse 
across the plasma membrane of a cell. Depending on the machinery in that cell, 
Τ can either bind to the nuclear androgen receptor (AR), be metabolized by 5σ-
reductase to dihydrotestosterone (DHT), which in turn can bind to the same AR, 
or it can be further metabolized by other enzymes (3-hydroxysteroid 
oxidoreductases, sulfatase, etc.) and be excreted. 
enzyme [2, 3, 4, 118, 156] and the impressive potential of molecular biological 
techniques, several puzzling aspects of the ontogeny, expression, function, physiology 
and pharmacology of 5o-reductase has been elucidated [119, 174]. 
1.3 ROLE AND FUNCTION OF PUTATIVE MULTIPLE 5o-REDUCTASE ISOZYMES 
It was generally assumed that metabolism of testosterone served to inactivate and to 
promote the excretion of this androgen hormone. One of the enzymes responsible for 
the metabolism of testosterone, 5a-reductase, was initially characterized in rat liver 
slices based on the metabolism of desoxycorticosterone [181, 182]. This organ is 
equipped with a variety of enzymes, mainly engaged in the catabolism of both 
endogenous substances and xenobiotics into highly polar metabolites which are more 
easily excreted. As the 3-oxo group of steroid substrates is rendered more susceptible 
to reduction by 3σ- and 3ß-hydroxysteroid oxidoreductases (HSOR) and to sulfation 
and glucuronylation after 5a-reduction [14], 5a-reductase was thought to participate in 
the catabolism of steroids. 
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However, as the latter enzyme would not catalyze the back reaction 
(dehydrogenation) -although this was originally contended [57 ] - it was hypothesized 
that 5a-reduction was a regulatory step [227]. It had already been established that 
DHT was a more potent androgen than testosterone in bioassays [177]. After 
administration of radiolabelled testosterone to rats, tritiated DHT accumulated in the 
nuclei of the prostate [1 , 22]. Furthermore, DHT was shown to bind preferentially to 
specific nuclear (androgen) receptor proteins [41, 127]. Altogether, DHT appeared a 
more potent androgen than testosterone and accumulated in the presumed subcellular 
compartment of androgenic action, the nucleus of androgen target cells. Thus, the 
enzyme responsible for the formation of DHT, 5o-reductase, could play an important 
role in the augmentation of the anabolic effects of testosterone 
Originally, it was surmised that at least five distinct isoforms of 5a-reductase were 
expressed in rat liver tissue, based on the differential regulation of the reduction of 
specific substrates [136]. Two different isoforms with specific pH-optima and kinetic 
properties were found in cultured human fibroblasts of which one was absent in 
pseudohermaphrodites [139, 143]. As both testosterone and Cortisol reduction were 
impaired in patients with male pseudohermaphroditism it was proposed that one 
enzyme, responsible for the 5o-reduction of all A4-3-oxosteroids, was mutated in these 
patients [46]. Analysis of human prostatic tissue 5a-reductase activities also led authors 
to suggest two isoforms, one in stroma, the other in epithelial cells [167]. However, as 
it seems that in some patients with male pseudohermaphroditism all 5a-reductase 
enzymatic activity was impaired, it was subsequently surmised that only one enzyme 
was responsible [85]. Based on a differential age-dependency and sensitivity to 
enzyme inhibition of the 5a-reduction of testosterone versus androstenedione in rat 
prostate, the possible existence of two enzyme forms was again proposed [134]. Only 
with the isolation of the cDNA's of two 5o-reductase isozymes [2, 3, 4, 156], it was 
finally established that indeed (at least) two isoforms exist in both rat and human, 
each with surprising specific characteristics [174]. The affinity constants and tissue-
specific expression of the isozymes led authors to propose a catabolic role for the type 
I and an anabolic role for the type II isozyme [156]. 
As mentioned earlier, DHT has been implicated in benign prostatic hyperplasia (BPH) 
[191, 228]. As patients with male pseudohermaphroditism have been diagnosed with 
5o-reductase type II deficiency [2, 93] and these patients have atrophic prostates [86], 
a specific type II inhibitor, finasteride (Proscar®), was developed for the management 
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of prostatisms [60]. This inhibitor might also be beneficial in the treatment of prostatic 
cancer [59]. The proposed anabolic role for the type II isozyme [156] is in line with its 
reported involvement in the growth of the prostate and in the pathogenesis of BPH. 
Involvement of 5a-reductase in skin disorders as male pattern baldness [13], hirsutism 
[95, 106, 186], and acne [175] might be attributed to the type I isozyme that is 
expressed in non-genital skin [165, 205]. This is in contradiction with the proposed 
catabolic role of this isozyme [156] and would implicate the type I isozyme also to 
participate in the anabolic amplification of androgen action. 
1.4 GENE STRUCTURE 
The first cDNA for 5a-reductase was isolated from female rat liver by injecting liver 
mRNA in Xenopus laevis oocytes [42], which were subsequently assayed for 5a-
reductase enzymatic activity by measuring the metabolism of radiolabelled 
testosterone [3]. 
The rat cDNA was then used as a hybridization probe to screen a human prostate 
cDNA library [4]. A 2.1 kilobase cDNA sequence was identified, from which the 
protein sequence was deduced. This protein shared 60 % identity in amino acid 
composition with the rat enzyme. Expression of this enzyme in COS cells gave some 
unexpected results. The expressed 5o-reductase enzyme exhibited a neutral pH-
optimum [4], whereas the tissue from which it was isolated, the human prostate, 
expresses a 5o-reductase enzyme activity with an optimum at pH 5.0-5.5 [120]. 
Furthermore, the sensitivity of the human 5a-reductase activity in the prostate for the 
enzyme inhibitor finasteride was not exhibited by the cloned enzyme, and the gene 
encoding this enzyme was normal in subjects with 5o-reductase deficiency [93]. This 
led to the hypothesis that the enzyme expressed by the isolated 5a-reductase cDNA 
and the prostatic 5a-reductase enzyme activity were in fact two different isozymes 
[93]. 
Therefore, the total cDNA of the human prostate was monitored for 5a-reductase 
enzymatic activity in cultured human cells to screen for another isozyme. After 
division of the cDNA pool into progressively smaller groups, a single 5a-reductase 
clone was isolated that was different from the first human 5a-reductase cDNA [2]. 
Expression of this 5a-reductase clone revealed the acidic pH-optimum and the 
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sensitivity to finasteride exhibited by the 5o-reductase enzymatic activity found in the 
human prostate. The gene encoding this type of 5a-reductase was shown to be 
mutated in subjects with 5o-reductase deficiency [2]. 
Subsequently, oligonucleotides derived from this second human 5a-reductase cDNA 
were used in polymerase chain reactions to isolate the rat homologue from mRNA of 
regenerating prostate [156]. Both the rat and human isozymes were designated type I 
and type II in the chronological order of their isolation [2, 156]. 
Similar 5c-reductase isozymes were later also detected in the mouse [174]. Recently, 
the type I and type II 5a-reductase genes were described in the Cynomolgus monkey 
with approximately 95 % nucleotide sequence identity with the human genes and 
coding for isozymes with biochemical characteristics (relative substrate affinities, pH-
dependencies and inhibitor sensitivities) closely paralleling those of its human 
homologues [118]. Mouse, rat and human 5o-reductase isozyme genes all contain five 
exons separated by four introns [94, 107, 174, 203] (figure 7.2). As this arrangement is 
conserved between species, the isozymes probably originated from an ancient 
duplication and subsequently diverged into the present ¡soforms. The human type I 
gene (SRD5A1) is located on band p i 5 of chromosome 5, whereas the type II gene 
(SRD5A2) resides on band p23 of chromosome 2. On the long arm of the X-
chromosome (q24-qter) a pseudogene (SRD5AP1) is found which is not believed to 
encode for a functional 5a-reductase [94]. 
Information concerning the functional domains of the 5a-reductase enzymes came 
from the analysis of mutations in the disorder of male pseudohermaphroditism [173, 
225]. These mutations have only been found in the type II isozyme [93]. So far, no 
type I 5o-reductase deficiency has been described. Point mutations in exon 1 of the 
type II gene (figure 1.2) that caused a substitution of arginine for glycine (mutation 
G34R) led to an enzyme with a dramatically decreased affinity for steroid substrate, 
suggesting that the amino terminus of 5o-reductase is involved in substrate binding 
[173]. As another mutation that also led to decreased affinity for substrate (H231R) 
was later mapped to exon 4, it seemed that both ends of the enzyme are involved in 
substrate binding [174]. Only a non-linear arrangement of the isozyme could implicate 
both ends of the protein in steroid binding (figure 1.2). Two mutations that disrupt the 
cofactor binding (G196S and R246W) were found in the carboxyl terminus (figure 
1.2), suggesting that this part of the enzyme is responsible for the binding of NADPH 
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[173]. However, this kind of mutations has now also been mapped to exons 2, 3, 4 
and 5 [174]. Based on the analysis of these mutations, the cofactor binding domain(s) 
thus map(s) almost throughout the entire type II isozyme. 
COFACTOR binding: RHSW P181L " " ^ * ? « n 
G183S 01S6S НДОО 
Ею
№
^у \j] g [г щ 
hydrophilic 
Л Г "
1
—
г 1 Г"» !""S Г"1- ! "-
ι ! l - J «•-1 ι J ·• 
hydrophobic 
u 
FINASTERIDE 
SUBSTRATE binding: 
G34R H231R 
I « вжоп number — — — ж hydropathy 
Figure 1.2: Simplified graphic presentation of i) the biochemical effects of point mutations in the steroid 
5<r-reductase gene (denoted by their schematical numbers, for instance R145W: indicating amino acid 
changed, residue number, and ammo acid changed to), either leading to decreased cofactor affinity 
(above line) or decreased substrate affinity (under line) [173, 225]. ii) exon numbering, boxed numbers 
[3]. iii) hydropathy plot [dashed line] (hydrophilic above, hydrophobic under solid line) [3]. iv) the 
cofactor (NADPH) binding domain that binds the probe 2-az¡do-NADP* [11]. ν) the tetrapeptide 
segment that confers sensitivity to finasteride, and is therefore probably part of the substrate binding 
domain [204]. 
1.5 PROTEIN STRUCTURE 
From the nucleotide sequences {section 1.4) the primary structure of the rat, monkey 
and human isozymes can be determined. Rat and human share 60 % amino acid 
sequence identity for the type I and 77 % for the type II isozymes [173]. The monkey 
type I and type II share approximately 93 and 95 % sequence identity with its human 
homologues [118]. 
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The isozymes of all three species are highly hydrophobic [3, 118, 173]. The human 
isoforms are composed of 254 and 260 amino acids with predicted molecular weights 
of 28 and 29 kDa. No distinct transmembrane regions are found in hydropathy plots, 
but hydrophobic amino acids are found throughout the protein [3] (figure 1.2). This 
suggests that the isozymes are strongly membrane-bound, and are in fact integral 
membrane proteins embedded in the lipid bilayer. This explains many problems in 
the attempts of solubilization and purification of the enzyme [38, 49, 77, 119, 121, 
140, 141, 176]. The loss of enzyme activity after solubilization from the membrane 
suggests an important role for the surrounding membrane in the regulation of 5a-
reductase enzymatic activity. Indeed, phospholipases inhibited 5a-reductase activity in 
rat epididymis [28] and prostate [38] (see section 1.6.5.2). The hydrophobic nature of 
the enzyme may also cause the deviant molecular weights on SDS Polyacrylamide 
gels ranging from 21 to 27 kDa [3, 202, 205]. 
Remarkably, the rat hepatic 5o-reductase - n o w considered the type I isozyme [156] — 
can be solubilized with non-ionic detergents, by high salt treatment, sonication or by 
repeated freeze-thaw cycles, suggesting it is a peripheral membrane protein, in 
contrast to the prostatic enzyme [38]. The hepatic enzyme could be solubilized in an 
active state, whereas prostatic 5a-reductase isozyme activity - type I and type II 
[156]- was completely inactivated after solubilization [38]. The reason for this tissue-
specific difference for rat steroid 5o-reductase is unclear, but suggests a post-
transcriptional event for the hepatic isozyme, making it more hydrophilic than its 
predicted amino acid sequence would indicate. Reportedly, no consensus sequences 
were identified for either N-linked or for O-linked glycosylation [174], but the human 
type II isozyme, purified from the prostate, has now been described as O-glycosylated 
with oligosaccharide side chains containing mannose, N-acetyl galactosamine, fucose, 
galactose and sialic acids [163]. Such a glycosylation would make the protein more 
hydrophilic, but this glycosylation has not yet been reported for the hepatic isozymes, 
nor specifically for the type I isozyme, either from human or rat. 
By genetically engineering rat and human type I 5o-reductase chimeric proteins, and 
exchanging progressively smaller segments, a tetrapeptide-coding sequence in exon 1 
of the rat isozyme (residues 22-25) was identified that conferred sensitivity for the 5a-
reductase inhibitor finasteride from the rat type I to its human homologue [204]. As 
finasteride competes with substrate for binding to 5o-reductase, this tetrapeptide 
(residues 26-29 for the human type I isozyme) is considered to form part of the 
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substrate binding domain {figure 1,2). Surprisingly, this tetrapeptide segment is not 
completely conserved in the Cynomolgus monkey isozymes, despite the fact that the 
monkey homologues exhibit biochemical characteristics highly comparable to the 
human isoforms [118]. 
No consensus adenine dinucleotide-binding sequences were identified in rat or 
human 5a-reductase isozymes [174], although the enzyme is totally dependent on 
NADPH as cofactor. Mutations that alter cofactor binding affinity have been mapped 
throughout the type II isozyme [174] {figure 1.2). The associated amino acids are 
highly conserved in both isozymes and in the rat homologues, suggesting the cofactor 
binding domain to be similar in both species. By using polyclonal antibodies against 
the carboxyl terminus of the human isozymes in Chinese Hamster Ovary (CHO) cells 
transfected with 5a-reductase cDNA, it was established that the carboxyl terminus of 
both human isozymes is on the cytoplasmatic side of the endoplasmatic reticulum in 
these cells [202]. This carboxyl terminus contains a hydrophilic domain (amino acid 
232-253 of the rat type I) [3]. Enzyme activity in the transfected CHO cells requires 
the addition of NADPH when only the cell membrane is permeabilized and the 
endoplasmatic reticulum is left intact [202], suggesting that the hydrophilic carboxyl 
terminus of the protein is involved in cofactor binding. 
Recently, by labelling of the rat hepatic microsomal 5o-reductase (type I) with [2'-32P]-
2-azido-NADP+ [12] and subsequent purification, an 11-amino acid peptide was 
identified that would be (part of) the cofactor binding domain [11] (figure 1.2). 
Sequence analysis of the purified peptide indicated that it corresponded to residues 
170-180 of the rat 5o-reductase type I, that was not equivalent to a consensus adenine 
dinucleotide-binding sequence [5, 184]. The rat 5a-reductase type I residues 160-190 
share approximately 97 % homology with the human type I isozyme (residues 164-
194) [11] and the corresponding residues of the monkey type I [118]. The 
corresponding rat, monkey and human type II isozyme residues show approximately 
70% homology vs. the rat type I. 
These residues are located in a hydrophilic portion of the rat type I peptide in the 
exon 3 region according to hydropathy plots [3], and can thus interact with the 
hydrophilic cofactor NADPH [11]. Several of the mutations described (R171S, P181L 
and G183S [225] (figure 1.2), resulting in decreased affinity for NADPH, lie within the 
human homologue of this proposed adenine dinucleotide-binding domain. However, 
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other mutations do not lie within this sequence, emphasizing the necessity of 
regarding the 5a-reductase isozyme proteins as three-dimensional structures in order 
to better understand their functional domains. 
1.6 ENZYMATIC ACTIVITY 
The comparability of 5o-reductase enzyme activity measurements was (and is) 
hampered by differences in experimental protocol, species and tissues analysed and 
—originally— the unawareness of the existence of multiple isozymes. This led to a wide 
range of results in reported enzyme characteristics. In this section several of the 
characteristics of 5a-reductase activity measurements and their intricacies wil l be 
discussed. 
1.6.1 pH-optima 
One of the most striking characteristics of the mouse, rat, monkey and human 5σ-
reductase isozymes is the acidic pH-optimum reported for the type II subtype [2, 93, 
118, 143, 156, 174]. In 1970 5(7-reductase enzyme activity was reported in 
homogenates of human foreskin with an optimum at pH 5.5 [217]. Based on the 
presence of two distinct pH-optima in 5o-reductase activity in human fibroblasts, 
Moore and Wilson were the first to -correct ly- postulate the existence of two 
isozymes of 5o-reductase [143]. 
These specific pH-optima can be applied to assign 5o-reductase enzymatic activity in 
a tissue to a particular isozyme [174]. The acidic pH-optimum for 5o-reductase activity 
found in genital skin fibroblasts [139, 143] and the more alkaline pH-optimum found 
in non-genital skin [143] can be attributed to type II and type I isozyme activity 
respectively, as has been confirmed by Northern blotting and immunoblotting [205]. 
The ratio of 5a-reductase velocities at pH 7.0 and pH 5.0 have been used as an 
indication of the ratio of type I and type II 5a-reductase isozyme activities in human 
tissues [205]. 
The cloned and expressed human [93] and rat [156] cDNA of type I isozymes specify 
enzymes which have a broad pH-optimum from 6.0-8.0, whereas the cloned and 
expressed type II isozymes have a narrow optimum around pH 5.0 [2, 156]. 
However, reports on the pH-optimum of 5o-reductase activity in tissues have yielded 
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a wide range of results. For the rat prostate pH-profiles have been described with 
optima at pH 5.0 and around 7.0 [156], pH 6.2 (microsomal) and 6.8 (nuclear) [49], 
pH 6.5 [120], 6.9 [172], and at 7.2 [189]. For the rat epididymal 5a-reductase, optima 
have been found at pH 5.0 [156] and 6.2 [137]. Finally, in the human prostate the 
optimum of 5ff-reductase enzymatic activity was found at pH 5.0 [93, 120], 5.5 [132], 
6.5 (epithelium) and 7.4 (stroma) [83], and at pH 7.0 [80, 84]. These results were 
obtained with a variety of experimental protocols, and —in the human prostate— with 
both normal and diseased tissue. The problem of enzyme inactivation [83] or cofactor 
depletion [132] at acidic or alkaline pH is not always adequately acknowledged. This 
could explain at least part of the differences in pH-optima found in literature. 
The biochemical basis for the acidic pH-optimum of the rat and human type II 
isozyme is unclear. However, mutations that alter the affinity for cofactor or 
testosterone —as in the disorder of male pseudohermaphroditism— can shift the pH-
optimum to a more alkaline pH [203], indicating that these mutated amino acids 
could be implicated in the particular acidic pH-optimum of the type II 5o-reductase. 
The pH-optimum could reflect a localization of this subtype in an acidic subcellular 
compartment. However, incubation of CHO cells transfected with type II 5a-reductase 
cDNA with compounds known to disrupt the pH of internal organelles (NH4Cl, 
chloroquine or monensin) did not affect enzyme activities [202]. Thus, the acidic pH-
optimum is unlikely to be the consequence of an acidic subcellular localization of the 
isozyme. Furthermore, gentle permeabilization of these cells with digitonin preserved 
a pH 7.0 5a-reductase enzymatic activity in transfected CHO cells, which suggests 
that the acidic pH-optimum might be a result of cell lysis. Finally, a pH-profile of the 
efficiency ratio, Vmax/Km, indicated that the type II isozyme was most efficient in 
metabolizing low testosterone concentrations at pH 7.0 [202]. For the microsomal 
fraction of the human prostate, the Vmax/Km ratio had an optimum at pH 6.0 [40]. 
The higher efficiency ratio at neutral pH is mainly a consequence of the lower affinity 
constant, Km, (and not of a higher Vmax) at this pH [40, 202]. 
1.6.2 Affinity constants 
1.6.2.1 steroidal substrates 
Besides distinct pH-optima, the isozymes of 5a-reductase have dissimilar affinities for 
steroid substrates like testosterone. Cells transfected with the human or rat type I 
isozyme exhibit 5o-reductase enzymatic activity with an apparent affinity constant 
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(Km) for testosterone ¡π cell lysates at pH 7.0 of 1.5 to 5 μΜ and 1 to 1.5 μΜ 
respectively [156, 202, 204]. Cells transfected with the human or rat type II isozyme 
exhibit enzyme activity, at pH 5.0, with a Km of 230 nM and 74 nM respectively 
[156, 202]. This 6-20 fold higher affinity of the type II enzyme for testosterone implies 
that it is better suited to metabolize lower concentrations of testosterone. This 
difference in Km could also be established for several other steroids like progesterone, 
androstenedione and, in the rat, corticosterone [156, 202]. Both rat isozymes had a 
low affinity for Cortisol (10-20 μΜ) [156]. The Km of the rat type I isozyme is 
consistently at least 2-fold lower than that of the human isoform in transfected cells 
[204]. However, by exchanging amino acid 22-25 of the rat type I isozyme with those 
of the human isoform, a similar reduced Km could be found for the chimera relative 
to the human parent [204]. Thus, this tetrapeptide segment in the amino terminal 
region of the type I isozyme effects the substrate affinity. 
At neutral pH —that is, the optimal pH in plots of Vmax/Km vs. pH [40, 202]— the 
affinity of the rat, monkey and human type II isozyme for testosterone is in the low 
nanomolar range (2.5 to 20 nM) [40, 118, 202]. The low endogenous testosterone 
concentrations [103] or the fairly low concentrations of testosterone produced by the 
fetal testes are thus best metabolized by the type II isozyme at neutral pH, supporting 
the hypothesis that this isozyme operates at neutral pH in vivo [202]. 
Differences in affinity constants between 5a-reductase activities in tissues might 
indicate dissimilar isozyme activities. After mechanical separation of stroma and 
epithelium of human prostate, 5o-reductase activities with distinct Km's have been 
reported [21, 83, 103, 167, 222]. These studies reported Km's for testosterone of 23 to 
230 nM in stroma and of 11 to 90 nM in epithelial cells. These values are all in the 
range characteristic for the cloned and expressed type II isozyme, but have led authors 
to suggest the existence of two different isozymes in the human prostate [e.g. 167]. 
Measurements in human BPH tissue homogenates yielded a wide range of affinity 
constants for testosterone varying from 11 nM [21] to 15 μ Μ [120]. As these values 
are apparent affinity constants because they are obtained in vitro and several 
compounds and experimental procedures are known to influence 5o-reductase 
enzymatic activity (see section 1.6.5), these differences can be attributed to a variety 
of causes. 
In fact, some reports have indicated that only the type II isozyme is expressed in 
human prostatic tissue [194, 205], although controversies exist [93]. For example, 
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mRNA for the type I isozyme has also been detected in this tissue [15, 126] and an 
earlier report on 5o-reductase activities in the human prostate suggests enzyme 
activity with characteristics (pH-optima, affinity constants) of the type I isozyme [80]. 
1.6.2.2 cofactor 
The affinity constants for the cofactor NADPH has been reported as 3-5 μΜ for the 
human type I and 7-10 μΜ for the type II isozyme in transfected CHO cells [202]. In 
human liver -probably type I 5a-reductase- the Km for NADPH was 6 μΜ, in the 
prostate -probably mainly type I I - the Km was 2.5 μΜ [79]. Therefore, the affinity 
for the cofactor is approximately similar in transfected cells and tissues. As these 
values also do not differ significantly between the human isoforms, it is not possible 
to establish the Km for NADPH so as to distinguish between subtypes in a tissue. 
However, in rat epididymis the nuclear-bound 5a-reductase activity exhibited an 
apparent affinity constant of 1 μΜ for NADPH, whereas the microsomally-located 
enzyme activity had a Km for NADPH of 30 μΜ. Both had a Km of approximately 
300 nM for testosterone [179]. The pH optima and competitive inhibition profiles 
were similar for both subcellular fractions, indicating that these two forms are different 
from those established so far in rat and human. Similarly, in the human prostate 5a-
reductase isozymes with a Km of 20 nM for testosterone, but 0.42 and 82 μΜ for 
NADPH have been described [110]. Together, this data suggests the existence of a 
third isozyme with a different affinity for NADPH of 30 (rat) to 82 (human) μΜ, 
which, however, has found no confirmation on the protein or mRNA level. 
1.6.3 Mechanism of Sa-reduction 
An earlier report on the mechanism of 5o-reduction in rat liver demonstrated that the 
electrons are transferred from the cofactor NADPH to coenzyme Q10 via the enzyme 
NADPHxoenzyme Q10-oxidoreductase, and then to testosterone [57]. If coenzyme 
Q10 was used as electron-acceptor the reaction was reversible. Subsequent reports, 
however, failed to inhibit this electron transfer in the rat epididymis and seminal 
vesicle [27] and in rat prostate [27, 38]. It is now generally accepted that the 5a-
reductase enzyme does not require intermediates of electron transfer, but directly 
transfers electrons from NADPH to T. 
The prostatic and hepatic 5o-reductases are considered to follow a sequential kinetic 
mechanism, which precludes the utilization of an electron transport system. The 
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proposed mechanism [16, 79, 117] of the 5o-reductase reaction states that the cofactor 
NADPH is the first to bind to 5a-reductase and that NADP+ is the last to leave the 
enzyme. It thus includes the steps as shown in figure 1.3. 
NADP ^Salpha-REDL NADPH Y 
NADP-RED 
NADPH-RED 4 DHT, 
NADP-RED-DHT 
NADPH-RED-T 
Figure 1.3: Sequential kinetic mechanism of the 5o-reductase 
reaction. The cofactor NADPH is the first to bind and 
NADP* is the last to leave the enzyme. RED is the enzyme 
5oF-reductase, Τ is the substrate testosterone and DHT is the 
product dihydrotestosterone [16, 79, 117]. 
1.6.4 Allosterism, cooperativity, hysteresis 
The high degree of specificity exhibited by enzymes prompted Fisher in 1894 to 
suggest a lock-and-key analogy of enzyme-substrate interaction [cited in 185]. The 
enzyme possesses a region, the substrate binding domain, that is complementary to 
the substrate molecule. After binding of the substrate, the enzyme can convert it to a 
product. It is now recognized that this is a simplification [185]. According to the lock-
and-key analogy testosterone should be able to bind to 5a-reductase before the 
cofactor, NADPH. As this is not the case (figure 1.3), this analogy does not apply to 
5ff-reductase. Another hypothesis for the enzyme-substrate interaction is the flexible 
enzyme or Induced fit hypothesis [101]. The cofactor will induce a conformational 
change in the enzyme that results in a precise alignment of the catalytical groups of 
the enzyme with the susceptible bonds of this substrate. After binding of the cofactor 
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the conformational change in the 5a-reductase enzyme makes it susceptible to 
testosterone binding. The concept of a flexible enzyme is the basis for theories on 
allosterism [185], which indeed seems to apply to 5a-reductase [111]. 
An ¡η-depth analysis of the 5o-reductase kinetics in the particulate fraction of human 
prostatic tissue revealed that the enzyme exhibited non-michaelian behavior at acidic 
pH [111, 132], showing an 'initial burst' in the time course of testosterone metabolism 
[111], which could be attenuated with ATP or dephosphorylating agents [112]. Such 
an 'initial burst' is described by the term 'hysteresis' [50, 51] and is a consequence of 
a slow transient in enzyme activity, changing from a higher to a lower steady state 
rate of activity on a measurable time scale. This hysteretic behavior can be the 
consequence of a ligand-induced slow transition of the enzyme into another activity 
state, and can exist with and without cooperativity [155]. The physiological function 
of such a non-michaelian behavior would be the buffering (damping) of DHT 
production against oscillations in Τ concentration [111, 155]. 
5a-Reductase also exhibited negative cooperativity in acetate buffer at pH 5.5, but not 
in citrate buffer [111]. The lack of negative cooperativity in citrate buffer in contrast to 
other buffers is also exhibited by yeast hexokinase [188]. Negative cooperativity is a 
consequence of the binding of one substrate molecule influencing the binding of the 
next, either in oligomeric or monomeric enzymes [154]. This makes the enzyme 
responsive over a wider range of substrate concentration than it would be for a 
'michaelian' response [155]. 
1.6.5 Regulation 
1.6.5.1 cations 
Early reports indicated possibly regulatory effects of cations on 5o-reductase enzymatic 
activity in the rat prostate [49], and epididymis [137], and the human prostate [80] and 
epididymis [33]. In rat prostatic nuclear fraction, at pH 6.6, Hg 2 + , Cu 2 + and Z n 2 + 
exhibited a potent inhibitory effect on 5a-reductase enzymatic activity [49]. 
Intraprostatic injection of male rats with 10 or 20 mg of zinc-arginine ('neutralized 
zinc') in vivo led to reduced prostatic weight and 5o-reductase enzymatic activity [39]. 
In the microsomal fraction of rat epididymis, at pH 6.2, the same effect of these 
cations was established [137]. In human epididymis, at pH 5.3, 5o-reductase was 
inhibited by C u 2 \ Z n 2 + , Cd 2 + and Ba2+ [33]. 
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In the human prostate, Z n 2 + was shown to exhibit a dual effect on enzyme activity, 
stimulating at lower concentrations (2 μΜ) and inhibitory at higher concentrations (2 
mM) [61, 66, 80, 108, 219], with a stronger stimulatory effect on epithelial enzymatic 
activity, but a more inhibitory effect on stromal 5a-reductase [83]. Zinc is present in 
the prostate at a concentration of 0.1 mM [195]. Concentrations of zinc are altered in 
plasma [226] and prostates [161] of patients with BPH. In adenomas of the human 
prostate the concentration of zinc is increased [183, 206]. Sinquin and colleagues 
showed that the stimulation of 5o-reductase activities in human prostatic homogenates 
by Cd 2 + , Cu 2 + and Z n 2 + resulted from augmentation of Vmax, but not from changes in 
Km [195]. A physiological role for zinc in the regulation of 5o-reductase enzymatic 
activity and possibly in the pathogenesis of BPH and/or prostatic cancer has been 
proposed [70]. 
Recently, it has been shown that the human type II isozyme, expressed in SW-13 
cells, is inhibited only by Cu 2 + (K, - 11 μΜ), whereas the expressed human type I 
isozyme is inhibited by Cd 2 + , Cu 2 + and Zn 2 + with K¡ values of 0.61, 3.47 and 1.51 
μΜ respectively [198]. 
The addition of EDTA in in vitro incubations led to a potent stimulation of 5σ-
reductase enzymatic activity in homogenates of whole human prostate at pH 7.4 [80] 
and in stromal (pH 7.4) or epithelial (pH 6.5) fractions of this tissue [83]. However, 
this stimulatory effect of EDTA was shown to result from an EDTA-induced decrease 
of pH of the incubation medium, and not from the capacity of EDTA of binding 
cations [195]. The aforementioned effects of cations and/or EDTA wil l undoubtedly 
have contributed to the wide range of results concerning 5a-reductase characteristics 
in literature. 
1.6.5.2 membrane environment 
Attempts to solubilize and purify 5o-reductase have always met great difficulties as 
enzyme activity was rapidly lost after chromatography [38, 49, 77, 119, 121, 140, 
141, 176]. The strong membrane-bound nature of 5a-reductase may be responsible for 
these difficulties in purifying the enzyme, and may indicate a role of the membrane 
environment in stabilizing or modulating enzyme activity. 
Specific phospholipids, phosphatidylcholines containing either unsaturated or 
saturated acyl chains of 12 carbon atoms, were shown to enhance the activity of 
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solubilized 5o-reductase from rat epididymis [28]. On the other hand, certain 
polyunsaturated fatty acids were shown to inhibit 5a-reductase activity from rat and 
human liver microsomes, and from the human prostatic cancer cell-lines LNCaP and 
PC-3 [122]. Furthermore, the modulatory effect of phosphatidylcholines on solubilized 
5a-reductase enzymatic activity from rat epididymis was later shown to strongly 
depend on the length of the acyl-chains, the long chains being stimulatory, the short 
inhibitory [99]. 
In line with these results, it was shown that phospholipases also modulate 5a-
reductase enzymatic activity. Phospholipases С and A2 increased the Km of rat 
epididymal 5a-reductase activity [28]. Prostatic 5cr-reductase activity was more 
inhibited by phospholipase С and A2 treatment than was hepatic enzyme activity [38]. 
Together, these results suggest a role for the membrane environment in the regulation 
and modulation of 5a-reductase enzymatic activity. Thus, differences in 5o-reductase 
characteristics in separate tissues could arise from variations in membrane 
phospholipid composition in these tissues, and complicate the assessment of isozyme 
activities. 
1.6.5.3 steroids/cofactor 
The expression and enzymatic activity of 5o-reductase are, amongst others, regulated 
by estrogens and/or androgens. Estrogens have been implicated in the promotion of 
prostatic growth [8, 34, 65, 221]. A direct inhibitory effect of estrogens on 5a-
reductase activity in prostatic tissue in vitro has been reported, although only at high, 
non-physiological concentrations [6, 96, 97, 104, 157, 189]. This direct effect of high 
concentrations of estradiol on 5a-reductase activity has also been established in vitro 
in pubic female skin [24]. At low concentrations, estradiol enhances 5o-reductase 
activity in cultured prostatic explants, but reduces 5o-reductase activity in the prostate 
of adult rats [130]. This effect was not found in castrated rats. Treatment with 
estrogens (diethylstilbestrol, 1 mg per day for three years) led to a strong suppression 
of type II 5o-reductase in epididymis of man [193]. It has been suggested that the 
inhibitory effect of estradiol on prostatic 5a-reductase in intact rats was the result of 
the reduction of the concentration of circulating androgens, direct or indirect by LH-
suppression [130]. As estrogens are not substrate for 5a-reduction, a direct competitive 
inhibition is unlikely. A variety of steroids with a A4-3-oxo-structure can serve as 
substrate for 5o-reductase [174] and thus act as competitive inhibitors, as has been 
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described for progesterone [24, 33, 211, 212, 217]. 
Castration of rats led to a marked regression in size and weight of the ventral prostate 
[141] by apoptosis of the epithelium [164]. Treatment with the 5o-reductase inhibitor 
finasteride also caused atrophy and apoptosis of epithelial cells in the prostate of rats, 
although to a lesser extent than castration [169, 187]. Prostatic 5o-reductase enzymatic 
activity decreases after castration and can be restored by administration of 
testosterone, DHT [55, 141, 156] and of 3a-androstanediol [141]. Neither 
administration of estradiol, nor adrenalectomy or hypophysectomy attenuated the 
effect of suppletion with testosterone on prostatic 5o-reductase after castration [141]. 
Finasteride blocks the induction by testosterone of prostatic 5a-reductase enzymatic 
activity and of type I and type II specific mRNA in castrated rats [3, 55, 156]. 
Therefore, it can be concluded that DHT per se induces both type I and type II 5a-
reductase expression. This positive-feedback regulation mechanism is characteristic for 
a number of genes that play crucial roles in development [174]. The formation of trace 
amounts of DHT would induce 5a-reductase expression, increase DHT formation, and 
thus amplify a positive developmental cascade [55]. 
Pituitary [207] and adrenal [114] 5a-reductase activities seem to be regulated 
differently from the prostatic enzyme. Pituitary 5o-reductase is controlled by both 
direct and indirect gonadotrophin-releasing hormone-mediated mechanisms. Castration 
led to enhancement of 5o-reductase enzymatic activity, whereas administration of 
testosterone decreased pituitary 5a-reductase activity in both intact and castrated rats 
[207]. Castration of male rats led to a threefold increase in adrenal 5o-reductase 
activity and a sevenfold increase in 5a-reductase mRNA that could be restored to 
normal values by DHT administration. Pregnant mare serum gonadotropin decreased 
adrenal 5o-reductase activity in immature female rats [114]. Thus, pituitary and 
adrenal 5a-reductase activities are suppressed by androgens, which is in marked 
contrast with the prostatic enzyme activity. 
DHT has been shown to non-competitively inhibit 5o-reductase activity in vitro [79]. 
However, other reports deny product inhibition of 5a-reductase [111]. The reported 
non-competitive inhibition by NADP+ [16, 79, 117] is in line with the proposed 
sequential ordered mechanism of 5a-reductase (see section 1.6.3). One could 
speculate on a possible regulatory role for NADPH and/or NADP+ in vivo, especially 
as NADPH is also considered to stabilize enzyme activity [115, 120, 225]. In any 
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case, the possibility of product inhibition by DHT or NADP+ is a matter of 
consideration in the assay of 5a-reductase. 
1.6.5.4 other regulatory factors 
A regulatory factor of 5a-reductase enzymatic activity that could play a role in vivo or 
in vitro (in the assay of this enzyme) is citrate [111, 132]. Citrate, a commonly used 
buffer-component, is present in prostatic epithelium and is in fact a major secretory 
component of it [30]. Tissular citrate concentrations are elevated in BPH, but low in 
prostatic carcinoma [30, 31]. Citrate as buffer component was shown to abolish the 
negative cooperativity exhibited by BPH 5a-reductase activity when assessed in 
acetate buffer [111] {section 1.6.4). Prostatic citrate metabolism is possibly regulated 
by testosterone and prolactin [31]. The 5a-reductase activity in testes of both immature 
and mature rats has been reported to be stimulated by prolactin, both in vivo and in 
vitro [26, 200]. Furthermore, ATP was shown to stimulate 5a-reductase activity, 
whereas DNP (2,4-dinitrophenol, a reagent that lowers intracellular ATP levels [74]) 
inhibited enzyme activity in BPH microsomes [112]. In the same study, a negative 
correlation was established between PAP (prostatic acid phosphatase) content and 5a-
reductase activity. PAP is located in the epithelial cells of the prostate [196], 
suggesting that 5a-reductase can be regulated by phosphorylation of the enzyme in 
the human prostate in vivo. Variation in established enzyme activities between 
different BPH biopsies or discrepancies in literature on 5o-reductase activities may be 
due to differences in citrate, ATP, PAP [111, 112, 132] or zinc {section 1.6.5.1) 
content of the prostate. 
Gonadotrophs reportedly stimulate 5a-reductase enzymatic activity in homogenates 
of whole testis [147], interstitial cells [153], cultured Leydig cells [148] and in cultured 
Leydig cell precursors [151]. Platelet derived growth factor (PDGF) inhibits 
gonadotrophin-stimulated 5o-reductase activity in immature Leydig cells [150], 
whereas insulin-like growth factor-l (IGF-I) and transforming growth factor ß (TGF-ß) 
were implicated in the DHT-mediated induction of 5o-reductase activity [76, 218]. 
The negative cooperativity and hysteresis exhibited by 5a-reductase [111, 112] and 
described in section 1.6.4 wil l not only have a physiological function (damping of 
DHT production against Τ oscillations and making the enzyme responsive over a 
wider concentration range [154, 155]), but also has major consequences for the 
correct measurement of 5a-reductase enzymatic activity [132]. Finally, Kaufman and 
colleagues found the 5o-reductase enzyme to influence the behavior of testosterone-
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androgen receptor complexes, by coupling with this hormone-receptor complex [98]. 
What the rationale or effect of this mechanism is, is still to be resolved. 
1.7 LOCALIZATION 
The localization of 5a-reductase isozymes has been the subject of ample research, as 
this could shed more light on the possibly distinct roles of these isozymes. This 
section addresses the localization of 5a-reductase isozyme-specific mRNA and 
immunoreactivity, and of 5o-reductase enzymatic activities. The isozyme identity of 
enzymatic activity is difficult to ascertain, as both isozymes catalyse the same reaction. 
So far, tissular 5o-reductase isozyme activities have been usually identified by their 
specific pH-optima, although these optima are most probably non-physiologic. 
1.7.1 Tissue distribution 
mRNA 
5a-Reductase is expressed in a wide variety of tissues (table 1.1). Both type I and type 
II mRNA were found in rat prostate and epididymis [9, 156]. The expression of 5a-
reductase mRNA in rat epididymis precedes detectable enzymatic activity in this 
tissue, suggesting a posttranslational control mechanism [213, 214]. 
In human, both type I and type II mRNA's have been detected in the prostate [15, 
126], although other authors reported only type II 5a-reductase mRNA in this tissue 
[125, 205]. 
Immunoreactivity 
Western blots of extracts of rat prostate and immunocytochemical studies in ventral 
prostate and epididymis revealed immunoreactivity that can probably be attributed to 
type I 5o-reductase [75], whereas both type I and type II specific antisera resulted in 
staining of regenerating rat ventral prostate sections [9] {table 1.1). 
The rat type l-specific antiserum stained human prostatic sections [75]. Type II 5a-
reductase immunoreactivity was detectable in human prostate [37, 193, 194, 205]. 
Enzymatic activity 
5o-Reductase enzymatic activity has been demonstrated in the prostate and 
epididymis of lion, dog, mouse, guinea pig, bobcat and bull [56]. 
In rats, enzyme activity was found in liver [135, 136], neural tissues [7, 10, 25, 210], 
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prostate, epididymis [156], lung, seminal vesicles, kidney, submaxillary glands, testis, 
spleen, skin and uterus [56, 210]. The enzymatic activity in the rat prostate exhibits 
two pH-optima, one at acidic pH (»type II) and one at neutral pH («type I). The rat 
epididymal 5o-reductase activity is optimal at acidic pH, indicative of type II 5a-
reductase [156]. Neuronal 5a-reductase enzymatic activity is, amongst others, 
implicated in the formation of 5a-dihydroprogesterone, which is a potent natural 
ligand of the p-amino-butyric
 a d d A receptor [72, 100, 129]. However, formation of 
DHT is also considered important in the mammalian brain and pituitary [133]. 
5o-Reductase enzymatic activity can be found in numerous tissues of the rhesus 
monkey (Macaca mulatta). In the male monkey the adrenal, testis, prostate, seminal 
vesicle, intestine, kidney, liver, lung, foreskin, mesenteric fat, pituitary, cerebellum 
and cerebral cortex exhibited 5o-reductase activity [131]. In the female monkey, this 
distribution was similar p.p., and further included the ovary, endometrium and 
myometrium [131]. In fetal neural tissues, heart, muscle and lung, 5a-reductase 
activity was also detectable [190]. Based on its acidic pH-optimum, the 5o-reductase 
activity in the cynomolgus monkey (Macaca fascicularis) prostate has been identified 
as type II [118]. 
In man, 5ff-reductase activity can be found in genital (acidic pH-optimum) and non-
genital skin (neutral pH-optimum) [13, 58, 143, 230], prostate [20, 43, 56], epididymis 
[33, 56], ovary, adrenal, kidney, seminal vesicle, testis, hypothalamus, pons, 
cerebellum and liver [174, 205]. The pH-optimum in the human prostate is acidic, 
indicative of type II 5a-reductase [20, 43, 56]. The 5a-reductase activity in cultured 
beard dermal papilla cells also exhibits an acidic pH-optimum, whereas the papilla 
cells derived from occipital scalp hair exhibit a type I -like (neutral) pH-optimum [90]. 
As mentioned earlier, the ratio of enzymatic activity at pH 7.0 over that at pH 5.0 was 
used to estimate type I / type II activity in human tissues [205]. The adrenal, 
hypothalamus and pons only exhibited activity at pH 7.0 (type I), whereas the testis 
would express only type II activity. Other tissues express a variety of pH 7.0 over pH 
5.0 activity ratios [205]. 
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1.7.2 Cell-type specific localization 
mRNA 
In regenerating ventral prostate, type I antisense RNA probes demonstrated labelling of 
the basal epithelial cells, whereas a type II probe led to almost exclusive staining of 
stromal cells [9] (table 1.2). Both type I and type II mRNA's were expressed in the 
epithelial cells of the rat epididymis [9], in a gradient, i.e. highest in the segment 
closest to the testis (initial segment) and decreasing towards the tail of the gland 
(cauda epididymis) [156, 213, 214]. In the rat liver, mRNA for the type I 5o-reductase 
subtype was also found to be expressed in a spatial gradient, being highest in 
hepatocytes surrounding the portal triads and lowest around the central veins [9] 
In the human prostate both type I and type II mRNA's have been found [15, 126], but 
their cell-type specific localization has not yet been reported. The DU-145 cell-line, 
derived from a cerebral metastasis of an epithelial prostate cancer, was shown to 
express only type I 5a-reductase mRNA [35]. 
Immunoreactivity 
The stromal localization of the type II and epithelial localization of the type I isozyme 
mRNA in regenerating rat ventral prostate was confirmed by their immunoreactivity 
localization [9] (table 1.2). Immunocytochemical evidence substantiated the spatial 
gradient of type I expression in the rat epididymis [216]. 
In the human prostate type II immunoreactivity seems to be restricted to (basal) 
epithelial cells [37]. However, Silver and colleagues reported type II immunoreactivity 
to be predominantly localized in stromal cells, whereas the type I 5a-reductase 
protein was not detectable in the human prostate [193, 194]. 
Enzymatic activity 
In human skin, the apocrine sweat gland exhibited the highest 5a-reductase activity, 
followed by sebaceous glands and hair follicles. The enzyme activity in the epidermis 
was negligible [199]. The enzyme activity in the sebaceous glands had a pH-optimum 
of 7.5, at which pH the apparent affinity constant was high (24 μΜ) [199], indicative 
of type I 5o-reductase. As mentioned in section 1.6.2.1, differences in affinity 
constants between 5or-reductase activities in tissues might indicate dissimilar isozyme 
activities. After mechanical separation of stroma and epithelium of the human 
prostate, 5o-reductase activities with distinct Km's have been reported in these 
compartments [21, 83, 103, 167, 222]. 
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These studies reported affinity constants for testosterone of 23 to 230 nM in stroma 
and 11 to 90 nM in epithelial cells, all in the range characteristic for the cloned and 
expressed type II isozyme, but suggesting a preferentially stromal localization of type I 
5o-reductase in this tissue. The difference in finasteride-sensitivity of epithelial (K, - 7 
± 3 nM, IC50 - 38 nM) and stromal (K¡ - 31 ± 3 nM, IC50 - 112 nM) 5tf-reductase 
activity [105, 222] might also indicate a preferentially stromal localization of the type I 
isozyme in the human prostate, although botri inhibition constants are in the range of 
type II. The difference in pH-optima of 5o-reductase activity in the human prostate 
(pH 6.5 in epithelium and pH 7.4 in stroma) would substantiate this hypothesis [83]. 
In contrast, the epithelium derived cell-line DU-145 exhibited only type I 
characteristics (pH-optimum, inhibitor sensitivity) [35]. 
1.7.3 Intracellular localization 
Immunoreactivity 
In rat prostate 5a-reductase type I staining of nuclear components was observed in 
Western blots [75] (table 1.2). Both type I and type II specific antibodies showed 
intense perinuclear staining in regenerating rat prostatic sections [9]. 
Immunohistochemical studies in the rat epididymis have shown that the type I 5a-
reductase isozyme was located in the endoplasmatic reticulum of epithelial cells 
[216]. Along the epididymis, this intracellular localization changes, and in the 
proximal initial segment an infranuclear staining was found [216]. Another report, 
however, indicated that 5a-reductase immunoreactivity —probably type I— in rat 
epididymis was nuclear bound [75]. Type I immunoreactivity in rat liver has been 
reported as either microsomal [37,75] or both nuclear and microsomal [178]. 
In the human prostate, the rat type I antiserum stained the nuclei of both stromal and 
epithelial cells [75]. Human type II specific antiserum localized 5o-reductase 
immunoreactivity in the nuclei of stromal cells of the human prostate [193, 194]. 
Another study, however, reported type II immunoreactivity preferentially in the 
cytoplasm of the epithelial cells [37]. 
Enzymatic activity 
In rat epididymis, 5a-reductase activity is found in both the nuclear and microsomal 
fractions [137, 170]. This intracellular localization of 5a-reductase activity in rat 
epididymis is dependent on age and differs between epididymal sections [180]. The 
nuclear and microsomal subtypes differ in cofactor affinity [179], sensitivity to 
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phosphoNpase treatment [29], and in effect of addition of phosphatidylserine [99]. The 
intracellular localization of 5a-reductase activity in the rat prostate has been the 
subject of extensive investigation. After differential centrifugation, enzymatic activity 
was found in the nucleus, with a considerable amount of 5a-reductase in 
mitochondrial and microsomal fractions, ranging from 24 to 74% [3Θ, 49, 140, 142, 
210]. The mitochondrial and microsomal 5o-reductase activities might have arisen 
from contamination of these fractions with nuclear particles, due to the forces during 
homogenization. Houston and colleagues have shown that in the human prostate this 
contamination can range from 25 to as high as 90% [78]. The human prostatic 5a-
reductase activity is considered to be exclusively nuclear [78, 80, 83]. 
1.8 30-HYDROXYSTEROID OXIDOREDUCTASE 
One of the major DHT-degrading enzymes in the prostate is 3a-hydroxysteroid 
oxidoreductase (HSOR, E.C. 1.1.1.50). This enzyme is capable of catalyzing both the 
reduction of DHT to 5o-androstane-3o,17ß-diol (Adiol) and the back-oxidation of 
Adiol to DHT. HSOR activities have been described in the rat prostate [47, 52, 109, 
124, 208] and in the rat epididymis [73, 162, 170, 180]. This enzyme is responsible 
for most of the DHT metabolism in these tissues [47, 116, 124], as in the human 
prostate [92, 105] . 
Because of the extensive back-oxidation potential of Adiol to DHT by HSOR [19], it 
was thought that Adiol could play a role as prehormone for the accumulation of DHT 
in the prostate, and —as DHT is considered to be the active androgen in the prostate— 
possibly in the development of human benign prostatic hyperplasia (BPH) [145]. Adiol 
was indeed shown to induce BPH in the dog, the only other species besides man that 
spontaneously develops prostatic hyperplasia [221]. Adiol levels correlated positively 
with prostate size in dogs [92]. However, this induction of prostatic hyperplasia by 
Adiol might not only have arisen due to its back-oxidation to DHT, but could also be 
a direct effect of Adiol itself, as Adiol has recently been shown to induce cAMP 
formation in dog and human prostatic tissue expiants [152]. 
Diminished degradation of DHT by HSOR wil l also lead to accumulation of this 
potent androgen. Therefore, it was hypothesized that the activity ratio of DHT-fórming 
and DHT-degrading enzymes might be altered in BPH and would be a more accurate 
pathogenic factor for BPH than 5a-reductase enzymatic activity per se [17, 20]. 
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Endogenous DHT levels were reportedly elevated and Adiol levels decreased in 
human hyperplastic vs normal prostate [53, 69, 103]. However, HSOR activities in 
hyperplastic prostates have been reported higher [43, 92] or lower [17, 89] than, or 
similar to [146] those in normal prostates. Studies indicated that 5a-reductase, as well 
as HSOR activities were both higher in stroma than in epithelium of the human 
hyperplastic prostate [32, 71]. Other studies indicated that only 5a-reductase was 
higher in BPH stroma vs normal stroma, whereas HSOR did not differ between stroma 
or epithelium of hyperplastic or normal prostates [103]. Localized regional variation in 
the 5o-reductase- over HSOR-activity ratio has also been described in the human 
prostate [67]. 
HSOR activity has been detected in rat prostatic cytosol [88, 201, 208], but also in 
nuclear fractions [208]. These rat prostatic HSOR enzymatic activities differed in 
cofactor-dependency and in pH-optimum. In rat epididymis, the pH-profile of HSOR 
activity was optimal at pH 4.0-4.8 [162]. The NADPH-dependent HSOR activity in rat 
pituitary had a pH-optimum ranging from 6 to 9, whereas the NADH-dependent 
activity was optimal at pH 5.5 [102]. In the dog prostate optimal activity was found at 
pH 4.5-7.0 [91]. HSOR activities with dissimilar characteristics were also found in 
cytosol vs microsomes of human prostate [81, 82, 92]. The cytosolic HSOR was 
totally dependent on NADPH as cofactor, whereas the microsomally-bound enzyme 
could use both NADPH and NADH. In these reports, both enzymes were less active 
in the degradation of DHT in hyperplastic prostates when compared to normal 
prostates [81, 82]. Further, the cytosolic HSOR activity was optimal at pH 7.0 to 8.0, 
whereas the microsomal enzyme exhibited maximal activity at pH 4.5-6.0 [92]. This 
variety in results strongly suggests the possible existence of multiple isozymes of 
HSOR, which in turn could cloud the quantification of enzymatic activities in different 
tissues. As for 5o-reductase, the aforementioned characteristics must all be taken into 
account for a correct apprehension of HSOR-mediated DHT forming and degrading 
dynamics [105]. 
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1.10 SCOPE OF THIS THESIS 
Several techniques have been used to identify and quantify the 5o-reductase isozymes. 
Although mRNA measurements (by in situ hybridization or Northern blot) are highly 
specific, their levels do not always correlate with tissular enzyme activity. Protein 
detection studies (¡mmunohistochemistry, immunocytochemistry, immunoblotting) 
have the unique possibility to assess the specific localization (tissue-specific, cell-type 
specific and intracellular, see section 1.7) of the isozymes in tissue sections, but this 
kind of technique is hampered by the high degree of homology between the two 
isozymes {sections 1.4 and 1.5). It is particularly difficult to obtain the necessary 
specific antibodies for this purpose. To ensure binding of antibodies in tissue sections, 
the antibodies should be raised against isozyme-specific hydrophilic portions of the 
isozymes. Furthermore, correct determination of the level of enzyme expression with 
this method is, at the best, semi-quantitative. 
Lack of specificity is also one of the problems associated with 5ar-reductase enzymatic 
activity measurements. As both isozymes obviously perform the same reaction, i.e. 
conversion of testosterone to DHT, discrimination between isozymes is difficult. 
However, if this problem can be adequately overcome, 5a-reductase activity 
measurements offer better means of quantifying and comparing the in vivo enzymatic 
capacities of normal and diseased tissues than do the aforementioned techniques. 
The data obtained with the aforementioned techniques are complex to interpret (figure 
1.4). The expression of the enzyme can differ between tissues, which could cause lack 
of correlation between mRNA levels and enzymatic activity. Furthermore, comparing 
isozymes on the mRNA- protein- and enzymatic activity level is also problematic. The 
control of each of the steps as depicted in figure 1.4 can differ between tissues and/or 
between isozymes. For instance, high levels of type II 5o-reductase mRNA could be 
associated with a relatively higher level of type I activity, if this subtype is more 
efficiently expressed in a tissue. Even the quantification of protein (immunoblotting) is 
precarious, as the catalytic efficiency from protein to activity might differ between 
tissues or between isozymes. Finally, for 5a-reductase isozyme activities, several 
methods have been used to assess their quantification. Normally, enzyme activities are 
measured at optimal conditions of substrate and cofactor concentrations, temperature, 
buffer composition and pH. As the isozymes have different pH-optima, isozyme 
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Figure 1.4: Several steps at which 5<r-reductase isozyme activities could be 
differentially controlled. The product of this activity, DHT, is subsequently 
metabolized by several enzymes, amongst others HSOR. 
activities can be quantified at their optimal pH, thus at pH 5.0-5.5 and at pH 7.0-8.0, 
for type II and type I respectively. However, the supposition that the isozymes operate 
at neutral pH in vivo would argue for measuring isozyme activities at an equal, i.e. 
neutral pH. 
To get more insight into the regulation of tissular DHT concentrations, it has to be 
taken into account, apart from the intricacies adherent to the quantification of 5a-
reductase isozymes, that these tissular DHT concentrations are controlled by a number 
of degrading enzymes, amongst others 3o-hydroxysteroid oxidoreductase (HSOR). This 
enzyme can also catalyse the back-oxidation of Adiol to DHT and therefore might 
play an important role in the control of DHT formation degradation and formation. 
The aim of this thesis is to assess both 5a-reductase isozyme activities at their 
physiological pH, i.e. pH 7.0 in three different tissues: i) the rat prostate, in which 
both isozymes have been detected on mRNA, protein and activity level (based on two 
distinct pH-optima) (table 1.1). ii) the rat epididymis, in which the type II isozyme has 
been detected on the mRNA and enzymatic activity level, and the type I isozyme on 
the mRNA and protein level (table 1.1). iii) the human prostate, in which the type II 
isozyme has been found on all three levels, but in which the type I has only been 
detected on the mRNA level (table 1.1). 
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First, this thesis addresses the intricacies of the kinetics and activity measurements of 
the type II isozyme in rat prostate and epididymis. The stability of enzymatic activity, 
the non-linear time course of testosterone metabolism —which precludes correct 
activity measurements in a single time point assay— and the consequences of the 
establishment of a pH-optimum of 5a-reductase activity are evaluated (chapter 2). 
Furthermore, isozyme activities are assessed at neutral pH in rat prostate and rat 
epididymis. The isozyme activities are obtained by applying a wide range of substrate 
concentrations and by plotting according to Eadie-Scatchard. This proofed to be an 
appropriate method to detect and quantify isozyme activities [chapter 3). 
Type II 5a-reductase is considered to mediate the anabolic effects of testosterone in 
the human prostate, generating the most potent androgen DHT, and therefore is 
implicated in benign prostatic hyperplasia (BPH). A specific type II inhibitor, 
finasteride (Proscar®) has been developed for treatment of patients with BPH. 
However, as mRNA for type I 5ff-reductase has reportedly been found in the human 
prostate, type I 5o-reductase enzymatic activity might also be present in this tissue, in 
addition to type II (table 1.1). Applying the assay we devised as described in chapters 
2 and 3, 5a-reductase isozyme activities are investigated in human hyperplastic 
prostate tissue (chapter 4). 
The proposed distinct roles of the isozymes (catabolic versus anabolic) are puzzling in 
light of the ample expression of type I activity in the classical androgen-target organ, 
the rat prostate. To get more insight in the roles of the isozymes in androgen-target 
tissues, the subcellular localization of the isozyme activities is studied (chapter 5). 
DHT tissular concentrations are primarily regulated by the enzymes 5a-reductase and 
HSOR. To get a better insight into the dynamics of DHT formation and degradation, 
HSOR activities —both NADP(H) and NAD(H)-dependent— are quantified in rat prostate 
and epididymis and combined with the enzyme activity parameters we obtained for 
5o-reductase (chapter 6). 
4 7 
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RAT STEROID 5o-REDUCTASE KINETIC CHARACTERISTICS: 
EXTREME pH-DEPENDENCY OF THE TYPE II 
ISOZYME IN PROSTATE AND EPIDIDYMIS HOMOGENATES 
P.N. Span, A.C.H. Smals, C.G.J. Sweep and Th.J. Benraad 
Journal of Steroid Biochemistry and Molecular Biology (1995) 54: 185-192 
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2.1 SUMMARY 
Reevaluating the assay for rat steroid 5a-reductase isozymes in prostate and 
epididymis homogenates we encountered an extreme pH-dependency of the type II 
isozyme. The time-course of the metabolism of testosterone (T) to 17ß-hydroxy-5a-
androstan-3-one (DHT) at acidic pH shows an initial burst when the homogenate is 
not brought to pH before the start of the incubation. Therefore, the rat type II 5a-
reductase isozyme does not follow Michaelian law under these conditions making a 
single time point measurement invalid. Assessing the pH-optimum of 5a-reduction in 
both rat prostate and epididymis homogenates we found a strong substrate-
dependency: at high substrate concentrations a pH-optimum for the type II isozyme of 
pH 5.0 was found, whereas at lower concentrations pH 5.5 is optimal. Establishing 
Vmax (maximum velocities) and Km (affinity constants) for the 5o-reduction of Τ at pH 
4.5 to 8.0, the efficiency optimum Vmax/Km appeared to be pH 5.5 in both prostate 
and epididymis homogenates. Specifically at acidic pH these kinetic characteristics of 
the type II isozyme vary manifold. Discrepancies in literature concerning 5o-reductase 
characteristics can - a t least in part- be attributed to the choice of optimal pH, or to 
pH shifts during the assay. 
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2.2 INTRODUCTION 
Steroid 5a-reductase (5a-reductase E.C. 1.3.99.5) ¡s a NADPH-dependent enzyme 
capable of 5a-reducing a number of steroids with a 4,5 double bond and a 3-oxo 
group, including glucocorticoids, progestogens, mineralocorticoids, androgens [1] and 
non-androgens such as the pheromone precursor 4,16-androstadien-3-one [2, 3]. 
5a-Reductase can serve an anabolic purpose, catalyzing the conversion of testosterone 
(T) into the more potent androgen dihydrotestosterone (DHT) [4]. DHT binds with 
higher affinity to the androgen receptor than does Τ [5, 6]. DHT has been implicated 
in the pathogenesis of benign prostatic hyperplasia (BPH), prostate cancer, acne 
vulgaris, androgenic alopecia and hirsutism [7, 8, 9, 10, 11]. 5a-Reductase can also 
play a catabolic role, as 5a-reduced metabolites are susceptible to 3a/3ß-reduction. 
These 3-hydroxylated metabolites can be excreted after subsequent hydroxylation or 
conjugation. 
In 1970 Voigt et al. described a 5a-reductase with a pH-optimum of 5.5 in 
homogenates of human foreskin [12]. It was not until 1976 that Moore & Wilson 
postulated the existence of two 5o-reductase subtypes with distinct pH-optima [13], 
later designated type I and II according to the chronological order in which their 
cDNA's were isolated [14, 15, 16, 17]. Research on patients with a type II 5a-
reductase deficiency (pseudohermaphroditism) has underlined the importance of the 
type II isozyme in the development of several androgen-dependent organs [18, 19, 
20]. This signifies an anabolic role of this type II isozyme. The role of the type Ι 5σ-
reductase isozyme is not known as patients with a deficiency have not yet been 
described, but is assumed to be catabolic [14]. 
The 5a-reductase isozymes are highly conserved as rat and human tissues both exhibit 
two subtypes [14, 15, 16, 17, 21, 22]. Amino acid sequence homology between rat 
and human subtypes is higher than between type I and type II of either species [1]. 
Both rat and human type II 5o-reductase show a narrow acidic pHoptimum, while 
both type I isozymes have a broad pH-optimum of 6.0-8.0 [14, 22]. 
In literature the pH-optimum of surmised type II activity in rat or human tissue 
homogenates differs from pH 5.0 [14, 22], to 5.5 [12, 20, 23, 24, 25, 26], to 6.2 [27] 
or even 7.0 [28, 29]. Recent work of Thigpen et al. has shed new light upon the 
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concept of pH-optimum [30]. They postulated the efficiency optimum Vmax/Km. 
Unlike the classical pH-optimum which only determines velocities at a single substrate 
concentration, the efficiency optimum has the advantage of taking into account the 
substrate-dependency of enzyme reaction velocity. However, apparent affinity 
constants (Km's) for 5a-reductase isozymes differ widely in literature [cf. 23]. 
Because of these inconsistencies we set out to reevaluate the assay for both isozymes 
in two rat androgen target tissues: the epididymis, containing predominantly type II 
5o-reductase [1 , 14], and the prostate, containing both subtypes [14]. We detected a 
pH-dependent non-linear time course in the 5o-reduction of testosterone in both rat 
tissue homogenates which could be resolved by bringing the enzyme to the 
appropriate pH before the start of the reaction. Furthermore, we demonstrated that the 
reported controversy about the pH-optimum of type II 5a-reductase could - a t least in 
part - be explained by the substrate-dependency of 5ff-reduction. Also, we 
investigated the pH-dependency of enzyme kinetics of both 5a-reductase isozymes. 
Our results indicate an extreme pH-dependency of the type II isozyme with regard to 
enzyme characteristics Vmax, Km and Vmax/Km. This pH-dependency could explain 
- i n conjunction with the intricacy of establishing a pH-optimum- many of the 
discrepancies in affinity constants and velocities found in literature. 
2.3 MATERIALS AND METHODS 
Materials 
[1,2,6,7-3H]Testosterone (3.74 TBq/mmol) and [1ff,2a(n)-3H]17ß-hydroxy-5o-androstan-3-one 
(dihydrotestosterone) (2.00 TBq/mmol) were purchased from Amersham (Amersham, U.K.). 
[9,11-JH]5ff-androstane-3<7,17ß-diol (1.48 TBq/mmol) was obtained from Du Pont-New 
England Nuclear (Boston, MA). All radiolabelled steroids were purified by high performance 
liquid chromatography (HPLC, see below) before use. Testosterone was purchased from 
Steraloids (Wilton, NH). (L + )-Ascorbic acid, ATP (adenosine 5'-triphosphate disodium salt) 
and EDTA (ethylenediaminetetra-acetate disodium salt dihydrate) were obtained from Merck 
(Darmstadt, FRC). Glutathione and σ-monothioglycerol (3-mercapto-1,2-propanediol) were 
obtained from Sigma Chemical (St. Louis, MO). TLCK (Tosyl-lysine chloromethyl ketone) and 
TPCK (Tosyl-phenylalanine chloromethyl ketone) were from Calbiochem (Lajolla, CA) and 
Pefabloc was obtained from Boehringer (Mannheim, FRC). Diethylether (p.a.), n-hexane 
(Lichrosolv) and 2-propanol (Lichrosolv) were purchased from Merck. All other chemicals used 
were of analytical grade. 
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Protein levels were determined by a method modified from Lowry [31] against a standard of 
bovine serum albumin (OHRD 20/21, Hoechst-Behring, Marburg, FRG). The assay was 
modified for microtiter-plates and had a sensitivity of 25 μ% per well. Endogenous steroid 
levels were determined by radioimmunoassay, as described previously [32]. Steroid 
concentrations were: testosterone 0.2 nM, androstenedione 0.06 nM and corticosterone 5.79 
nM in the prostate homogenate, and testosterone 0.2 nM and androstenedione 0.05 nM in the 
epididymis homogenate. As these concentrations are low compared to the concentrations 
employed -and the homogenates are diluted over 20-fold in the final assay- endogenous 
steroids could not interfere with the measurement of 50-reductase enzyme activity. 
Buffers 
Homogenization buffer consisted of 20 mM phosphate (Merck), 1 mM monothioglycerol and 
0.25 M sucrose (Merck), pH 7.0. The incubation buffer consisted of 200 mM Tris (2-Amino-2-
hydroxymethylpropane-1,3-diol, Merck), citric acid monohydrate (Merck) and 2 mM NADPH 
tetrasodium salt (Merck) in a final volume of 1 ml, pH 4.5-8.0. Final assay pH was checked in 
control tubes without tracer, before and after incubation. 
Tissue preparation 
Wistar rats of 7-13 weeks old (200-250 gram) were killed by decapitation and whole prostates 
and epididymides were removed, freed of adhering fat and brought in liquid nitrogen for 
transport. Tissues were kept at -80°C or processed immediately. All subsequent procedures 
were performed on ice. Tissues were thawed and minced with razor blades into small pieces. 
Minced tissue was homogenized in ice-cold homogenization buffer with a 7 ml Dounce tissue 
grinder (Kontes Glass Co., Vineland, NJ) with a loose and a tight fitting pestle. The 
homogenate was filtered twice through nylon netting of 50 and 140 mesh respectively to 
remove cell debris. By this procedure -without centrifugation- a full homogenate with 
nuclei and cytosol is obtained. For rat prostate the final preparation contained 29.1 mg 
protein/ml, while rat epididymis homogenate contained 1.1 mg protein/ml. 
5a-Reductase assay 
Radiolabelled testosterone in ethanol was brought to final concentration by isotopie dilution 
with non-labelled steroid in Pyrex culture tubes (borosilicate glass, 12x75 mm, Corning Inc., 
Corning, NY). Ethanol was evaporated under a mild nitrogen stream at room temperature. 
Incubation buffer was added and the tubes were put in a shaking water bath at 37°C for at 
least 10 minutes before the start of the incubation to ensure dissolving of substrate (97%). A 
tube with cofactor (NADPH) in incubation buffer and a tube with the homogenate were 
placed in the water bath for 10 minutes to obtain the appropriate temperature. In a number of 
experiments, performed to optimize the assay, several anti-oxidants or protease inhibitors were 
added before pre-heating the homogenate, i.e. 10 minutes before starting the incubation. 
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Immediately after adding the cofactor (200 μ\) to the substrate, the incubation was started by 
adding the pre-heated homogenate (10-50 μ\). After 10-30 minutes the incubation was 
terminated by adding 100 μ\ of 3 M NaOH. To extract metabolites, 4 ml of ice-cold ether was 
added, the tubes were capped and shaken. The water phase was frozen in an alcohol bath 
with dry-ice, the organic phase was decanted and evaporated under nitrogen. Metabolites 
were dissolved in 100 μ\ hexane for HPLC. 
HPLC 
Metabolized steroids were separated on a Hibar LiChrosorb Diol-column (length 250 mm, 5 
//m, Merck), equipped with a guard column (Resolve Silica, Waters Corp., Milford, MA). The 
HPLC-system included a Waters 610 Fluid Unit, a Waters 600E System Controller and a 
Waters U6K injector. The isocratic flow of the mobile phase (hexane-propanol 96:4, v/v) was 
1.5 ml/min at a pressure of 680 psi. Radioactivity was monitored with a FloOne Beta 
Radiomatic A500 radio-chromatography detector (Packard-Canberra Benelux, Tilburg, The 
Netherlands) with a 500 μ\ cell and a liquid scintillation flow of 1.5 ml/min (Aqua-Luma, 
Lumac-LSC, Olen, Belgium). The counting efficiency for tritium was 47%. The percentage 
formation of DHT and 5ff-androstane-3a/ß, 17ß-diol were used to estimate 5o-reductase 
activity. Overall experimental recoveries for testosterone, dihydrotestosterone and 5σ-
androstane-3a,17li-diol were 90-93%. 
Enzyme characteristics 
5o-reductase enzyme characteristics were obtained by the Lineweaver-Burke method with a 
double reciprocal plot of velocity against substrate concentration at pH 4.5-8.0. Affinity 
constants (Km's) and maximum velocities (Vmax) were determined and the efficiency ratio 
Vmax/Km was calculated. 
2.4 RESULTS 
Enzyme stability 
Initially, cofactor was added to the incubation mixture containing substrate, and the 
reaction was started by adding the pre-heated homogenate. Measured velocities, 
however, differed with time used to pre-heat the homogenate. The enzyme appeared 
to be unstable at 37°C. Within 10 minutes only 8 % of the total enzyme activity 
could yet be recovered. This applied for 5a-reductase isozymes type I and II in both 
rat tissues. 1 mM monothioglycerol was added in the homogenization buffer 
beforehand. Neither antioxidants (ascorbic acid (50 mg/L) or glutathione (10 mg/L), or 
both), nor EDTA (1 mM), ATP (2 mM), nor protease-inhibitors (Pefabloc (100 mM), 
TPCK (200 mM) or TLCK (100 mM), alone or simultaneously), did prevent the 
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deterioration of enzymatic activity at 37°C. After the enzyme had deteriorated, adding 
NADPH before starting the incubation did not restore enzyme activity. However, 
adding NADPH before the 10 minutes pre-heating of the homogenate greatly 
preserved enzymatic activity. Keeping the homogenate on ice with NADPH until 
adding it to the incubation mixture gave best results, preserving 80% of enzyme 
activity. Although the homogenate then would not attain the appropriate temperature 
at the start of the incubation, we used this protocol in the subsequent study. 
Non-linear time course 
The time course in metabolism can be considered linear, allowing for a single time 
point measurement to estimate initial velocities, until substrate depletion leads to a 
substantial decrease in velocity. Percentual conversion of Τ to DHT was not allowed 
to exceed 15%, by varying incubation times with different substrate concentrations, to 
prevent this substrate depletion. Analysis of the time course of testosterone 
metabolism, however, showed an "initial burst": in the first 30 seconds the measured 
velocity was higher than during the subsequent 10 minutes. This phenomenon was 
observed only at acidic pH in both rat prostate and epididymis homogenates (figure 
2.1 A and B). For the type I isozyme - in rat prostate homogenate at pH 7.0- the time 
course of testosterone metabolism was linear (figure 2.1Q. The initial burst precluded 
the correct estimation of initial velocities of 5o-reductase type II at acidic pH in a one­
time point measurement. In our initial protocol pH was presumably obtained almost 
immediately, as the homogenization buffer was a 20 mM phosphate buffer, the 
incubation buffer used was a 200 mM Tris-citrate buffer and only 10 to 50 μ\ of the 
homogenate were added to a final volume of 1 ml incubation buffer of the 
appropriate pH. However, bringing the enzyme to pH before starting the incubation 
by adding 0.2 ml of incubation buffer of the appropriate pH to the homogenate, the 
"initial burst" could be prevented (figure 2.1A and B). 
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Figure 2.1: Time course in the conversion of Τ to 
DHT. A: rat prostate homogenate. B: rat 
epididymis homogenate. 5o-Reductase was 
assessed at pH 5.5 using 30 nM Τ as substrate. 
When the homogenate is kept in homogemzation 
buffer pH 7.0 an initial burst is found ( · ) . When 
the enzyme is brought to pH 5.5 by the addition 
of incubation buffer, the time course is linear (A). 
C: In rat prostate the time course at pH 7.0 and 
using 300 nM Τ (type I So-reductase) is linear 
( · ) . The protocol and control of buffer pH are as 
described in Material and Methods. 
Figure 2.2: pH-dependency of Τ conversion in: A: 
rat prostate homogenate. B: rat epididymis 
homogenate. 5o-Reduction was assessed with 1 
μΜ Τ ( · ) or with 10 nM Τ (A) at pH 4.0 to 8.0 as 
described in Materials and Methods. The 
optimum pH for the type II isozyme at acidic pH 
is dependent on the substrate concentration used. 
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pH-dependency of rat 5a-reductase isozymes 
pH-profiles showed that rat prostate contains both 5a-reductase isozymes {figure 
2.2A): enzyme activity can be detected at pH 5.0-5.5, indicative of type II 5σ-
reductase, and at pH 6.0-8.0, the earlier described optimum of the type I isozyme. Rat 
epididymis showed high type II activity at acid pH, but only minimal activity at pH 
6.0-8.0 {figure 2.2B). The type II 5ff-reductase isozyme has been reported to have a 
narrow pH-optimum of either pH 5.0 or pH 5.5. In our hands both pH's were 
optimal, albeit under different conditions (figure 2.2A and B). A careful analysis of 
substrate dependency at both pH's showed that at testosterone concentrations above 
80 nM an optimum of pH 5.0 would be found, whereas smaller amounts of 
testosterone are metabolized more efficiently at pH 5.5 {figure 2.3A and B). The type 
II isozyme in the rat prostate shows the same substrate-dependency at acidic pH as in 
the epididymis. In the epididymis only a low maximum velocity - w i t h a high 
affinity- is attained at pH 7.0 {figure 2.3B). In rat prostate homogenate the type I 
isozyme (at pH 7.0) is more efficient in metabolizing high concentrations of Τ (figure 
2.3A). 
0.0 Í 
0.00 022 0.44 0.66 0.88 1.10 0.00 0.03 0.07 0.10 0.14 0.17 
[S] (μΜ) 
Figure 2.3: Substrate dependency of pH-optimum. A: rat prostate homogenate. B: rat epididymis 
homogenate. 5o-reductase enzyme activity was assessed at pH 5.0 (-О-), at pH 5.5 (-·-) and at pH 7.0 
(-Δ-). At low substrate concentrations in both tissues the highest initial velocity is found at pH 5.5. 
Higher Τ concentrations are more efficiently metabolized at pH 5.0. At Τ concentrations higher than 
'\μΜ, pH 7.0 would become optimal in rat prostate, but not in rat epididymis homogenates. 
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The type I isozyme in rat prostate homogenate has a broad classical optimal pH of 
6.0-8.0 {figure 2.2A). Enzyme characteristics Vmax, Km and Vmax/Km for this isozyme 
did not differ substantially in this pH-range (figure 2.4A, В and Q. The enzyme 
characteristics for the type II isozyme, however, differed widely. At acidic pH, Vmax 
and Km showed a strong pH-dependency in both tissues (figure 2.4). At pH 4.5 to 6.0 
Vmax and Km varied by a factor 20. The efficiency ratio Vmax/Km was also extremely 
pH-dependent in the acidic range and had an optimum at pH 5.5 in rat prostate and 
epididymis (figure 2.4C and F). 
PROSTATE EPIDIDYMIS 
40 45 SO 56 00 96 70 75 B0 
Figure 2.4: Enzyme characteristics Vmax (A, D), Km (В, E) and Vmax/Km (С, Π at pH 4.75-7.5 (rat 
prostate A, B, C) and pH 4.5-8.0 (rat epididymis D, E, F). Vmax and Km were determined by a double 
reciprocal plot of estimated initial velocity against substrate concentration according to Lmeweaver-
Burke. The Vmax vs. pH shows the pH-optimum at high (saturating) substrate concentrations. Vmax/Km 
plotted vs. pH shows its pH-optimum at pH 5.5 in both tissue homogenates. In both tissues enzyme 
characteristics vary manyfold, especially at acidic pH. 
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2.5 DISCUSSION 
Several papers have shown the existence of at least two isozymes of 5o-reductase in 
both rat [14, 16, 21] and human [16, 17, 22] tissues. Most recent research has focused 
on the measurement of 5a-reductase mRNA and 5a-reductase expressed in transfected 
cell systems [15, 16, 17, 2 1 , 30, 33, 34]. However, correlation between mRNA level 
and assayable 5a-reductase activity (protein) is sometimes poor, especially in human 
tissues [ 1 , 22, 35]. Therefore research at the protein level is still warranted. As kinetic 
data concerning 5o-reductase differ widely in literature -reported affinity constants of 
testosterone for 5o-reductase range from 10 nM to 15 μΜ [23, 3 0 ] - we reevaluated 
the assay of this enzyme in two androgen-dependent rat tissues, the prostate and the 
epididymis. We used a full homogenate to keep conditions as close to the in vivo 
environment as is possible in this kind of in vitro measurements. In rat prostate both 
isozymes type I (with a physiological pH-optimum) and type II (acidic pH-optimum) 
are found [14]. In rat epididymis the pH-optimum suggests mainly type II 5o-reductase 
activity [14], as does the apparent affinity constant at pH 7.0 (see below). 
A major problem we initially encountered was the instability of both isozymes at 
37°C. Antioxidants and protease inhibitors could not prevent this deterioration of 
enzyme activity and neither ATP nor EDTA did influence 5a-reductase activity. It has 
been established that NADPH binds to 5o-reductase first, allowing testosterone to 
bind subsequently [36, 37]. Liang et al. reported that inactivation of human and dog 
5ff-reductase preparations could be prevented by addition of the cofactor NADPH 
while homogenizing the tissues [38]. Mutant human 5a-reductase enzymes in both 
fibroblasts and transfected cells with a shorter half-life than normal enzyme 
preparations have been reported with a lower affinity for NADPH [ 1 , 4, 18, 20]. A 
role for the cofactor to stabilize the enzyme in the cell and to regulate enzyme 
turnover has been suggested [4]. Therefore we investigated the influence of adding 
NADPH on the encountered enzyme deterioration. In our hands, NADPH pre-binding 
had a pronounced stabilizing effect on both rat isozymes, but could not restore 
enzyme activity after pre-heating at 37°C. Several studies have shown the importance 
of specific membrane components and the effect of phospholipases - w h i c h would 
influence membrane f lu idi ty- on 5a-reductase enzyme activity [39, 40]. During cell 
homogenization perturbations in the membrane environment of the tightly membrane-
bound enzyme might cause a conformational change in the protein. Binding of the 
cofactor might make the enzyme less susceptible to these membrane perturbations 
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during homogen ¡zation, leaving the enzyme receptive for testosterone binding and 
metabolism. 
Apart from the deterioration of 5o-reductase activity which could be prevented by the 
addition of NADPH, we encountered a non-linear time course in the metabolism of 
testosterone at acidic pH in both rat epididymis and prostate (figure 2.1). Earlier the 
group of Martin et al. reported that the 5a-reductase in the particulate fraction of BPH 
(Benign Prostatic Hyperplasia) homogenates also did not follow first-order Michael¡s-
Menten kinetics due to a similar non-linear time course at pH 5.5 [23, 41 , 42]. This 
would have a profound effect on the measurement of enzyme characteristics Km and 
Vmax, when a single time point measurement is used. When we brought the tissue 
homogenate to the desired pH before starting the incubation, a linear time course was 
obtained. In rat prostate high substrate concentrations are efficiently metabolized at 
neutral pH by the type I isozyme. A sudden pH-shift from neutral to acidic pH might 
explain the initial burst encountered in this tissue, when one assumes that at the start 
of the incubation a part of the substrate is metabolized by the type I isozyme. cDNA 
for type I 5c-reductase has been derived from the human prostate, although an acidic 
pH-optimum of enzyme activity in prostate extracts is found [22], typical for the type 
II isozyme. Recent evidence however does suggest the expression of type Ι 5σ-
reductase activity (P.M. Martin & F.K. Habib, pers. communication). Also in rat 
epididymis no [ 1 , 14] or only minimal [43] type I 5o-reductase activity is found [see 
below]. Because of the lack of measurable type I activity in rat epididymis, no higher 
velocity at any substrate concentration is found at neutral pH in our assay. We believe 
interference between the two isozymes not to explain the encountered initial burst. 
Rather this burst is an intrinsic aspect of the type II isozyme per se. The sudden pH-
change in the micro-environment of the membrane-bound enzyme, when starting the 
reaction, might induce a short change in activity by influencing membrane fluidity 
and/or inducing a conformational change of the isozyme. 
In the rat epididymis type I 5a-reductase has been described by immunocytochemistry 
[43]. Our results, however, are at variance with this finding. At pH 7.0 in the rat 
epididymis only minimal 5a-reductase activity is found (figure 2.3B). Furthermore, the 
affinity constants we found at pH 6.0-8.0 in this homogenate are very low 
(approximately 10 nM) (figure 2.4E), while the type I isozyme has a characteristic Km 
for Τ as high as 1 μΜ (figure 2.4B). For the human type II isozyme, expressed in 
Chinese hamster ovary cell lines, Thigpen et al. established a high affinity for Τ of 
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about 10 nM at neutral pH [30]. Although one has to be aware of the species 
difference and the difference in experimental conditions (in prostate or epididymis 
homogenates, and expressed human type II enzyme in CHO cells), we believe that 
the enzyme activity at neutral pH we found in rat epididymis can be attributed to the 
type II isozyme. One might argue that the ¡mmunocytochemical detectable 5a-
reductase type I enzyme is inhibited or is non-active, as also discrepancies between 
mRNA and enzyme activity have been reported in human BPH-tissue [22]. However, 
immunocytochemistry is much more sensitive than our biochemical assay and is 
capable of detecting extremely small amounts of enzyme. Furthermore, type Ι 5σ-
reductase is reportedly highly concentrated in the initial segment of the epididymis 
[43]. We might therefore not have been able to detect this activity in a homogenate of 
the whole epididymis. Whether this type I activity in the rat epididymis has any 
physiological significance -considering its low affinity for T - needs to be addressed 
in studies using discrete segments of this tissue. 
The pH-optimum of 5a-reductase activity in rat or human tissue has been the subject 
of mild controversy. pH-optima in tissues considered to contain mainly type II 5σ-
reductase differ in literature; an optimum of 5.0 has been described for the type II 
enzyme in rat epididymis and prostate and in human prostate [14, 22], and an 
optimum of 5.5 for the human epididymis and BPH tissue, fibroblasts and other 
human and rat tissues [12, 20, 23, 24, 25, 26]. In addition, an optimum of 6.2 was 
found in the rat epididymis by Monsalve and Blaquier [27], while the group of 
Houston et al. reported a pH-optimum of 7.0 in the human prostate [28, 29]. The 
normal procedure to obtain a pH-optimum is by incubating an enzyme preparation 
with a single substrate concentration. Velocity, however, depends strongly on 
substrate concentration. 
From the Michael¡s-Menten equation: V - (Vmax*Km) / ([S] + Km), where [S] is the Τ 
concentration follows: when S > > Km, a pH-profile would indicate Vmax vs. pH. 
And when S < < Km: V - Vmax/Km * [S]. The velocities found are than proportional 
to Vmax/Km. 
In this paper we described the initial velocities at different testosterone concentrations 
and pH's. At testosterone concentrations below 80 nM a higher initial velocity is 
found at pH 5.5, whereas at higher testosterone concentrations the optimum in rat 
epididymis was 5.0. The pHoptimum shift from pH 5.0 to pH 5.5 reported for some 
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mutant human 5a-reductase enzymes might be explained by the reported change in 
substrate or cofactor affinity [4, 20]. As both testosterone and NADPH were kept at a 
constant concentration in these studies, a change in affinity by a mutation in the 
enzyme can cause the chosen concentration to induce a different pH-optimum, as a 
different affinity constant implies a different substrate-dependency. 
Unlike the classical pH-optimum, the efficiency ratio Vmax/Km takes into account the 
substrate-dependency of velocity. This ratio reflects also the potential in vivo velocity 
of DHT formation from T, as endogenous Τ concentrations are much lower than the 
Km. In our hands, the optimum of the efficiency ratio for the type II isozyme was at 
pH 5.5 in rat prostate and epididymis. This ratio has been reported to be optimal at 
pH 6.0 for a microsomal preparation of human prostatic tissue [44] or at pH 7.0 for 
the expressed human type II isozyme in a hamster ovary cell line [30]. Preliminary 
results from our laboratory also indicate that the efficiency optimum in human BPH 
tissue homogenate is at pH 6.5 (unpublished observations). In rat prostate both 5a-
reductase isozymes are present, so the Vmax/Km ratio for the rat type II isozyme at 
neutral pH cannot be determined in this tissue, as at this pH the type I isozyme wil l 
interfere. Because of the high Km of the type I isozyme, low efficiency ratios are 
found at neutral pH in rat prostate. The low efficiency ratio at this pH in rat 
epididymis, however, can not be explained by the presence of type I 5o-reductase. In 
contrast to the rat prostate, affinity constants are 100 fold lower at neutral pH in the 
epididymis. The decreased Vmax/Km ratio at pH 6.5-8.0 in this tissue is caused by the 
10 fold lower Vmax at this pH as compared to pH 5.5, with similar affinity constants. 
Since we found the enzyme characteristics Vmax and Km to be highly dependent on 
minor pH-changes in the acidic pH region, the choice of pH has considerable effects 
on reported kinetic data. Some effects of modifying substances might be explained by 
even minor shifts in the pH during the assay [as reported in 45 for EDTA]. 
The present study discloses that in rat prostate and epididymis homogenates the 
metabolism of Τ at acidic pH by the type II 5a-reductase isozyme shows a non-
linearity in the time course when not brought to the desired pH before the start of the 
incubation. Therefore estimation of initial velocities at acidic pH in these tissues is 
incorrect in a single time point measurement. Bringing the enzyme to the appropriate 
pH before the start of the incubation leads to a linear time course. When a pH-
optimum is attained one has to consider the substrate-dependency of enzyme reaction 
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velocity. At high substrate concentrations a pH-optimum of pH 5.0 is found for the rat 
type II isozyme, while at low substrate concentrations an optimum of pH 5.5 is found, 
equalling the Vmax/Km efficiency ratio pH-optimum in rat prostate and epididymis 
homogenates. The extreme pH-dependency of the rat type II 5a-reductase isozyme 
strongly influences enzyme characteristics. The choice of pH for the assay of 5a-
reductase type II could explain discrepancies in reported affinity constants in 
literature. 
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3.1 SUMMARY 
Immunocytochemical studies and mRNA measurements have shown that the rat 
epididymis - l i k e the rat prostate- expresses both rat steroid 5a-reductase isozymes 
i.e. type I and II. So far, enzyme activity measurements in rat epididymis 
homogenates, however, do not support the presence of type I 5a-reductase activity. 
Incubating homogenates of both tissues with a wide range of substrate concentrations, 
we were able to detect activity of both isozymes in rat prostate and epididymis tissues 
at neutral pH. In rat prostate the amount of type I activity, as measured by the Vmax 
at pH 7.0, exceeds that of type II 5o-reductase 50-fold. The efficiency ratio, Vmax/Km, 
of the type I isozyme accounts for 25 % of the total in vivo potential activity. A 
possible anabolic role for the type I isozyme in rat prostate was thus surmised. In rat 
epididymis the Vmax of type I and type II 5o-reductase at pH 7.0 were similar. 
Comparison of the efficiency ratio Vmax/Km of either isozyme in the rat epididymis, 
however, suggested that the type II isozyme would play the major role in the 5σ-
reduction of testosterone at physiological concentrations and at neutral pH. The 
specific localization of the isozymes should be considered to allow for correct 
quantification of their in vivo contribution to DHT formation. 
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3.2 INTRODUCTION 
Dihydrotestosterone (DHT) is the major androgen formed by 5o-reduction of 
testosterone (T) in both androgen target- and non-target tissues [1]. The enzyme 
responsible for this conversion, 5o-reductase (EC 1.3.99.5), is membrane-bound, 
NADPH-dependent, and capable of 5o-reducing a number of other steroids with a 4,5 
double bond and a 3-oxo-group [1]. 
To date, two subtypes of steroid 5c/-reductase with specific pH-optima and inhibitor 
sensitivities, designated type I and type II, have been described in both human and rat 
[2, 3, 4, 5, 6, 7]. Their existence is well documented, but has found little rationality. 
The tissue specific expression and affinity constants of the isozymes has led 
investigators to propose an anabolic role for the type II isozyme, which is expressed in 
the prostate and other classical androgen target tissues, and a catabolic role for the 
type I isozyme, as it is amply detectable in liver tissue [7]. Both the human and rat 
type I isozymes have a broad pH-optimum of 6.0 to 8.0, whereas the type II isozymes 
have a pH-optimum of 5.0 to 5.5 [5, 6, 7]. The rationale for the acidic pH-optimum of 
the type II isozyme has fascinated many researchers over the years. Recently, applying 
the efficiency ratio Vmax/Km to the question of pH-optimum for human 5o-reductase 
isozymes expressed in a Chinese hamster ovary cell line, it has been shown that the 
type II isozyme is capable of metabolizing physiological Τ concentrations most 
efficiently at pH 7.0. The acidic pH-optimum of the type II isozyme would be an 
artifact [8]. Both 5a-reductase subtypes are now thus considered to operate at neutral 
pH. 
We studied the 5o-reduction of Τ in rat prostate and epididymis homogenates at pH 
7.0 to gain insight into the contribution of both isozymes to DHT formation. In rat 
prostate both subtypes are present and their activities have been reported [7]. In rat 
epididymis both subtypes have also been described. The type II isozyme is 
unequivocally present and its activity has been described. Type I 5or-reductase has 
been detected immunocytochemically [ 1 , 9] and by mRNA measurements [7, 10, 11]. 
Enzyme activity measurements, however, do not support type I activity in the rat 
epididymis [7, 9, 11]. Because of this discrepancy between 5a-reductase protein and 
activity we investigated whether type I activity could be found in rat epididymis 
homogenates at pH 7.0 using an in-depth kinetic analysis of 5a-reductase activity in 
this tissue, with the rat prostate as a control. 
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3.3 MATERIALS AND METHODS 
Materials 
[1,2,6,7-3H]T (3.74 TBq/mmol) and [1a,2o(n)-3H]17B-hydroxy-5o-androstan-3-one (DHT) (2.00 
TBq/mmol) were purchased from Amersham (Amersham, U.K.). [^ll-SHJSo-androstane-
3o,17ß-diol (1.48 TBq/mmol) was obtained from Du Pont-New England Nuclear (Boston, MA). 
All radiolabelled steroids were purified by high performance liquid chromatography (HPLC, 
see below) before use. Τ was purchased from Steraloids (Wilton, NH). Diethylether (p.a.), n-
hexane (LiChrosolv) and 2-propanol (LiChrosolv) were purchased from Merck (Darmstadt, 
FRG). All other chemicals used were of analytical grade. 
Buffers 
Homogenization buffer consisted of 20 mM phosphate (Merck), 1 mM monothioglycerol and 
0.25 M sucrose (Merck), pH 7.0. The incubation buffer consisted of 200 mM Tris (2-Amino-2-
hydroxymethylpropane-1,3-diol, Merck) and citric acid monohydrate (Merck), pH 4.0-8.0 or 
pH 7.0, and 2 mM NADPH tetrasodium salt (Merck). 
Tissue preparation 
Wistar rats of 7-13 weeks old (150-250 gram) were killed by decapitation and whole prostates 
and epididymides were removed, freed of adhering fat and placed into liquid nitrogen for 
transport. Tissues were kept at -80 °C or processed immediately. All subsequent procedures 
were performed on ice. Pooled tissues were thawed and minced with razor blades into small 
pieces. Minced tissue was homogenized in ice-cold homogenization buffer with a 7 ml 
Dounce tissue grinder (Kontes Glass Co., Vineland, NJ) with a loose and a tight fitting pestle. 
The homogenate was filtered twice through nylon netting of 50 and 140 mesh respectively to 
remove cell debris. By this procedure -without centrifugation- a full homogenate with 
nuclei and cytosol is obtained. The pooled rat prostate homogenate was diluted with 
homogenization buffer to 29.1 mg protein/ml, while rat epididymis homogenate was diluted 
to 1.1 mg protein/ml. 
Protein levels were determined by a modification of the method of Lowry et al. [12] against a 
standard of bovine serum albumin (OHRD 20/21, Hoechst-Behring, Marburg, FRG). The assay 
was modified for microtiter-plates and had a sensitivity of 25 μ% per well. 
5a-reductase assay 
Radiolabelled Τ in ethanol was brought to final concentration by isotopie dilution with пол-
labelled steroid in Pyrex culture tubes (borosilicate glass, 12x75 mm, Corning Inc., Corning, 
NY). Ethanol was evaporated under a mild nitrogen stream at room temperature. Incubation 
buffer (800 μ\) was added and the tubes were put into a shaking water bath at 37 °C at least 
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10 minutes before the start of the incubation to ensure the substrate was dissolved (97 % ) . A 
tube with the homogenate (10-50 μ\) and the appropriate amount of cofactor (NADPH, 2 mM 
final concentration) was diluted to 200 μ\ with 150-190 μ\ incubation buffer and kept on ice. 
The incubation was started by adding 200 μ\ of the homogenate and cofactor mixture to the 
pre-heated tubes with substrate [13]. After 10-30 minutes the incubation was terminated by 
adding 100 μ\ of 3 M NaOH. Τ metabolism was not allowed to exceed 15 % by varying 
enzyme amount and incubation time. This 5o-reductase assay protocol was validated and 
optimized as reported in an earlier paper [13]. To extract metabolites, 4 ml of ice-cold 
diethylether was added, and the tubes were capped and shaken. The water phase was frozen 
in an alcohol bath with dry-ice, the organic phase decanted and evaporated under nitrogen. 
Metabolites were dissolved in 100 μΙ hexane for HPLC. 
HPLC 
Metabolized steroids were separated on a Hibar LiChrosorb Diol-column (length 250 mm, 5 
μνη, Merck), equipped with a guard column (Resolve Silica, Waters Corp., Milford, MA). The 
HPLC-system included a Waters 610 Fluid Unit, a Waters 600E System Controller and a 
Waters U6K injector. The isocratic flow of the mobile phase (hexane-propanol 96:4, v/v) was 
1.5 ml/min at a pressure of 680 psi. Radioactivity was monitored with a FloOne Beta 
Radiomatic A500 radic-chromatography detector (Packard-Canberra Benelux, Tilburg, The 
Netherlands) with a 500 μ\ cell and a liquid scintillation flow of 1.5 ml/min (Aqua-Luma, 
Lumac-LSC, Olen, Belgium). The counting efficiency for tritium was 47 %. The percentage 
formation of DHT and 5<7-androstane-3o/ß,17ß-diol was used to estimate 5o-reductase activity. 
Overall experimental recoveries forT, DHT and 5ff-androstane-3a/ß, 17ß-diol were 90-93 %. 
Calculation of enzyme characteristics 
Velocities were plotted against Τ concentration, and Km and Vmax were calculated using a 
non-linear regression procedure based on the Michaelis-Menten equation on a PC with the 
software-program Enzfitter. A double reciprocal plot of the obtained estimated initial velocities 
against substrate concentration was used. This Lineweaver-Burk plot appeared to be non-linear 
only at high substrate concentrations. An Eadie-Scatchard plot of velocity over substrate 
concentration against velocity was used for a more even weighting of points [14] and was 
non-linear over practically the whole substrate concentration range tested. Two 5cr-reductase 
enzyme activities with a different Vmax and Km could be calculated using the same non­
linear regression procedure with fitting to least squares, based on a Michaelis-Menten 
equation for two isozymes. For the use of the Vmax/Km ratio as an index of potential enzyme 
activity one has to consider that endogenous Τ concentrations are much lower than the Km of 
either 5of-reductase subtype [15]. Therefore applying K m > > [S] in the Michaelis-Menten 
equation gives: V - Vmax/Km*[S] . So, at physiological Τ concentrations, the enzyme 
reaction velocity is proportional to Vmax/Km. 
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3.4 RESULTS 
In this study we investigated the 5a-reductase characteristics of rat prostate and 
epididymis homogenates. The validity of the 5o-reductase assay was checked and 
reported in an earlier paper [13]. With this assay, the time course of the 5ff-reduction 
of Τ in these rat tissue homogenates was linear and the enzyme stable for at least 30 
minutes at 37 °C with 2 mM NADPH. Therefore, the velocities measured can be 
considered valid estimates of initial velocities. 
1 0 -
8 8.5 
Figure 3.1: pH-profiles of 5e-reductase activity in A) Tat prostate homogenate and B) rat epididymis 
homogenate in the pH range 4.5 to 6.0 with 2 mM NADPH as cofactor and 1 μΜ Τ as substrate. The 
pH-profile in rat prostate suggested the presence of the two established 5<r-reductase isozymes, i.e. type 
II 5o-reductase activity at pH 5.0 and type I 5tr-reductase from pH 6.0 to 8.0. In the rat epididymis a 
pH-optimum was found at pH 5.0, indicative of type II 5a-reductase activity. 
In rat prostate homogenate 5o-reductase activity was determined with a single 
substrate concentration of 1 μΜ Τ in the pH range of 4.0 to 8.0 (figure 3.1A). The two 
pH-optima suggest the presence of two isozymes in this tissue as the type II 5a-
reductase isozyme is primarily responsible for the 5a-reductase activity at pH 5.0, 
whereas the type I isozyme has a broad pH-optimum from 6.0 to 8.0. 
Enzyme activity for 5a-reductase was further established at pH 7.0 with substrate 
concentrations ranging from as low as 2 nM to as high as 3.2 μΜ {figure 3.2A). A 
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double reciprocal plot of these data was non-linear at high substrate concentrations 
(figure 3.2B). For a more even weighting of points, an Eadie-Scatchard plot of V/S 
against V was used {figure 3.2Q. 
200 300 40O 500 
1/3 (μΜΗ 
1 0 2 0 3 0 4 0 5 0 
V (рпюІ/(ілйміів рпИЫп)) 
0 0 0 2 0 4 Οβ OS 1 0 1 2 1 4 
V (pfnoV(mln>mg p n U n ) ) 
Figure 3.2: A) Estimated initial velocities (V) of 
5o-reductase activity in rat prostate homogenates 
at pH 7.0 with 2 mM NADPH and with 2 nM to 
3.2 μΜ Τ as substrate (S). Values are mean of two 
duplicate assays carried out on different days. B) 
A double reciprocal plot of these data was non­
linear at high substrate concentrations. Q An 
Eadie-Scatchard plot of estimated initial velocities 
over substrate concentration (V/S) against velocity 
(V) in rat prostate homogenates at pH 7.0. This 
plot gives a more even weighting of points and is 
non-linear. It could be described by two enzyme 
activities, an alleged type I (—) and type II (...) 5a-
reductase isozyme. The abscissa intercepts give 
the respective Vmax's, while the slope indicates 
-Km"1. 
Figure 3.3: A) Estimated initial velocities (V) of 
5ff-reductase activity in rat epididymis 
homogenates at pH 7.0 with 2 mM NADPH as 
cofactor and 2 nM to 3.2 μΜ Τ as substrate (S). 
Values are mean of two duplicate assays carried 
out on different days. B) A double reciprocal plot 
of these data was non-linear at high substrate 
concentrations. Q An Eadie-Scatchard plot of 
estimated initial velocities over substrate 
concentration (V/S) against velocity (V) in rat 
epididymis homogenates at pH 7.0. This plot 
could be described by two enzyme activities, an 
alleged type I (—) and type II (...) 5e-reductase 
isozyme. The abscissa intercepts give the 
respective Vmax's, while the slope indicates 
-Km'. 
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The affinity constants of the subtype activities calculated from these plots were 
characteristic for the already established 5o-reductase isozymes: the mean Km was 
752 nM for the alleged type I isozyme and 5.29 nM for the type II. The mean Vmax 
value of the type I was 50-fold higher than that of the type II isozyme: 5.78 vs. 0.113 
pmol/(min*mg proteinHtab/e 3.7). The efficiency ratio Vmax/Km in the rat prostate at 
pH 7.0 was 7.68*10"* l/(min*mg protein) for the type I and 21.3*10"6 l/(min*mg 
protein) for the type II 5a-reductase subtype {table 3.1); the total Vmax/Km ratio for 
5o-reductase activity at pH 7.0 in rat prostate homogenate was 29.0*10"6 l/(min*mg 
protein). Almost 75 % of this ratio was accounted for by the type II and 25 % by the 
type I isozyme. 
Table 3.1: Enzyme characteristics of type I and II 5ff-reductase in rat prostate and epididymis 
homogenates at pH 7.0. Values are mean of two duplicate measurements with S.E.M. (n-4) carried out 
on two different days. 
subtype: type I 
tissue: 
prostate 
epididymis 
Vmax 
pmol/(min* 
mg protein) 
(S.E.M.) 
5.78 
(0.09) 
0.980 
(0.16) 
Km 
nM 
(S.E.M.) 
752 
(32.5) 
1397 
(539) 
Vmax/Km 
4 0 * 
l/(min*mg 
protein) 
7.68 
0.70 
type II 
Vmax 
pmol/(min" 
mg protein) 
(5.E.M.) 
0.113 
(0.02) 
0.780 
(0.03) 
Km 
nM 
(S.E.M.) 
5.29 
(1.85) 
3.14 
(0.41) 
Vmax/Km 
•10* 
l/(min*mg 
protein) 
21.3 
248 
Figure 3.1 В shows the pH-dependency of 5a-reductase activity in rat epididymis 
homogenate at a pH-range of 4.0 to 8.0 with 1 μΜ Τ as substrate. Highest enzyme 
activity was found at pH 5.0, indicative for the presence of type II 5o-reductase. 
Activity was low at neutral pH. 5a-reductase characteristics were also assessed at pH 
7.0 with a substrate range of 2 nM to 3.2 μΜ (figure 3.3A). As in the rat prostate, a 
Lineweaver-Burk plot of the data was non-linear at high substrate concentrations 
(figure 3.3B). These data were also analyzed using an Eadie-Scatchard plot of V/S 
against V {figure 3.3Q. The enzyme characteristics obtained were typical for the type I 
and type II 5a-reductase isozymes. The mean Km values were 1397 and 3.14 nM 
respectively. The Vmax values of the type I and II 5o-reductase were similar: 0.98 and 
0.78 pmol/(min*mg protein) respectively (table 3.1). The Vmax/Km ratio was 0.70*10" 
6
 l/(min*mg protein) for the type I and 248*10'6 l/(min*mg protein) for the type II 5a-
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reductase subtype. Thus in epididymis, only about 0.3 % of the total Vmax/Km ratio 
at pH 7.0 was accounted for by the type I isozyme. 
In figure 3.4 the Vmax of the respective subtypes at pH 7.0 were compared with the 
Vmax/Km efficiency ratios at this pH of both isozymes in rat prostate and epididymis. 
The relative amount of isozyme activity present can be measured by the specific 
activity, Vmax; in rat prostate (figure 3.4A) a 50-fold higher Vmax for the type I 
isozyme was found than for the type II isozyme, in the epididymis {figure ЗАВ) the 
specific activities for both isozymes were almost equal. Nevertheless, measuring the 
potential in vivo activity in the prostate as reflected by the efficiency ratio, Vmax/Km 
{figure 3.4A), it appeared that isozyme type I accounts for 25 % of total enzyme 
activity at pH 7.0, In the epididymis (figure ЗАВ) the type II isozyme was 
quantitatively responsible for 5ff-reductase activity at physiological Τ concentrations 
and at neutral pH (99.7 %). 
5. 1.0 · 
D 
300 w 
type I type II 
Figure 3.4: 5tr-Reductase type I and type II isozyme activity in A) rat prostate and B) rat epididymis 
homogenates as measured by the Vmax (solid bars) or Vmax/Km ratio (open bars) at pH 7.0. Each 
enzyme quantification method would indicate a different isozyme activity ratio in these tissues. 
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3.5 DISCUSSION 
The assay employed in this paper has been validated in an earlier paper [13]. The 
putative hysteretic behavior of the isozyme, which would extensively hamper valid 
measurement of enzyme activity was only observed at the acidic pH-optimum of the 
type II isozyme [13, 16]. With the work of Thigpen et al. in mind, we measured both 
isozyme activities at neutral pH, as it was reported that the acidic pH-optimum of the 
type II isozyme was an artifact [8]. At neutral pH, we did not observe hysteresis [13]. 
Therefore, the enzyme activities we measured were valid estimates of initial velocity. 
The affinity constants established at pH 7.0 in the present study in rat prostate (752 
and 5.29 nM) and epididymis (1397 and 3.14 nM) are characteristic for the type I and 
type II rat and human steroid 5o-reductase subtypes reported in literature [7, 8, 13]. 
This strongly suggests that the non-linear plots found in rat prostate and epididymis 
homogenates can be attributed to these two isozyme activities. Moreover, as we 
measured isozyme activities at neutral pH and applied a citrate buffer, in which 
negative cooperativity as observed in an acetate buffer was not exhibited, the present 
findings did not represent the negative cooperativity of the human type II isozyme 
exhibited in the hyperplastic prostate at acidic pH [16]. 
Classically, type I or II 5o-reductase isozyme activities are detected by measuring their 
specific pH-optima. The presence of type II 5a-reductase can indeed be assessed by 
the use of a pH-profile as presented here for the rat prostate, where the peak at pH 
5.0 indicates type II activity. The acidic pHoptimum of the type II 5o-reductase 
isozyme and the broad neutral pH-optimum of the type I isozyme would indicate that 
the maximum velocities at pH 5.0 and pH 7.0 are a measure for respectively type II 
and type I 5o-reductase isozyme activity. This Vmax at optimal pH has been used to 
characterize type I and II tissue specific distribution [17]. Using this definition, 
according to previous results [13] in rat prostate equal amounts of isozyme activities 
would be found. However, as there is now growing evidence that the type II isozyme 
does operate at neutral pH [8], the enzyme activity measured at acidic pH does not 
properly reflect true type II activity. In a tissue where considerable type I activity is 
present, like rat prostate [7], quantification of type II isozyme activity at neutral pH 
usually is hampered. In this paper a method is described by which both isozyme 
activities can be assessed simultaneously. The Vmax values at pH 7.0 of both 
isozymes were quite different from those measured at optimal pH: the results for 5σ-
reductase enzyme activity in rat prostate homogenate would indicate a major role for 
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the type I isozyme (50-fold higher Vmax). The efficiency ratios, Vmax/Km, indicate a 
predominant role of the type II isozyme in the rat prostate at neutral pH. The type I 
isozyme, however, has a ratio which is still 25 % of the total 5o-reductase efficiency 
ratio at pH 7.0. 
The pH-profile of 5a-reductase activity in the rat epididymis reveals minimal activity at 
neutral pH and high activity at pH 5.0. The maximum activity found at pH 5.0 far 
exceeds that found at pH 7.0, indicating that the major amount of 5a-reductase in this 
tissue must be attributed to the type II isozyme. However, the activity at neutral pH 
can be attributed to either subtype, depending on the affinity constants at this pH. 
When similar amounts of both isozyme activities are present, detection of either 
subtype depends on the range of substrate concentrations used. At lower, 
physiological, concentrations a high affinity enzyme (type II 5a-reductase) wi l l be 
found. At high concentrations the enzyme activity found wil l be largely attributable to 
the type I 5o-reductase. In an earlier study [13] we were not able to detect type Ι 5σ-
reductase activity in rat epididymis homogenates as we used.T concentrations below 1 
//M. However, incubating epididymis homogenates with higher Τ concentrations, we 
now did detect type I activity. The similar specific activities, Vmax, of type I and type 
II 5a-reductase at pH 7.0 indicate the presence of similar amounts of isozyme 
activities in this tissue. This agrees with results from immunocytochemical studies [9] 
and with studies in which type I and type II mRNA content is quantified in rat 
epididymis tissue [7, 10, 11]. However, as the efficiency ratio Vmax/Km is a better 
indicator of potential 5a-reductase activity [8, 15], our results indicate that at pH 7.0 
only approximately 0.3 % of the total Vmax/Km ratio is accounted for by the type I 
isozyme. However, this type I isozyme is reportedly expressed in a small portion of 
the epididymis, the initial segment [9]. A highly concentrated expression in a specific 
segment could -notwithstanding our results presented in this paper- imply a significant 
contribution of this isozyme to DHT formation. Our results mark the intricacies when 
comparing immunocytochemical studies, 5a-reductase mRNA measurements and 5a-
reductase activity measurements in rat epididymis, even more so as 
immunocytochemistry and mRNA measurements semi-quantitatively detect the 
presence of enzyme and not enzyme activity per se. 
The role of the type I isozyme has been described as catabolic as it is amply found in 
liver tissue [7]. However, the presence of the type I 5o-reductase isozyme in the rat 
androgen target tissues prostate and epididymis suggests an additional role for this 
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subtype. On the other hand, considering the rather high affinity constant, the type I 
isozyme wil l only be active at high concentrations of Τ in the microenvironment of 
the isozyme. As all prostatic rat steroid 5a-reductase activity is reportedly located in 
the nucleus [18, 19, 20], one can hypothesize that the type I isozyme could therefore 
be active when Τ accumulates in the nucleus, e.g. due to binding to the androgen 
receptor [21, 22]. As the Vmax/Km ratio of the type I isozyme still contributes 
substantially to the total potential in vivo 5o-reductase activity, an anabolic function 
for this subtype in rat prostate is plausible. In rat epididymis distinct 5o-reductase 
activities have been detected in the nucleus and microsomes [23, 24, 25]. 
Immunocytochemical studies suggest a microsomal localization of the type I isozyme 
[9]. Accumulation of T, necessary for the type I 5o-reductase to be active in the rat 
epididymis, should thus occur in the cytoplasm. The role of the type I isozyme in this 
tissue is therefore different from that in the prostate, even more so as it is reportedly 
confined to the initial segment of the epididymis [9]. 
In summary, we present here evidence for type I 5o-reductase activity in rat 
epididymis homogenates in addition to the well established type II activity. The non­
linear plots of 5a-reductase activity we found in rat prostate and epididymis 
homogenates at neutral pH could be adequately explained by the presence of two 
isozymes with affinity constants characteristic of the type I and type II isozymes. In rat 
prostate the presence of both isozymes is undisputed and this tissue can thus serve as 
a control for the results presented here for the rat epididymis. The results obtained for 
the type I activity in the rat prostate indicate a possible anabolic role for this subtype. 
Although the Vmax in the epididymis indicates similar amounts of type I and type II 
5o-reductase activity at neutral pH, almost all potential in vivo 5o-reductase activity, 
as determined by the efficiency ratio Vmax/Km, is probably attributable to the type II 
isozyme. The highly segmental expression of the type I isozyme in the epididymis 
should be considered to allow for correct quantification of its in vivo contribution to 
DHT formation. 
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4.1 SUMMARY 
In human benign prostatic hyperplastic (BPH) tissue homogenates 5a-reduction of 
testosterone was examined at neutral pH. As Lineweaver-Burk and Eadie-Scatchard 
plots of estimated initial velocities against a wide range of substrate concentrations of 
2 nM to 3.2 μΜ were non-linear, the existence of two 5o-reductase isozymes in this 
tissue was surmised. Indeed, enzyme parameters at pH 7.0 suggested the presence of 
two isozymes with affinity constants of 1995 nM and 11.8 nM, characteristic of the 
well established human steroid 5a-reductase isozymes type I and II respectively. The 
physiological roles of these isozyme activities remain puzzling. The specific activities, 
Vmax, of these subtypes indicated an approximately 6-fold higher maximum velocity 
of type I than of type II 5a-reductase in the human hyperplastic prostate at this pH. In 
contrast, the efficiency ratios, Vmax/Km, demonstrated that the type II isozyme had a 
nearly 27 times higher potential in vivo activity than the type I isozyme, and is 
therefore most probably quantitatively responsible for di hydro testosterone formation at 
physiological testosterone levels in this tissue at neutral pH. This is the first full paper 
on type I 5ff-reductase activity in human BPH tissue. 
82 
TYPE I S^REDUCTASE IN HUMAN PROSTATE 
4.2 INTRODUCTION 
Steroid 5a-reductase (E.C. 1.3.99.5) is a NADPH-dependent enzyme capable of So-
reducing a number of steroids with a 4,5 double bond and a 3-oxo group, including 
glucocorticoids, progestogens, mineralocorticoids, androgens [1] and non-androgens 
such as the pheromone precursor 4,16-androstadien-3-one [2,3]. The 5a-reduction 
product of testosterone (T), dihydrotestosterone (DHT), has been implicated in the 
pathogenesis of benign prostatic hyperplasia (BPH) [4]. 
Earlier studies on the 5c-reductase enzyme characteristics in prostatic epithelium and 
stroma revealed a difference in affinity constants, which might indicate the existence 
of two isozymes in the human prostate [5,6,7,8]. As it is now well established that 
there are two human 5o-reductase isozymes i.e. type I and type II, with distinct pH-
optima, tissue distribution, affinity constants and sensitivity to inhibitors [as reviewed 
in 1], one might assume that the human prostate indeed contains both of these 
isozymes. 
Prostatic 5ff-reductase type II mRNA, -protein and -activity have been detected using 
cDNA probes [9,10], immunoblotting and ¡mmunocytochemistry [10,11,12], and pH-
profiles of 5o-reductase activity [1,13] respectively. In patients with 5a-reductase type 
II deficiency (male pseudohermaphroditism) prostate development is impaired, 
indicating the importance of this 5a-reductase isozyme for the growth and 
development of the human prostate [14,15]. It is therefore intelligible that a specific 
type II isozyme inhibitor, finasteride, has been developed for treatment of benign 
prostatic hyperplasia. 
Data concerning the presence of the type I 5a-reductase in human prostate, however, 
are conflicting; the first human 5o-reductase cDNA was derived from prostatic tissue 
[13,16] and was shown to code for the type I isozyme. Using cDNA probes, mRNA 
for the type I 5a-reductase has been found in the human prostate [9], whereas other 
investigators failed to demonstrate type I 5o-reductase mRNA in this tissue [TO]. 
Furthermore, immunoblotting studies using specific antibodies against the 5a-
reductase protein denies type I immunoreactivity [10,12]. On the other hand, apparent 
affinity constants for 5o-reductase found in human prostatic tissues are consistent with 
type I activity [17] and preliminary data have been published in abstract form 
indicating both type I and type II 5o-reductase activity in this tissue [18]. 
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There is growing evidence that both 5a-reductase isozymes operate at neutral pH [19]. 
By incubating homogenates of rat prostate and epididymis with a wide range of 
substrate concentrations, we were recently able to measure both rat isozymes 
simultaneously [20]. In the present study we applied the same procedure to human 
BPH homogenates. A careful analysis of 5a-reductase activity at pH 7.0 showed non-
linear Lineweaver-Burk and Eadie-Scatchard [21] plots of initial velocity against 
substrate concentration. This could be adequately explained by the presence of two 
isozymes in BPH tissue. The kinetic characteristics of these isozymes were in 
concordance with those of the well established human steroid 5a-reductase type I and 
II isozymes. Both the type I and type II isozyme specific activities and potential in 
vivo activities were determined. 
4.3 MATERIALS AND METHODS 
Materials 
[1,2,6,7-3H]T (3.74 TBq/mmol) and [1o,2o(n)-3H]17ß-hydroxy-5a-androstan-3-one (DHT) (2.00 
TBq/mmol) were purchased from Amersham (Amersham, U.K.). [9,11-3H]5o-androstane-
3</,17ß-diol (1.4Θ TBq/mmol) was obtained from Du Pont-New England Nuclear (Boston, MA). 
All radiolabelled steroids were purified by high performance liquid chromatography (HPLC, 
see below) before use. Non-labelled Τ was purchased from Steraloids (Wilton, NH). 
Diethylether (p.a.), n-hexane (LiChrosolv) and 2-propanol (LiChrosolv) were purchased from 
Merck (Darmstadt, FRG). All other chemicals used were of analytical grade. 
Protein levels were determined by a modification of the method of Lowry et al. [22] against a 
standard of bovine serum albumin (OHRD 20/21, Hoechst-Behring, Marburg, FRG). The assay 
was modified for microtiter-plates and had a sensitivity of 25 μ% per well. 
Buffers 
Homogenization buffer consisted of 20 mM phosphate (Merck), 1 mM monothioglycerol and 
0.25 M sucrose (Merck), pH 7.0. The incubation buffer consisted of 200 mM Tris (2-amino-2-
hydroxymethylpropane-1,3-diol, Merck) and citric acid monohydrate (Merck), pH 4.5-8.0 or 
pH 7.0, and 2 mM NADPH tetrasodium salt (Merck). 
Tissue preparation 
Human benign prostatic hyperplastic tissues were obtained from 15 different patients, age 53-
69 years, undergoing transurethral resection. Prostatic tissue chips were placed in liquid 
nitrogen for transport to the laboratory. Aliquots of each specimen were sent to the 
Department of Pathology for histological confirmation of BPH. Tissues were kept at -80 °C or 
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processed immediately. All subsequent procedures were performed on ice. Tissues (9.3 gram 
total w.w.) were pooled, thawed, and minced with razor blades into small pieces. Minced 
tissue was homogenized in ice-cold homogenization buffer with a 7 ml Dounce tissue grinder 
(Kontes Glass Co., Vineland, NJ) with a loose and a tight fitting pestle. The homogenate was 
filtered twice through nylon netting of 50 and 140 mesh respectively to remove cell debris. 
By this procedure -without centrifugation- a full homogenate with nuclei and cytosol is 
obtained. The pooled BPH homogenate was diluted with homogenization buffer to 5.4 mg 
protein/ml. 
5<r-reductase assay 
Radiolabelled Τ in ethanol was brought to final concentration (2 nM to 3.2 μΜ) by isotopie 
dilution with non-labelled steroid in Pyrex culture tubes (borosilicate glass, 12x75 mm, 
Corning Inc., Corning, NY). Ethanol was evaporated under a mild nitrogen stream at room 
temperature. Incubation buffer (800 μ\) was added and the tubes were put into a shaking 
water bath at 37 °C at least 10 minutes before the start of the incubation to ensure the 
substrate was dissolved (97%). A tube with the homogenate (50-100 μ\) and the appropriate 
amount of cofactor (NADPH, 2 mM final concentration) was diluted to 200 μ\ with 100-150 
μ\ incubation buffer and kept on ice. The incubation was started by adding 200 μ\ of the 
homogenate and cofactor mixture to the pre-heated tubes with substrate. After 10-30 minutes 
the incubation was terminated by adding 100 //I of 3 M NaOH. This 5o-reductase assay 
protocol was optimized for rat tissues (prostate and epididymis) in an earlier paper [23]. The 
assay was evaluated for BPH tissues, and was checked for linearity in time and protein 
concentration. Τ metabolism was not allowed to exceed 15% by varying enzyme 
concentration and incubation time. To extract metabolites, 4 ml of ice-cold diethylether was 
added, and the tubes were capped and shaken. The water phase was frozen in an alcohol 
bath with dry-ice, the organic phase decanted and evaporated under nitrogen. Metabolites 
were dissolved in 100 //I hexane for HPLC. 
HPLC 
Metabolized steroids were separated on a Hibar LiChrosorb Diol-column (length 250 mm, 5 
μπ\, Merck), equipped with a guard column (Resolve Silica, Waters Corp., Milford, MA). The 
HPLC-system included a Waters 610 Fluid Unit, a Waters 600E System Controller and a 
Waters U6K injector. The isocratic flow of the mobile phase (hexane-propanol 96:4, v/v) was 
1.5 ml/min at a pressure of 680 psi. Radioactivity was monitored with a FloOne Beta 
Radiomatic A500 radio-chromatography detector (Packard-Canberra Benelux, Tilburg, The 
Netherlands) with a 500 μ\ cell and a liquid scintillation flow of 1.5 ml/min (Aqua-Luma, 
Lumac-LSC, Olen, Belgium). The counting efficiency for tritium was 47%. The percentage 
formation of DHT and 5o-androstane-3or/ß,17ß-diol was used to estimate 5o-reductase activity. 
Overall experimental recoveries forT, DHT and 5o-androstane-3o,17ß-diol were 90-93%. 
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Calculation of enzyme characteristics 
Velocities were plotted against Τ concentration, and Km and Vmax were calculated using a 
non-linear regression procedure based on a Michaelis-Menten equation for two isozyme 
activities. A double reciprocal plot of the obtained estimated initial velocities against substrate 
concentration was used. This Lineweaver-Burk plot appeared to be non-linear at high Τ 
concentrations. Furthermore, an Eadie-Scatchard plot of velocity over substrate concentration 
(V/S) against velocity (V) was used for a more even weighting of points [21]. This plot was 
clearly non-linear and indicated the presence of isozyme activities. Two 5o-reductase activities 
with different Vmax and Km could be calculated using the same non-linear regression 
procedure with fitting to least squares. For the use of the Vmax/Km ratio as an index of 
potential enzyme activity one has to consider that endogenous Τ concentrations are much 
lower than the Km of either 5<weductase subtype [5]. Therefore applying Km> > [S] in the 
Michaelis-Menten equation gives: V - Vmax/Km*[S]. So, at physiological Τ concentrations, 
the enzyme reaction velocity is proportional to Vmax/Km. 
4.4 RESULTS 
Validity of the 5a-reductase assay 
In this study we investigated the 5a-reductase characteristics in human benign 
prostatic hyperplastic tissue homogenates. The 5a-reductase assay we applied was 
optimized and its validity checked in rat tissues as reported in an earlier paper [23]. 
The validity of this protocol was confirmed for the present study in BPH homogenates. 
In the absence of cofactor, the enzyme was unstable at 37 °C. This deterioration 
could be countered by adding cofactor during the preincubation. With 2 mM 
NADPH, the enzyme activity was stable for at least 30 minutes at 37 °C. This 
stabilization of the enzyme activity by preincubating with cofactor has been reported 
earlier by others [24, 25]. Furthermore, the initial burst in the time course of the 5a-
reduction of T, reported by others in BPH particulate fractions [26] and by us in rat 
epididymis and prostate [23], was also countered with the applied protocol in the 
present study. This procedure led to a linear time course during the incubation period 
for at least 30 minutes, allowing for the estimation of initial velocities. Finally, 10 to 
100 μ\ of the diluted homogenate (0.054 to 0.54 mg protein) was incubated under the 
established conditions mentioned in the Materials and Methods section. The velocities 
were linear for the entire protein concentration range tested (results not shown). 
pH-optimum 
A pH-profile of enzyme activity was made over the pH range 4.5 to 8.0 using 4 
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substrate concentrations (figure 4.1). For purpose of comparison, the initial velocity at 
the optimum pH is arbitrarily set at 100% for each of the Τ concentrations. At Τ 
concentrations of 100, 200 and 1000 nM, the optimum of initial velocity was found at 
pH 5.5. However, at a lower Τ concentration of 10 nM, the optimum was at pH 6.0. 
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Figure 4.1: pH-Profiles of 5ff-reductase activity at 2 mM NADPH and with (-•-)10 nM, (-A-) 100 nM,(-
•-) 200 nM and (-·-) 1000 nM Τ as substrate. The optimum pH for 5o-reductase activity in human BPH 
tissue depends on the substrate concentration chosen. For purpose of comparison at each concentration 
the optimum activity was arbitrarily set at 100%. 
Isozyme activities at neutral pH 
At pH 7.0 the initial velocities were estimated over a wide concentration range of 2 
nM to 3.2 μΜ Τ (figure 4.2A). As the double reciprocal plot of these data was non­
linear at high Τ concentrations (figure 4.2B), a non-linear fit to least squares was used 
and the enzyme parameters of two 5o-reductase isozymes could be calculated. An 
Eadie-Scatchard plot of V/S against V was used for a more even weighting of points 
(figure 4.2Q and was more clearly non-linear. 
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Figure 4.2: A) Estimated initial velocities (V) of 5o-reductase activity in human BPH tissue homogenates 
at pH 7 0 with 2 mM NADPH and with 2 nM to 3.2 μΜ Τ as substrate (S). Values are given as mean ± 
S D. of three duplicate assays carried out on different days. B) A double reciprocal plot of the data in 
figure 4.2 is non-linear at high Τ concentrations. Q An Eadie-Scatchard plot of the data reported in 
figure 4.3 of estimated initial velocities over substrate concentration (V/S) against velocity (V) in human 
BPH tissue homogenates at pH 7.0. This plot gives a more even weighting of points and is clearly non­
linear. It could be described by two enzyme activities, an alleged type I (—) and type II (...) 5σ-
reductase isozyme. The abscissa intercepts of these lines give the respective Vmax's, while the slopes 
indicate -Km'1 values of the isozymes. Both the x-values and y-values are given as mean ± S.O. of three 
duplicate assays. 
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One subtype was calculated with a Vmax of 50.8 fmol/(min*mg protein) and a Km of 
11.8 nM, which is characteristic of the established type II isozyme at this pH. The 
other subtype could be defined as having a Vmax of 313.1 fmol/(min*mg protein) and 
a Km of 1995 nM, corresponding to Km values reported for the type I isozyme. The 
efficiency ratio Vmax/Km of the alleged type I isozyme was 0.16*IO"6 l/(min*mg 
protein), whereas the type II isozyme had an approximately 27-fold higher Vmax/Km 
ratio of 4.30* 10"6 l/(min*mg protein). For purpose of comparison, the Vmax and the 
Vmax/Km ratios of both isozymes at pH 7.0 are shown in figure 4.3. Although the 
Vmax of the type I 5o-reductase isozyme was 6.2-fold higher than that of the type II, it 
yet appeared that the potential in vivo activity at pH 7.0 is mainly attributable to the 
type II isozyme, as evidenced by its much higher Vmax/Km ratio. 
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Figure 4.3: 5o-Reductase type I and type II isozyme activity in human BPH tissue homogenates at pH 
7.0 as described by the Vmax (black bars) or Vmax/Km ratio (shaded bars). The specific activities, 
Vmax, indicate a quite different isozyme composition in this tissue than does the efficiency ratio 
Vmax/Km. 
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4.5 DISCUSSION 
In this study we investigated the 5a-reductase characteristics of human benign 
prostatic hyperplastic tissue homogenates. In a previous paper [23] we described 
deterioration of enzyme activity at both pH 5.0 and at pH 7.0 in the absence of 
cofactor at 37 °C in rat prostate and rat epididymis. The enzyme activity was stable 
for 30 minutes at 37 °C with 2 mM NADPH. This also applied to 5o-reductase 
activities in BPH homogenates described in the present paper. The initial burst in the 
time course of 5a-reductase activity [23, 26] was not present with the protocol applied 
in this study. Furthermore, the activity was linear over the whole protein 
concentration range tested. Therefore, we conclude that the values we here 
established are reasonable estimates of initial velocity. 
We established the pH-optimum for 5a-reductase activity in BPH homogenates. This 
pH-optimum of 5a-reductase activity in human prostate has been reported to vary 
from as low as pH 5.0 [13], to pH 5.5 [26] or even 7.0 [8,17]. In this study we 
measured the pH-dependency of 5a-reductase activity at substrate concentrations 
ranging from 10 to 1000 nM T. At the higher Τ concentrations (100 to 1000 nM), the 
pH-optimum was found at 5.5. At the lowest Τ concentration tested (10 nM), 
however, the optimum was at pH 6.0. Thus, the pH-optimum strongly depends on the 
substrate concentration chosen. As the affinity constant for 5o-reductase activity 
depends substantially on pH [19, 27], the pH-optimum found wil l greatly influence 
reported Km values for 5o-reductase in BPH tissue. This might -in part- explain the 
wide range of Km's reported for 5a-reductase activities [26]. We decided to measure 
enzyme activities at pH 7.0, as this is probably the physiological pH for both 
isozymes [19]. 
The existence of type II 5a-reductase in human prostatic tissue is now well accepted 
[9,10,11,12,13]. In patients with a type II 5a-reductase deficiency (male 
pseudohermaphroditism) the prostate is atrophic [14,15]. In these patients the type I 
isozyme is unaffected, indicating the crucial function of the type II isozyme in the 
development of the human prostate. Data concerning type I 5o-reductase diverge, as 
some authors deny the existence of the type I isozyme in the human prostate [10,12], 
whereas others claim its presence [9,13]. Preliminary data has been published 
reporting equal amounts of type I and type II activity in human prostatic tissue [18]. 
We describe here the presence of two isozymes in a full homogenate of BPH tissue, 
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by applying high Τ concentrations and by using an Eadie-Scatchard plot of the 
obtained data. This plot is particularly suitable for identifying two isozymes as it leads 
to a more even weighting of points as compared to the Lineweaver-Burk plot [21]. The 
affinity constants for these isozymes are typical for the type I and II 5a-reductase 
subtypes at neutral pH as reported in literature [16,19,27]. When Vmax is taken as a 
measure of enzyme concentration, our results imply that there is an approximately 6-
fold higher amount of type I 5o-reductase than of type II at pH 7.0 in the human 
hyperplastic prostate. However, one has to be cautious regarding these results; to 
preserve all cellular components we did not centrifuge our homogenate, but filtered 
the preparation through nylon netting which might have led to a preferential recovery 
of epithelial components [7]. Stroma and epithelium do probably not exhibit the same 
5ff-reductase isozyme composition [5,6,7,8]. Thus a better recovery for the epithelial 
components in this study would have led to a difference in relative isozyme 
concentrations found. Furthermore, unlike in this paper, most studies use a 
centrifugation step in their experimental procedure to remove cell debris. However, 
whole nuclei will also be lost at 800 g, and as there might be a difference in 
intracellular localization between both 5o-reductase subtypes, more of a nuclear 
bound isozyme could have been detected with our protocol than in these other 
studies. 
For enzyme quantification several definitions can be used: the maximum velocity at 
the optimum pH of the isozyme, the Vmax at neutral pH -as the acidic pH-optimum 
of the type II 5a-reductase is probably not physiological- or the efficiency ratio 
Vmax/Km as a measure of isozyme activity, instead of isozyme concentration. All 
these definitions can, and have been, used. At pH 5.5 a maximum velocity of 0.7 
pmol/(min*mg protein) was found, at pH 7.0 the Vmax was 0.13 pmol/(min*mg 
protein), indicating a 5.4-fold higher type II than type I isozyme specific activity 
(results not shown). Considering our data of isozyme activity at pH 7.0, the Vmax of 
the type I isozyme appeared to be 6.2 times higher than that of the type II. However, 
the Vmax/Km ratios for both isozymes point to a 26.9-fold higher potential in vivo 
activity for the type II than the type I isozyme in human prostatic tissue at pH 7.0. 
When this efficiency ratio is used as a measure of isozyme activity, the results suggest 
that a specific type II isozyme inhibitor, like finasteride, should suffice in decreasing 
prostatic DHT tissue levels in the clinical management of BPH. However, it has not 
been unequivocally ascertained whether the premise of Km > > [S] for the use of the 
efficiency ratio is valid in the microenvironment of the type I isozyme; human 
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prostatic 5o-reductase is reported to be located in the nucleus [28]. One can speculate 
that the type I isozyme could be active when Τ is accumulated in the nucleus to a 
higher substrate concentration, e.g. by binding to the androgen receptor. If this would 
be the case, the here reported substantial type I 5o-reductase activity might call for an 
evaluation of a combination therapy with type I and II isozyme inhibitors for BPH 
[15]. Experiments are underway in our laboratory to ascertain the intracellular 
localization of both isozymes and to check the validity of the Vmax/Km ratio. The 
discrepancies in isozyme specific mRNA, immunoreactivity and activity measurements 
in the human prostate might be attributable to differences in translation from mRNA to 
protein, or to differences in catalytic efficiency from protein to activity between the 
two isozymes. 
In conclusion, we present here evidence for the presence of a substantial amount of 
type I 5o-reductase in human benign prostatic hyperplastic tissue homogenates in 
addition to the well established type II. Nevertheless, although type I has an 
approximately 6-fold higher specific activity than type II 5o-reductase at neutral pH, it 
is most probably the type II isozyme that is quantitatively responsible for the 
formation of DHT in the human prostate, considering the efficiency ratio Vmax/Km of 
the isozymes in this tissue. However, the intracellular and cell-type specific 
localization of both isozymes has to be considered so as to shed more light on the 
possible physiological roles of both isozymes in this tissue. The role of the reported 
prostatic type I 5or-reductase isozyme in BPH remains intriguing. 
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CHAPTER 5 
5.1 ABSTRACT 
objective: The rat prostate, a classical androgen-target tissue, contains both known 
isozymes of steroid 5a-reductase, i.e. type I and type II. So far, the role of the type I 
isozyme has been proposed as catabolic. The abundant expression of type I 5a-
reductase in an androgen-target tissue is therefore puzzling. Assessment of the 
subcellular localization of 5a-reductase isozymes in rat prostate might contribute in 
elucidating their possibly distinct roles. 
methods: After obtaining crude subcellular fractions by differential centrifugation, both 
isozyme activities were measured at neutral pH by plotting according to Eadie-
Scatchard. The observations were extended by assessment of pH-dependent velocity 
ratios and type II 5o-reductase inhibitor sensitivities in these subcellular fractions. 
results: The results indicated a preferentially —although not exclusively— nuclear 
localization for the type I and a predominantly microsomal localization for the type II 
isozyme activity in the rat prostate. 
conclusion: The nuclear localization of the type I isozyme seems not to concur with 
its proposed catabolic role. 
96 
SUBCELLULAR LOCALIZATION OF So^ REDUCTASE ISOZYME ACTIVITIES 
5.2 INTRODUCTION 
Steroid 5o-reductase (3-oxo-5a-steroid A4-reductase, E.C. 1.3.1.22) is a membrane-
bound, NADPH-dependent enzyme capable of 5a-reducing a number of steroids with 
a 4,5 double bond and a 3-oxo group, including androgens [1]. 
The enzyme 5o-reductase was first described in rat liver [2, 3], were it was considered 
to function as a catabolic enzyme. After 5o-reduction, steroids are susceptible to 3a-
and 3ß-hydroxysteroid dehydrogenation, sulphation and glucuronylation, facilitating 
their excretion [1]. Later, 5a-reductase activity was also found in rat prostate [4-7], a 
classical androgen-target tissue. As dihydrotestosterone (DHT) accumulated in the 
nuclei of prostatic cells after administration of radiolabelled testosterone (T) to rats [4, 
8], and as DHT is a more potent androgen than Τ in binding to the androgen receptor 
[9, 10], an anabolic role for the prostatic 5o-reductase has been suggested. To date, 
two subtypes of steroid 5o-reductase with specific pH-optima and inhibitor 
sensitivities, designated type I and type II, have been described in both human and rat 
[11-16]. Both the catabolic and anabolic roles proposed for 5a-reductase could be 
attributed to the respective isozymes, based on their tissue-specific localization —type I 
being found in the liver, type II being the predominant isozyme in the prostate— and 
based on their respective affinity constants [16]. 
Studies on the subcellular distribution of 5a-reductase activity in the rat prostate show 
a wide variety of results. Investigators found nuclear-bound rat prostatic 5o-reductase, 
yet with a considerable amount of enzyme activity in mitochondrial and microsomal 
fractions, ranging from 24 to as high as 74 % of total activity [6, 17-20]. These latter 
activities, however, might have arisen from nuclear contamination, as has been 
described for the human prostate [21]. Subsequent research focused on the 
characterization, purification and solubilization of the nuclear-bound prostatic 5a-
reductase activity [6, 7, 17, 20, 22]. It is now recognized that the rat prostate 
expresses both isozymes of 5o-reductase [16]. Immunocytochemical studies 
established a nuclear localization of 5a-reductase immunoreactivity —probably 
attributable to the type I isozyme— in rat prostate epithelium [23]. To the best of our 
knowledge, the subcellular localization of 5o-reductase isozyme activities in rat 
prostate has not yet been elucidated. 
In the present study, the subcellular distribution of 5a-reductase isozyme activities in 
the rat prostate was investigated to get better insight into the functional roles of both 
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isozymes. The results suggest a differential subcellular distribution of the two subtypes 
in this tissue, based on activity measurements, isozyme-specific pH-dependent velocity 
ratios, and inhibitor sensitivities of 5a-reductase activity in crude subcellular fractions. 
5.3 MATERIALS AND METHODS 
Materials 
[1,2,6,7-3H]Testosterone (3.74 TBq/mmol) and [1a,2o(n)-JH]17ß-hydroxy-5<7-androstan-3-one 
(2.00 TBq/mmol) were purchased from Amersham (Amersham, U.K.). [9,11-3H]5o-androstane-
3a,17ß-diol (1.48 TBq/mmol) was obtained from Du Pont-New England Nuclear (Boston, MA). 
All radiolabelled steroids were purified by high performance liquid chromatography (HPLC, 
see below) before use. Testosterone (T) was purchased from Steraloids (Wilton, NH). 
Diethylether (p.a.), n-hexane (LiChrosolv) and 2-propanol (LiChrosolv) were purchased from 
Merck (Darmstadt, FRG). All other chemicals used were of analytical grade. The specific rat 
5<*-reductase type II inhibitor L-685,273 (21,21-pentamethylene-4-aza-5ff-pregn-1-ene-3,20-
dione) was a kind gift of the Merck, Sharp and Dohme Corp. (Rahway, N.J., USA) 
Buffers 
The homogenization buffer consisted of 20 mM phosphate (Merck), 1 mM monothioglycerol, 
50 μΜ NADPH tetrasodium salt (Merck) and 0.25 M sucrose (Merck) (pH 7.0). The incubation 
buffer consisted of 200 mM Tris (2-amino-2-hydroxymethylpropane-1,3-diol, Merck) / citric 
acid monohydrate (Merck) and 2 mM NADPH (pH 5.0 or pH 7.0). 
Animals and tissue preparation 
Ten Wistar rats from the local breeding facility of 7-13 weeks old (150-250 g) were killed by 
decapitation and whole prostates were removed, freed of adhering fat and placed in liquid 
nitrogen for transport to our laboratory. Tissues were processed on the same day. All 
subsequent procedures were performed on ice. Pooled tissues (2.3 g total w.w.) were minced 
with razor blades and homogenized in ice-cold homogenization buffer with a 7 ml Dounce 
tissue grinder (Kontes Class Co., Vineland, NJ) with a loose and a tight fitting pestle. The 
homogenate was filtered twice through nylon netting of 50 and 140 mesh respectively to 
remove cell debris. This full homogenate was diluted with homogenization buffer to a 
concentration of 21 mg protein/ml. 
Preparation of subcellular fractions 
Crude subcellular fractions were obtained by differential centrifugati on at 4 °C. After 
centrifugation at 1000 χ g for 15 min in a Sorvall RC24 with a SM24 fixed angle rotor, a 
crude nuclear pellet was obtained. The resulting supernatant was centrifuged at 10000 χ g for 
20 min in the same rotor to obtain a mitochondrial pellet. The 10000 χ g supernatant was 
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subsequently centrifugea at 108000 χ g for 60 min ¡η a MSE Prepspin 75 with a SP-2818 
fixed angle rotor, resulting in a microsomal pellet and a supernatant containing the cytosol. 
All pellets were resuspended in homogenization buffer with a glass-glass tissue grinder 
(Kontes) to 4 (mitochondrial fraction), 8 (microsomal fraction) and to 9 mg protein/ml (crude 
nuclear fraction). Aliquots of 1 ml were stored at -80 °C and assayed within 4 weeks. 
Protein levels were determined by a method modified from Lowry et al. [24] against a 
standard of bovine serum albumin (OHRD 20/21, Hoechst-Behring, Marburg, FRG). The assay 
was modified for microtiter-plates and had a sensitivity of 25 μg per well. 
5a-Reductase assay 
The assay has been described and validated in detail in earlier papers [25, 26]. In short, 
radiolabelled Τ was isotopically diluted to a range of 2 nM to 3 μ Μ (final concentration, 10 
duplicate points), dissolved in incubation buffer (800 μΙ) in Pyrex culture tubes (borosilicate 
glass, 12x75 mm, Corning Inc., Corning, NY) and subsequently preheated at 37 °C. For the 
inhibition experiments, the specific rat 5o-reductase type II inhibitor L-685,273 was added 
from stock solutions in ethanol (10 pM to 10 μ Μ final concentration) simultaneously with Τ 
(30 nM final concentration). This inhibitor is type II specific with inhibition constants of 0.04 
nM for type II and 2.8 nM for type I So^reductase respectively [16]. Ten to 100 μ\ of the 
enzyme preparation (40 μg to 2.1 mg protein) and the appropriate amount of cofactor 
(NADPH, 2 mM final concentration) was supplemented to 200 μ\ with incubation buffer and 
added to the tubes with substrate to start the incubation. After 30 minutes the incubation was 
terminated by adding 100 μΙ of 3 M NaOH, and metabolites were extracted with 4 ml of ice-
cold diethylether. Percentile metabolism ranged from 1 to 16 %. Extracted metabolites were 
reconstituted in 100 μΙ hexane for HPLC. 
HPLC 
Metabolized steroids were separated on a Η i bar LiChrosorb Diol-column (length 250 mm, 5 
μπι, Merck), equipped with a guard column (Resolve Silica, Waters Corp., Milford, MA). The 
HPLC-system included a Waters 610 Fluid Unit, a Waters 600E System Controller and a 
Waters U6K injector. The isocratic flow of the mobile phase (hexane / propanol 96:4, v/v) was 
1.5 ml/min at a pressure of 680 psi. Radioactivity was monitored with a FloOne Beta 
Radiomatic A500 radio-chromatography detector (Packard-Canberra Benelux, Tilburg, The 
Netherlands) with a 500 μΙ cell and a liquid scintillation flow of 1.5 ml/min (Aqua-Luma, 
Lumac-LSC, Olen, Belgium). The counting efficiency for tritium was 47 %. The percentage 
formation of DHT and 5o-androstane-3<7(6),17ß-diol (Adiol) was used to estimate 5o-reductase 
activity. 
Calculation of enzyme characteristics 
Velocities were plotted against Τ concentrations (over 10 duplicate points), and Km's and 
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Vmax's were calculated using a non-linear regression procedure to least squares, based on a 
Michael¡s-Menten equation for two independent isozyme activities, with the computer 
program Enzfitter. A double reciprocal plot (Lineweaver-Burk) of the obtained estimated initial 
velocities against substrate concentration was used. Furthermore, an Eadie-Scatchard plot of 
velocity over substrate concentration against velocity was also used, as this plot is reportedly 
best suited to detect isozyme activities [27]. IC^'s were determined from plots of enzyme 
velocity against inhibitor concentration. 
Statistical analysis 
Values were obtained in at least two duplicate assays carried out on different days. Statistical 
analysis was performed using a Pearson correlation test (p denoted by p*) or a one-tailed t-test 
according to Welch (p denoted by p). 
5.4 RESULTS 
The validity of the 5a-reductase assay was established and reported in earlier papers 
[25, 26]. Initial velocity data were obtained at a substrate concentration range of 2 nM 
to 3 μΜ Τ (f/gure 5.1 A) and plotted according to Lineweaver-Burk (figure 5.1 B) and to 
Eadie-Scatchard (figure 5.JQ. The best fit for isozyme activities are presented as solid 
lines in these figures. Lineweaver-Burk plots deviated from linearity only at the higher 
substrate concentrations. Eadie-Scatchard plots, however, were clearly non-linear and 
could be described by two enzyme activities as shown by two additional lines in 
figure 5.1 С All subcellular fractions exhibited similar non-linear plots (data not 
shown). 
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Figure 5.1: Detecting isozyme activities of rat prostatic 5<r-reductase. Best fit for isozyme activity is 
presented by solid lines. (A) Initial velocities were obtained at 2 nM to 3 μΜ Τ and 2 mM NADPH at 
37 °C in a full homogenate of rat prostate. Values are mean of at least two duplicate experiments 
carried out on two different days. (B) A double reciprocal (Lineweaver-Burk) plot of these data deviates 
from linearity only at high Τ concentrations. (C) An Eadie-Scatchard plot of V/S against V is clearly non­
linear. Activities of type I (—) and type II (···) 5o-reductase isozymes can be calculated from these data. 
In table 5.1 data obtained in crude subcellular fractions from rat prostate are 
summarized. Approximately 70 % of total protein was recovered in the subcellular 
fractions. The total recovery of enzymatic activity was 72.4 % for type I and 73.7 % 
for type II 5o-reductase respectively. The yield of type I activity was highest in the 
nuclear fraction (figure 5.2A). The mitochondrial and microsomal fraction contained 3-
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4 fold less type I 5a-reductase activity as compared to the njcle s fraction (p<0.01 
and ρ<0.005 respectively). No significant differences in yield were found for the type 
II isozyme between the subcellular fractions, approximately 25 % of total activity 
being present in each of the three fractions. No 5a-reductase activity was found in the 
108000 χ g supernatant (cytosol). 
Table 5.1: Protein and 5ff-reductase isozyme data obtained in crude subcellular fractions of rat prostate. 
subtype: 
full homogenate 
nuclei 
1000 χ g pellet 
mitochondria 
10000 χ g pellet 
microsomes 
108000 χ g pellet 
cytosol 
108000 xg 
supernatant 
protein 
(mg) (%) 
341.7 (100) 
59.2 (16.5) 
20.1 (5.B) 
15.7(4.6) 
149.7 (43.0) 
activity 
(pmol/min) (%) 
1 It 
1010.7 (100)| 48.2 (100) 
472.2 (46.7)! 13.4 (27.8) 
150.7 (14.9) ¡10.8 (22.4) 
109.4 (10.8) ¡11.3 (23.5) 
І 
specific activity 
(pmol/min'mg protein) 
1 II 
2.96 ¡ 0.141 
7.97 ! 0.226 
7.50 ¡ 0.538 
6.97 ¡ 0.722 
I 
Km 
(nM) 
1 II 
528 ¡ 7.2 
613 ¡ 4.9 
458 ¡ 4.8 
577 ¡ 5.2 
For both isozymes the specific activities in the subcellular fractions were all higher 
than in the full homogenate {table 5.1). The enrichment values for the isozymes, 
calculated as the ratio of specific activity in the subcellular fraction over that in the 
full homogenate, are shown in Figure 5.2B. No significant differences between the 
values in nuclei, mitochondria and microsomes can be seen for the type I isozyme. 
The enrichment for this isozyme was approximately 2.5 in all three fractions. For the 
type II isozyme activity, highest purification was achieved in the microsomal fraction 
(5 times higher specific activity), and lowest enrichment (1.6 times) in the nuclear 
fraction. The values for the type II isozyme in the mitochondrial and microsomal 
fractions were significantly higher than that in the nuclear fraction (p<0.025 and 
ρ < 0.005 respectively). 
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nuclei mitochon. microsom. nuclei mitochon. microsom. 
Figure 5.2: 5d-Reductase activities in crude subcellular fractions of rat prostate. Values are presented for 
the type I (solid bars) and type II (open bars) isozyme activities. (A) Percentile 5a-reductase isozyme 
activity (yield) in the different subcellular fractions. Values are mean + S.D. of at least two duplicate 
assays carried out on different days. The recoveries of type I activity in mitochondrial and microsomal 
fractions were significantly less as compared to the nuclear fraction. No significant differences between 
fractions were found for the type II isozyme activities. (B) Enrichment values (relative specific activities) 
were calculated as the ratio of specific activity in the subcellular fractions over that in the full 
homogenate. Values are mean + S.D. of at least two duplicate assays carried out on different days. The 
type II isozyme showed significantly higher purification in the mitochondrial and microsomal fractions 
as compared to the nuclear fraction. No significant differences between fractions were found for the 
type I isozyme activities. (*p<0.025, **p<0.01, ***p<0.005). 
The affinity constants for the type I isozyme were approximately 500-600 n M in the 
full homogenate, as well as in the subcellular fractions {table 5.1). The type II isozyme 
activity had a Km of approximately 5 nM. These affinity constants did not differ 
significantly between the subcellular fractions. 
To corroborate the isozyme activity assay and to further substantiate the subcellular 
distribution results, two other characteristics of 5o-reductase isozymes, i.e. pH-
dependency of velocities and inhibitor sensitivity, were investigated in the same 
subcellular fractions. The ratios of Vmax values of both isozyme activities obtained 
with Eadie-Scatchard plots (Vmax l/ll) in the subcellular fractions were correlated with 
isozyme-specific pH-dependent velocity ratios (v pH7.0/pH5.0) (figure 5.3A). The 
activities at pH 7.0 and pH 5.0 are generally considered indicative of type I and type 
II isozyme activity respectively [28]. Initial velocities were estimated with 1 μΜ Τ and 
2 mM NADPH at pH 7.0 and at pH 5.0. A high positive correlation of 0.942 
(p*<0.025) between the ratios in the different subcellular fractions was found. The 
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microsomal fraction exhibited the lowest isozyme type I over type II Vmax ratio and 
isozyme-specific pH-dependent velocity ratio (approximately 10 and 0.32 
respectively), the crude nuclear fraction on the other hand the highest values 
(approximately 35 and 0.78 respectively). The 10000 χ g pellet (mitochondria) and the 
full homogenate exhibited intermediate values. 
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Figure 5.3: Validation of isozyme activity measurements and their subcellular distribution. (A) Initial 
velocities were obtained with 1 ^ M Τ and 2 mM NADPH at both pH 7.0 (=type I) and pH 5.0 (*type 
II) in subcellular fractions of rat prostate. The ratio of velocities at pH 7.0 over pH 5.0 (v pH7.0/pH5.0) 
were correlated with isozyme Vmax ratio values calculated as described in Figure 5.1 (Vmax l/ll). A 
positive correlation was found of 0.942 (p*<0.025). (B) Full homogenate, crude nuclear, mitochondrial 
and microsomal fractions were incubated as described in the Materials and Methods section with 30 
nM Τ and 10 pM to 10 μΜ of the specific rat 5a-reductase type II inhibitor L-685,273. ICS0 values were 
calculated and correlated with isozyme Vmax ratio values obtained as described in figure 5.1. A 
positive correlation of 0.856 (p* <0.05) was found. 
Because of the differences in affinity constants for T, the contribution to total 5a-
reductase activity of each isozyme depends on the substrate concentration. The Τ 
concentration used for the inhibition experiments (30 nM) was chosen so that each 
isozyme would have an almost similar contribution to total 5ff-reductase activity. This 
relative contribution wil l depend on the ratio of isozyme activities. Therefore, 
differences in IC50 values at a fixed substrate concentration can be attributed to 
differences in isozyme activity ratios in the subcellular fractions. Initial velocities were 
estimated at 10 pM to 10 μΜ of the specific rat 5a-reductase type II inhibitor L-
685,273. IC50 values were 5, 10 and 7 nM for the full homogenate, mitochondrial and 
microsomal fractions respectively, but 30 nM for the crude nuclear fraction. As shown 
in Figure 5.3B the correlation between these IC50 values and the type I over type II 
Vmax ratios was statistically significant (0.856, p*<0.05). 
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5.5 DISCUSSION 
To get better insight into the differential roles of the two hitherto known 5a-reductase 
isozymes expressed in the rat prostate [16], the activities of both isozymes were 
evaluated in crude subcellular fractions. The rat prostate has been used as a model for 
the human prostate because growth and development of both tissues are androgen-
dependent, both contain high 5o-reductase activity, and because of the notable 
similarity between the human and rat 5o-reductase subtypes. 
The rat and human type I 5ff-reductase isozymes have been reported to have a Km for 
Τ of about 0.5 to 1 μΜ [16, 25, 26], whereas the type II isozymes have a Km, at 
neutral pH, of 4 to 50 nM [25, 26, 29, 30]. As the substrate concentration should 
ideally be in the neighbourhood of the Km [27], subcellular fractions of the rat 
prostate were incubated with a wide range of testosterone concentrations of 2 nM to 3 
μΜ. A Lineweaver-Burk plot of these data only deviated from linearity at high 
substrate concentrations, whereas Eadie-Scatchard plots were clearly non-linear over 
essentially the whole substrate range tested. 
The non-linearity of these plots might indicate negative cooperative binding of Τ to 
5a-reductase [27]. We propose, however, that this non-linearity can better be 
explained by the presence of two 5a-reductase isozyme activities. The affinity 
constants obtained (approximately 500 and 5 nM for the alleged type I and type II 
activities respectively) are similar to those reported in literature for the rat and human 
steroid 5ff-reductase isozymes at neutral pH [16, 25, 26, 29, 30]. In addition, data 
obtained with Eadie-Scatchard plots and isozyme-specific pH-dependent enzyme 
velocity ratios were closely related. Generally, the type II isozyme is considered to 
have an acidic pH-optimum [16]. Velocities at pH 5.0 do not properly reflect actual 
type II in vivo activity, as this isozyme is now considered to operate at neutral pH 
[30]. The ratio between activity at pH 7.0 and pH 5.0, however, does represent 
differences in isozyme activity ratios [28]. The correlation between data obtained by 
Eadie-Scatchard plots at pH 7.0 and the ratios of enzyme activity at pH 7.0 and pH 
5.0 was indeed highly significant. Furthermore, the correlation between isozyme 
Vmax ratios and IC50 values of the type ll-specific inhibitor L-685,273 in the 
subcellular fractions of the rat prostate was also significant. Altogether, these data 
strongly indicate the presence of two isozyme activities, resulting in the non-linear 
Eadie-Scatchard plots. 
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The subcellular localization of 5a-reductase in the rat prostate has been considered 
nuclear, both for enzymatic activity [6, 7, 17, 20, 22] and immunoreactivity [23]. In 
rat liver, type I 5a-reductase has been localized in the microsomal fraction [17], 
although this has been contended in a recent paper [31]. To the best of our 
knowledge, the subcellular localization of the isozyme activities in the rat prostate has 
not yet been elucidated. The results presented in this paper indicate a differential 
subcellular distribution of the two known subtypes of 5a-reductase in the rat prostate. 
Highest purification was obtained for the type II isozyme in the microsomal fraction. 
Furthermore, almost half of the type I activity sedimented in the 1000 χ g pellet. 
However, the specific activity of the type I isozyme was similar in all three 
subfractions. This might be attributed to the difficulty in obtaining pure subcellular 
fractions due to the structural continuity between the outer nuclear membrane and the 
rough endoplasmatic reticulum, which has also led to controversy on the subcellular 
localization of the 5o-reductase type I isozyme in rat liver [31]. Though the present 
study does not overcome the contamination problems associated with differential 
centrifugation as reported for the human prostate [21], either isozyme activity can 
serve as a marker for the other. If the isozyme activity ratio differs between subcellular 
fractions, as indeed is described here, a differential subcellular distribution can be 
surmised. Furthermore, the results on pH-dependent velocity ratios and inhibitor 
sensitivities in the crude subcellular fractions confirmed our conclusion on the 
subcellular distribution of isozyme activities. Surprisingly, it was the type I isozyme 
that appeared predominantly —although not exclusively— nuclear-bound, whereas the 
type II isozyme had a more microsomal localization. 
DHT formed by the nuclear type I isozyme wil l more likely bind to the androgen 
receptor, also located in the nucleus [32, 33], than that formed by the microsomal 
type II isozyme. This suggests an anabolic role for the 5a-reductase type I in this 
tissue. As in the rat prostate a high amount of 3o/ß-hydroxysteroid dehydrogenase 
(HSOR) activity is present in the cytoplasm [34], any DHT formed by the type II in the 
endoplasmatic reticulum would instantly be degraded to Adiol. Therefore, our results 
unexpectedly suggested a possibly catabolic role for the type II isozyme in the rat 
prostate. 
However, in hypothesizing about the function of the 5o-reductase isozymes, their cell-
type specific localization should also be considered. Type I 5o-reductase is expressed 
in the epithelial cells of the rat prostate [23, 35]. In the DHT-dependent epithelium 
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[36], nuclear-bound 5o-reductase type I [this study] would metabolize Τ to DHT to 
bind to the androgen receptor, suggesting a role of this subtype in the intracrinology 
of this tissue [42]. On the other hand, DHT formed by the type II in the endoplasmatic 
reticulum [this study] of rat prostatic stromal cells [35] is extensively metabolized to 
Adiol [34], which has been shown to induce BPH in the dog [39]. Stromal signals act 
on the epithelium in the development of certain glands [37, 38]. DHT and Adiol 
formed by the type II isozyme, could therefore act as paracrine factors in this tissue, 
influencing epithelial cell fate. 
Finally, another possible distinction in the roles of 5a-reductase might be considered. 
The high affinity of the type II 5a-reductase isozyme makes it well suited for 
metabolizing the low concentrations of Τ in fetal life [30], leading to the hypothesis 
that it is the type II isozyme that is responsible for the development of the prostate. At 
the higher Τ concentrations in adulthood, type I 5a-reductase might also contribute to 
DHT formation, and therefore be responsible for growth and maintenance of the 
prostate [35]. Because of the poor development of prostates in patients with 5a-
reductase type II deficiency (pseudohermaphroditism) [40], a type II inhibitor 
(Finasteride, Proscar®) has been developed for treatment of patients with BPH 
symptoms [41]. Recently, in addition to type II, we reported type I 5a-reductase 
activity in the human BPH prostate [26], necessitating research into this subtype and 
into its possible involvement in the pathogenesis of BPH. 
In conclusion, Eadie-Scatchard plots of 5a-reductase activities, pH-dependent isozyme-
specific velocity ratios and inhibitor sensitivities reported in this paper indicate a 
differential distribution of isozyme activities, i.e. a nuclear localization of the type I 
and a microsomal localization of the type II 5a-reductase isozyme in the rat prostate. 
To elucidate their roles, the cell-type specific localization of isozyme activities and the 
expression during ontogeny should also be taken into account. 
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6.1 SUMMARY 
The metabolism of Dihydrotestosterone (DHT) and 5ff-androstane-3or,17ß-diol (3σ-
Adiol) was assessed in full homogenates of rat prostate and epididymis. The major 
degradational route of DHT was catalysed by the enzyme(s) 3a-hydroxysteroid 
oxidoreductase (HSOR). Enzyme kinetic characteristics Vmax, Km and Vmax/Km ratio, 
were obtained for the NADP(H)- and NAD(H)-dependent interconversion of DHT and. 
3o-Adiol at pH 7.0 and at saturated cofactor concentration. For both the reduction of 
DHT and the oxidation of 3o-Adiol, NAD(H) was the preferred cofactor when 
activities were rated by their Vmax and Vmax/Km ratio. Combining the data with the 
earlier established Vmax/Km ratios for the 5ff-reductase isozyme type I and II activities 
in rat prostate and epididymis indicated that DHT —at saturated cofactor 
concentrations— would not be sustained in either tissue considering the reported 
enzyme characteristics. The reported exclusive bioavailability of the cofactors NADPH 
and N A D + in vivo, however, wil l direct the metabolic pathways in these tissues to 
sustain formation of DHT. 
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6.2 INTRODUCTION 
Growth and development of the rat prostate are androgen-dependent, 
dihydrotestosterone (DHT) being the most active androgen. Inhibition of the formation 
of DHT in the rat leads to apoptosis and cell death of prostatic cells [1]. This steroid is 
derived from testosterone (T) through 5o-reduction by the NADPH-dependent, 
membrane-bound 5<7-reductase (E.C. 1.3.99.5) of which two isozymes exist in both rat 
and human [2]. The rat and human isozymes share similar pH-profiles and affinity 
constants for several substrates [3, 4]. Earlier, our laboratory reported the 
quantification of the type I and type II 5a-reductase by enzyme activity studies in rat 
prostate and epididymis [Span et al. submitted]. 
DHT is metabolized by several enzymes [5, 6], the predominant DHT degrading 
enzyme in both rat prostate and epididymis being cytoplasmatic [7, 8] and/or nuclear 
[9] Зог-hydroxysteroid oxidoreductase (3o-HSOR, E.C. 1.1.1.50). In most male 
accessory sex tissues, 3ß-HSOR (E.C. 1.1.1.51) only accounts for minor DHT 
metabolism [6, 10, 18]. 3o-HSOR is capable of both reducing DHT (HSOR^) to 5a-
androstane-3a,17fi-diol (3o-Adiol) and back-oxidizing 3o-Adiol to DHT (HSOR,,,). Rat 
prostatic [11] and epididymal [12] HSOR enzymes are considered optimally active at 
neutral pH, like both 5a-reductase subtypes [13]. 
In the present paper, the NADP(H)- and NAD(H)-dependent HSOR activities were 
quantified at neutral pH in rat prostate and epididymis tissue homogenates, both for 
the reduction of DHT to 3o/ß-Adiol and the back-oxidation of 3a-Adiol to DHT, to get 
more insight into the role of these enzymes in the degradation and back-formation of 
the active androgen DHT. 
6.3 MATERIALS AND METHODS 
Materials 
[1,2,6,7-3H]Testosterone (3.74 TBq/mmol) and [1a,2o(n)-3H]17ß-hydroxy-5o-androstan-3-one 
(dihydrotestosterone, DHT) (2.00 TBq/mmol) were purchased from Amersham (Amersham, 
U.K.). [9,11-3H]5o-androstane-3or,17ß-diol (Adiol) (1.48 TBq/mmol) was obtained from Du 
Pont-New England Nuclear (Boston, MA). All radiolabelled steroids were purified by high 
performance liquid chromatography (HPLQ before use. Testosterone was purchased from 
Steraloids (Wilton, NH). Diethylether (p.a.), n-hexane (LiChrosolv) and 2-propanol (LiChrosolv) 
from Merck (Darmstadt, FRG). All other chemicals used were of analytical grade. 
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Tissue preparation 
Prostate and epididymis tissues were obtained from Wistar rats of 7-13 weeks old and 
processed as described earlier [14, 15]. In short, tissues were homogenized in a 20 mM 
phosphate buffer containing 1 mM monothioglycerol and 0.25 M sucrose using a Dounce 
tissue grinder. The homogenate was filtered through nylon netting of 50 and 140 mesh to 
remove cell debris. The resulting full homogenate was used in all further experiments. 
Enzyme assays and HPLC 
The HSOR enzyme assays and subsequent separation of metabolites on HPLC were modified 
from the assay for 5u-reductase described earlier [14, 15]. In short, tritiated substrate steroids 
(either 3H-DHT for HSOR,«, or 3H-3ff-Adiol for HSORJ were isotopically diluted to the 
desired concentration with unlabelled steroid and incubated at 37 °C in a 200 mM Tris-citrate 
buffer pH 7.0 with either 2 mM NADPH or NADH for HSOR^, or with either NADP* or 
NAD+ for HSOROI, in a final volume of 1 ml. The metabolites formed were extracted with 
diethylether and dissolved in 100 //I hexane for separation on HPLC. A Hibar LiChrosorb Diol 
column was used with an isocratic flow of 1.5 ml/min of hexane-propanol 96:4 (v/v). 
Radioactivity was monitored using a FloOne Beta Radiomatic A500 radio-chromatography 
detector. The percentile formation of either DHT or 3a/ß-Adiol was measured to estimate 
initial velocities. 
Calculation of enzyme characteristics 
Initial velocities were estimated against a substrate concentration range of 50 nM to 3.2 μΜ, 
and Km and Vmax were calculated by computerized fitting (Enzfitter program) of the data 
using a nonlinear regression procedure based on the Michaelis-Menten equation. Eadie-
Scatchard plots of obtained initial velocity estimates were applied [15]. The Vmax/Km ratio, 
used in this paper, can be considered a measure of enzyme activity at low (physiological) 
substrate concentrations, as at [S]< <Km, the Michaelis-Menten equation can be simplified to 
ν - Vmax/Km * [S]. 
6.4 RESULTS 
Maximum velocity (Vmax) and apparent affinity constant (Km) values for HSOR 
activities were established from Eadie-Scatchard plots of the obtained estimated initial 
velocities in rat prostate and epididymis homogenates {figure 6.1). These values were 
obtained for the reduction of DHT to 3ff/ß-Adiol (HSOR^), as well as for the back 
conversion of 3a-Adiol to DHT (HSORJ. Results were obtained at pH 7.0 for both 
NAD(H)- and NADP(H)-dependent metabolism at saturated (2 mM) cofactor 
concentrations. 
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Figure 6 . 1 : Eadie-Scatchard plots of HSOR activities obtained in A) rat prostate and B) rat epididymis 
homogenates. Initial velocities were estimated for the reduction of DHT to Adiol (HSOR^) (subfigures a 
and c) and the oxidative back-formation of DHT from 3ff-Adiol (HSOR,,,) (subfigures b and d). Both the 
NADP(H)-(subfigures a and b) and NAD(H)-dependent (subfigures с and d) activities were assessed. In 
this plot, the abscissa intercept denotes the maximum velocity, Vmax, whereas the ordinate intercept 
denotes potential in vivo activity, Vmax/Km. The slope in this plot equals -1/Km. 
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For each of the NADP(H)- or the NAD(H)-dependent activities, the Vmax values were 
approximately similar for both the reductive and oxidative pathways of HSOR in rat 
prostate as well as in epididymis {table 6.7). The Vmax values for NADH-dependent 
HSOR,«) were about ten-fold higher than the NADPH-dependent reductions in both 
tissues. The Vmax for NAD+-dependent HSOR,,, was also more than ten-fold higher 
than the Vmax for NADP+-dependent oxidation in the rat prostate. In the rat 
epididymis, however, the Vmax ratio of NADP+- and NAD+-dependent oxidation was 
only a factor three. The affinity constants for the NADPH- and NADH-dependent 
HSOR^ activities in both tissues were about 0.5 to 0.7 μΜ. The Km's for HSOROT 
were higher (approximately 0.8 to 7.3 μΜ). 
Table 6.1: Vmax and Km values for HSOR^ and HSOR0„ in rat prostate and epididymis. Both the 
NADP(H)- and NAD(H)-dependent activity kinetic characteristics were determined in homogenates at 
pH 7.0 as also shown in figure 6.1. 
tissue 
prostate 
epididymis 
cofactor 
NADP(H) 
NAD(H) 
NADP(H) 
NAD(H) 
HSOR^ 
Vmax 
pmol/(min"mg 
protetn) 
96 
1110 
51 
384 
Km 
nM 
614 
505 
645 
726 
HSOR„x 
Vmax 
pmol/(min"mg 
protein) 
54 
716 
94 
275 
Km 
nM 
1090 
781 
7331 
3042 
The efficiency ratios Vmax/Km were established from the ordinate intercepts of the 
Eadie-Scatchard plots (table 6.2). In both rat tissue homogenates the NAD(H)-
dependent HSOR efficiency ratios were manyfold (7-18 times) higher than the 
NADP(H)-dependent activities at low substrate concentrations. In an earlier paper the 
Vmax/Km ratios for 5a-reductase isozyme type I and type II activities in rat prostate 
and epididymis were described [Span et al. submitted]. Total 5a-reductase (type I and 
type II) Vmax/Km values are presented in table 6.2 for purpose of comparison. 5a-
reductase activity is completely dependent on NADPH as cofactor. 
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Table 6.2: Vmax/Km ratios (^l/(min"mg protein)) for rat prostate and epididymis homogenates of the 
enzymes 3o-hydroxysteroid-oxidoreductase, the reductive (HSOR^J and oxidative (HSORJ pathway, 
and 5ff-reductase type I and II [from Span et al. submitted]. 
tissue 
prostate 
epididymis 
cofactor 
NADP(H) 
NAD(H) 
NADP(H) 
NAD(H) 
HSOR^ 
156 
2198 
79 
529 
HSOR,, 
50 
917 
13 
90 
5o-reductase 
29 
— 
263 
— 
Of the enzyme activities we have measured in the rat prostate and epididymis, both 
5ff-reductase isozymes and HSOR0, contribute to the formation of DHT, while 
HSOR^j degrades DHT to Adiol. Comparison of the Vmax/Km values of 5a-reductase 
and HSOR,,,, with HSOR^ in table 6.2 approximates relative DHT-forming and 
degrading activities at low substrate concentrations. Total HSOR^-activity (NADPH-
and NADH-dependent) exceeds 5o-reductase activity by more than 80-fold in rat 
prostate. In rat epididymis, the total 5o-reductase activity found was much higher than 
in the prostate and total HSOR^ potential in vivo activity exceeded total 5o-reductase 
activity only approximately by a factor two in this tissue. The ratio of the metabolism 
of DHT to Adiol (HSORnJ over the back-conversion from 3a-Adiol to DHT (HSORJ 
was approximately 2.4 and 5.9 in rat prostate and epididymis respectively. Total 
potential in vivo DHT-degrading activity (Vmax/Km of HSOR^j) was 2354 and 608 
//l/(min*mg protein) in rat prostate and epididymis respectively, whereas the total 
Vmax/Km values of DHT-forming activities (total 5a-reductase and HSORo,) were 996 
and 366 /ul/(min*mg protein) respectively (figure 6.2A and 6.2Q. So, at pH 7.0, the 
potential in vivo activity —as measured by the Vmax/Km ratio— of degradation of DHT 
to Adiol predominated over the formation of DHT from Τ and the oxidative back-
conversion from 3o-Adiol at saturated (2 mM) cofactor concentrations in both tissue 
homogenates (figure 6.2). However, when only the NADPH- and NAD+-dependent 
activities were compared, considering the exclusive bioavailablity of these cofactors in 
vivo (vide infra), DHT accumulation would be sustained in both tissues (figure 6.2B 
and 6.2D). 
117 
CHAPTER 6 
PROSTATE 
o.uuu 
2,500 
2,000 
1,500 
1,000 
Φ 500 
О 
Q- η 
A 
В 
h/iXX 
HSOR,.d NADPH 
HSOR,.d NADH 
С 
E 
s -* 
--— 
3 
E 
ъс 
χ 
СО 
E 
> 
1,000 
800 
6 0 0 
400 
EPIDIDYMIS 
200 
D 
H S O R „ NADP* 
HSOR„,NAD + 
Ш 
53-REDUCTASE 
degradation vs formation degradation va formation 
NADP(H) 
NAD(H) 
NADPH 
NAD 
Figure 6.2: Potential in vivo activities (Vmax/Km in //l/(min*mg protein)) obtained in rat prostate (A and 
B) and in rat epididymis (С and D) homogenates. Left bars in each subfigure denote DHT-degrading 
enzyme activities (HSORJ, right bars denote DHT-forming activities (total 5&-RED and HSORJ. A and 
C: All enzyme activities (NADP(H)- and NAD(H)-dependent) reported in this paper obtained as 
described in Materials and Methods section. В and D: NADPH- and NAD+-dependent enzyme 
activities, thus DHT metabolism at 'in vivo' cellular cofactor concentrations: NADPH > > NADP* and 
NAD* > > NADH. 
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6.5 DISCUSSION 
In this study the reduction of DHT to Adiol and the back-oxidation of 3a-Adiol to 
DHT was investigated in rat prostate and epididymis homogenates. These steps in 
testosterone metabolism are performed by multiple isozymes of За- and 3ß-
hydroxysteroid-oxidoreductase (HSOR). There are ample reports about the presence 
and cofactor-dependency of these enzymes in both rat prostate [6, 9, 16, 17, 18] and 
epididymis [8, 12, 19, 20]. 
In our hands, formation of 3ß-Adiol was not detected, but it could not be 
unequivocally excluded that 3σ- and 3ß-Adiol epimeres were not separated with the 
applied HPLC system. However, in all experiments only a single Adiol peak was 
detected which eluted with the same retention time as tritiated 3a-Adiol. When the 
mobile phase was changed to hexane/propanol 98:2 v/v, thereby more than doubling 
the retention times, still no additional peaks could be detected. Furthermore, the 
affinity constants found in the rat prostate and epididymis .homogenate for HSOR^ 
(about 0.5 to 0.7 μΜ) and HSOR0X (0.8 to 7.3 μΜ) were comparable to those found in 
literature for За-HSOR activity [7, 9, 16, 17]. The affinity constant reported for rat 
prostatic 3ß-HSOR activity, 25.4 μΜ [16], is quite different from the Km's of HSOR,^ 
activity ascertained in the present study, indicating that most probably only За-HSOR 
activity was measured. According to literature, in most male accessory sex tissues, 
including the rat prostate, 3ß-HSOR only accounts for minor DHT metabolism [6, 10, 
18]. Sß-HSORfed activity is reportedly mainly located in the dorsal and lateral prostate 
and is not detectable in the ventral lobe [6, 16, 18]. In total rat prostate homogenate 
3B-HSOR activity might thus have been under the detection limit of our assay. Finally, 
as the Eadie-Scatchard plots of HSOR activities were basically linear, the conclusion 
seems to be justified that we have measured a single enzyme activity, most probably 
За-HSOR. The HSOR0„ activities were measured with tritiated За-Adiol as substrate 
and are therefore attributable only to 3a-HSOR0,. 
In the present study, an about ten-fold higher Vmax was ascertained for the NAD(H)-
dependent activities of both HSOR^ and HSOR0X than for the NADP(H)-dependent 
activities. The NAD+-dependent HSOR0X activity in the rat epididymis, however, was 
only three times the value of the NADP+-dependent HSOR,,,. These data are 
seemingly at variance with some earlier reports that indicated NADP(H)-dependent 
HSOR activity to be greater than the NAD(H) activity in rat prostatic cytosol [7, 11]. 
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However, when only the ventral prostate was assessed (800xg supernatant), the 
NAD(H)-dependent HSOR activity was found to exceed the NADP(H)-dependent 
activity [6, 18]. Furthermore, in rat prostate a nuclear-bound NADH-dependent 
HSOR^j activity has been reported, being 20-fold higher than NADPH-dependent 
activity [9]. Two distinct 3ff-HSOR activities have been found in rat pituitary, one 
cytosolic preferring NADPH, another membrane-bound with NADH as cofactor [21, 
22]. As in the present study a full homogenate was used, differences between our 
study and those in literature might be due to the experimental protocol applied: 
unlike in our study, in many others cytosolic fractions were used or homogenates 
were centrifuged at 800xg, thereby leading to loss of any nuclear- or membrane-
bound NADH-dependent HSOR activity. 
HSOR,,, activity has been reported to exceed that of HSOR,^ both for their maximum 
velocities in the ventral prostate [6], as for enzyme activities in cell-cultures at low 
substrate concentrations (50 nM) [5]. Unlike in the former study, the Vmax values for 
both HSORfgj and HSORox activities reported in the present paper for whole prostate 
homogenates were approximately similar, which is more in line with recent data 
reported for the ventral prostate [18]. However, due to the lower affinity for the back 
conversion of 3a-Adiol to DHT, the total enzyme efficiency ratios (Vmax/Km) reported 
here favoured degradation of DHT at low (i.e. physiological) substrate concentrations. 
The activities at these low substrate concentrations as reported by Orlowski & Clark 
[5] should be comparable with our Vmax/Km ratios, as this ratio indicates enzyme 
activity at [S] < < Km [23]. However, in the study of Orlowski and Clark a cell culture 
was used where no cofactor was added, whereas our results were obtained at 
saturating cofactor concentrations. The difference between our study and theirs might 
in fact be attributable to limited bioavailability of cofactor in mammalian cells [24, 25] 
(vide infra). 
The results presented in this paper do not favour accumulation of DHT in rat prostate. 
The high HSOR^ Vmax/Km ratios indicated a higher tissular 3o-Adiol concentration 
under steady-state conditions (figure 6.2A). The Vmax/Km ratios for HSOR^, HSOR,,, 
and total 5o-reductase obtained in the rat epididymis also do not favour accumulation 
of DHT (figure 6.2C). Reportedly, however, tissular cofactor concentrations in vivo are 
NADPH > > N A D P + and N A D + > > N A D H [24, 25]. These relative concentrations 
would therefore favour the reduction of DHT by the NADPH-dependent HSOR,«, and 
the back-oxidation by the NAD+-dependent HSORox. This profoundly changes the 
120 
HSOR ACTIVITIES IN RAT PROSTATE AND EPIDIDYMIS 
interpretation of our results (figure 6.2). As the NAD(H)-dependent HSOR activities 
were much higher than the NADP(H)-dependent activities, the in vivo cellular cofactor 
concentrations would favour DHT formation, in sharp contrast to results obtained at 
saturated cofactor concentrations in vitro. Early reports about the in vivo injection of 
tritiated androgens indeed showed an accumulation of 3H-DHT in the rat prostate [26, 
27, 28], but an accumulation of tritiated 3a-Adiol in the epididymis [28]. The latter 
observation might indicate that the tissular cofactor concentrations in rat epididymis 
are different from those in the prostate and from those generally assumed in vivo. 
These results indicate that a small amount of NADH wil l lead to extensive degradation 
of DHT, because of the high NADH-dependent HSOR^ capacity of these tissues. 
Thus, NAD(H) may serve as a potent regulatory factor in the degradation and back-
formation of DHT in these rat tissues, as has been proposed for NADPH in the human 
(hyperplastic) prostate [29]. 
In summary, in this paper reductive and oxidative 3a-HSOR activities have been 
described in rat prostate and epididymis homogenates. Both the NADP(H)- and 
NAD(H)-dependent HSOR activities were assessed. Comparison of the enzyme 
activities involved in formation and degradation of DHT in these tissues, indicated that 
DHT concentration would not be sustained in either tissue at saturated cofactor 
concentrations. Exclusive bioavailability of the cofactors NADPH and NAD+ in intact 
cells in vivo, however, would direct the metabolic pathways in these tissues to 
formation of DHT. 
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GENERAL DISCUSSION 
7.1 5CT-RE DUCT ASE ISOZYME ACTIVITIES: PITFALLS AND CONSIDERATIONS 
In many androgen-target tissues, testosterone is converted to the much stronger 
androgen DHT, and can thus be regarded a prohormone. The enzyme that catalyses 
this conversion, 5o-reductase, exists as two isozymes. 5o-Reductase isozyme activities 
exhibit a number of peculiar characteristics in vitro that hamper the correct 
apprehension of their function in vivo. In this section, a few of these pitfalls in 
determining enzymatic activities are discussed in light of the results described in this 
thesis and in literature. A more precise understanding of these kinetic features of the 
isozyme activities obtained in tissue homogenates wil l aid in better appreciating the 
results. 
7.1.1 Enzyme stability and membrane environment 
In chapter 2, the instability of both type I and II 5a-reductase isozyme activities in rat 
prostate and epididymis homogenates was described. The deterioration of enzyme 
activity at 37 °C could neither be countered by antioxidants or protease-inhibitors, 
nor by EDTA or ATP. The addition of saturating amounts of the required cofactor 
NADPH, during the homogen ¡zation- and preincubation-procedure, however, led to 
stabilization of enzyme activity. This stabilizing effect of NADPH prebinding has 
earlier been described for human and dog prostatic 5a-reductase preparations, but 
denied for the rat prostatic enzyme [69]. The results described in this chapter indicate 
that this instability of enzyme activity is also a matter of concern in the assay for the 
rat isozymes. In the disorder of male pseudohermaphroditism due to type II 5a-
reductase deficiency, mutations that altered the enzymes cofactor affinity, often also 
lead to instable enzymes [51, 66, 93, 116]. This led authors to propose a role for the 
cofactor in regulating enzyme turnover in vivo [116] {section 1.6.5.3). The mechanism 
by which this observed stabilizing effect of prebinding with NADPH is exerted is still 
unknown. The cofactor is able to bind to the enzyme before binding of the steroidal 
substrate [10, 46, 67]. The multitude of reports on problems in solubilization of the 
enzyme and on the membrane-dependency of 5a-reductase activity [15, 26, 30, 45, 
57, 67, 70, 77, 78, 94] would suggest a putative susceptibility of the enzyme 
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conformation to membrane perturbations during the homogenization procedure 
(section 1.6.5.2). Prebinding of the cofactor might make the enzyme less susceptible 
to these membrane perturbations, leaving the enzyme receptive for testosterone 
binding and subsequent metabolism. The three-dimensional conformation of the 
protein is undoubtedly crucial in the enzymes activity, considering the mutational 
analysis of the type II isozyme that implicates both ends of the isozyme in steroid 
binding and exon 2 to 5 in cofactor binding [54, 92, 93] (sections 1.4 and 1.5). 
The membrane-dependency of 5a-reductase enzymatic activity is also supported by 
the apparent correlation between the polarity of steroids and their Km for 5σ-
reductase. The hydrophobic steroid progesterone has the lowest Km for both human 
and rat isozymes, whereas the more polar corticosteroids have the highest Km's [3, 
82, 109]. 5o-Androsta-5,16-dien-3-one, the extremely apolar pheromone-precursor 
formed in the human testis [115], has an apparent affinity constant for rat epididymal 
5a-reductase equivalent to progesterone (unpublished observation). Progesterone has 
been reported to induce membrane-perturbations and alter the fluidity of artificial 
membranes and of spermatozoal membranes [100], which indicates that this steroid 
does indeed freely enter the membrane, and —by changing membrane fluidity— may 
influence enzyme activity. This process, i.e. inserting into the phospholipid bilayer 
membranes and subsequently altering its fluidity, is in fact one of the putative 
mechanisms whereby steroid hormones mediate rapid effects [11, 117] that can not be 
explained by the classical mechanism of androgen action mediated by the androgen 
receptor [14, 84, 85]. Mutations that alter the substrate binding [92, 93] and the 
tetrapeptide segment responsible for the isozymes sensitivity to finasteride [110] lie in 
hydrophobic portions of the enzyme in the exon 1 and exon 4 region (figure 1.2), 
suggesting that the substrate must enter the membrane in order to bind to the enzyme. 
Furthermore, phospholipases С and A2 decreased the affinity of testosterone for rat 
epididymal 5o-reductase [15]. Therefore, it seems that the affinities for steroid 
substrates are modulated —at least to a certain extent— by the membrane environment 
of the enzyme. 
In contrast to the steroid binding domain, the binding domain for the (polar) cofactor 
NADPH [8] lies within a hydrophilic portion of the protein in the exon 3 region 
(figure 1.2) [2]. It has been established that the carboxyl terminus of 5o-reductase is 
located on the cytoplasmatic side of the endoplasmatic reticulum of transfected CHO 
cells [109]. When these cells were gently permeabilized with digitonin —resulting in 
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broken cell membranes, but leaving the endoplasmatic reticulum (the subcellular 
compartment of 5a-reductase isozymes in these cells) intact— NADPH addition was 
required to sustain enzyme activity [109]. Therefore, the conclusion seems justified 
that the hydrophilic cofactor binding domain of the enzyme is located such that 
cytoplasmatic NADPH has easy access. Contrary to steroid-binding, binding of the 
cofactor is thus not regulated by the membrane-microenvironment of the enzyme. 
One might speculate on a chain of events during homogenization of the tissue 
(perturbations or folding of the membrane environment and thereby inducing an 
alteration in the enzyme conformation, or possibly the formation of 'inside-out' 
membrane vesicles, thereby secluding the cofactor binding site), leading to progressive 
difficulty in binding the cofactor to its hydrophilic binding site. This would ensue in 
loss of enzyme activity, which might only be countered by prebinding of the cofactor 
before these events irreversibly have taken place. 
7.1.2 Hysteresis and cooperativity 
In chapter 2, an initial burst in the enzyme activity in rat prostate and epididymis 
homogenates has been described, which impedes the correct estimation of initial 
velocities with a single time point measurement. This hysteretic behavior [31, 32] was 
also exhibited by human prostatic 5o-reductase activity (chapter 4). Previously this has 
been described by other authors for 5o-reductase activity at pH 5.5 in the particulate 
fraction of human prostatic tissue [64, 72]. This latter initial burst in the time course of 
testosterone metabolism [64], was reportedly modified by ATP or dephosphorylating 
agents [65]. 
Several considerations have to be met to ascertain whether the observed hysteresis in 
enzyme kinetic characteristics is veritable [81]. Firstly, the possibility of product 
inhibition or substrate depletion needs to be eliminated. Both have been checked and 
negated in the experiments described in chapter 2. Secondly, the burst in enzyme 
activity might be attributable to enzyme inactivation during the assay, which has also 
been refuted in that chapter. Finally, changes in temperature, buffer and pH could 
cause the kinetic transients. It appears from this thesis that the sudden change in pH 
per se at the start of the incubation causes the initial burst in the 5a-reduction of 
testosterone in rat prostate, rat epididymis and human prostate. Homogenates and 
subcellular fractions are obtained in neutral buffers to ensure stability of enzyme 
activity. The hysteretic behavior of the enzyme is only observed when the assay is 
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performed at acidic pH, without bringing the enzyme preparation to the appropriate 
pH prior to the start of the incubation (chapter 2). 
Thus, instead of a ligand induced hysteretic process [31, 32, 81], the results presented 
in this thesis strongly suggest that the switch from a higher to a lower activity state of 
the isozyme is the result of a sudden shift in pH in the microenvironment of the 
isozyme. These activity changes might be effectuated by the membrane environment 
or by certain amino acids of the enzyme, as several point mutations of the type II 
isozyme have also been shown to alter the acidic pH-optimum of the isozyme [51, 
116]. These mutated amino acids might be sensitive to changes in pH and crucial in 
the tertiary structure of the protein. The results described in chapter 2 indicate that the 
pH-dependent shift in enzyme activity (initial burst) differs from the variation of 
enzyme activity observed in a pH-profile. In the rat epididymis no higher enzymatic 
activity is found at pH 7.0 than at pH 5.5, although a pH-dependent initial burst in 
activity is exhibited by the 5o-reductase activity in this tissue (chapter 2). 
The negative cooperativity reported for the human enzyme at acidic pH [64] differs 
from the non-linear Eadie-Scatchard plots of 5o-reductase activity in rat epididymis 
and rat and human prostate described in chapters 3, 4 and 5, as the experiments in 
these chapters were performed at pH 7.0. Furthermore, in these experiments a Tris-
citrate buffer was used, whereas the negative cooperativity is reportedly not exhibited 
in citrate containing buffers [64]. The evidence presented in this thesis suggests that 
the apparent negative cooperativity encountered at neutral pH is caused by the 
activities of the two known isozymes of 5o-reductase. The affinity constants 
characteristic for the isozymes, and the correlation between isozyme ratio established 
from the non-linear Eadie-Scatchard plots and both the pH-dependent velocity ratio 
and inhibitor sensitivity, described in chapter 5, all strongly denote that this 
conclusion is valid. 
7.1.3 Acidic pH-optimum 
The peculiar acidic pH-optimum exhibited by 5a-reductase activity in certain tissues 
has led to the early —correct— assumption of existence of multiple isozymes of 5σ-
reductase [67, 79]. In literature the pH-optimum of 5o-reductase activity in rat or 
human tissue homogenates that express —mainly— the type II isozyme, varies from pH 
5.0 to 7.0. The pH-profiles presented in this thesis have shown dissimilar optima for 
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rat and human 5a-reductase activities. In rat prostate and epididymis optimal activity 
was observed at pH 5.0, whereas the human prostatic isozyme activity was optimal at 
pH 5.5 (chapter 2). The results presented in chapter 2 indicated that at different 
substrate concentrations distinct pH-optima of 5a-reductase activity would be 
established. As the pH-optima we obtained in rat and human tissue homogenates 
were equivalent to the enzymes pH-optima in Vmax, thus at saturated substrate 
concentrations, the point raised in chapter 2 on substrate-dependency of pH-optimum 
is not valid as an explanation for this pH-difference between rat and human 5a-
reductase. Therefore, presumably other mechanisms must also be responsible for the 
wide range of pH-optima obtained for 5o-reductase activity. 
In this respect it is noteworthy that Thigpen and co-workers have shown that the 
acidic pH-optimum is probably not physiological, and that in fact both isozymes 
operate at neutral pH in vivo [109]. The authors hypothesized that after cell lysis the 
type II isozyme could be prone to conformational changes, e.g. due to disruption of 
the membrane (see section 7.1.1), or due to association with or dissociation of an 
allosteric modulator, thereby inducing an artificial acidic pH-optimum. When CHO 
cells transfected with the type II isozyme are gently permeabilized with digitonin, 
enzyme activity at pH 7.0 is maintained [109]. The binding of a second 5a-reductase 
subunit or protein has been proposed as a possible explanation for the absence of 
enzyme activity at neutral pH (indicative for type I 5a-reductase activity) in BPH 
extracts, despite the fact that type I specific mRNA can be found in this tissue [54]. 
Martin and coworkers have used this same model, i.e. binding of a second 5a-
reductase subunit or protein, as a putative mechanism that would induce the initial 
burst they described in human prostatic tissue [22, 64]. 
The molecular weight of the 5a-reductase protein can be calculated as 28-29 kDa [2] 
and has been estimated as 26 kDa on SDS-PAGE [42]. 5o-Reductase proteins with a 
Mw of ~50 kDa, which might be homodimers, have been described for rat liver [69, 
95] and ventral prostate [25]. Therefore, dimerization might be a mechanism to 
influence 5<7-reductase isozyme activities, either effectuating the acidic pH-optimum 
[109], the reported lack of type I enzymatic activity in the human prostate [54], or the 
initial burst at acidic pH [22, 64]. Remarkably, allosteric enzymes are often dimeric. If 
dimerization indeed occurs after homogenization, the dimer might exhibit allosteric 
kinetics. Binding of substrate to one binding domain could subsequently influence 
binding to the other (through site-site interactions), leading to positive or negative 
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cooperativity [80]. Indeed, negative cooperativity has been reported in the human 
prostatic isozyme at pH 5.5 [64], thus at the peculiar acidic pH-optimum. 
Finally, in human prostatic epithelium the enzyme prostatic acid phosphatase (PAP) is 
highly active [105]. This enzyme is most active at pH 5.0 to 5.5 [98]. 5a-Reductase 
activity is reportedly influenced by (de)phosphorylation by PAP [65]. This might also 
be a cause for the acidic pH-optimum observed after homogenization. The 
experiments described in this thesis, however, could not corroborate an effect of the 
phosphate donor ATP on enzyme activity {chapter 2). 
Altogether, we agree with Thigpen and coworkers that the acidic pH-optimum of the 
type II isozyme is most probably non-physiological and likely to be a mere 
consequence of cell lysis. This prompted us to perform all further experiments on 5a-
reductase reported in this thesis at neutral pH (chapters 3, 4 and 5). As delineated in 
chapter 2, this choice of experimental pH will have a major impact on the results 
subsequently obtained for 5o-reductase kinetic characteristics. 
7.1.4 Quantification of enzyme activity in vitro and its relation to in vivo conditions 
The aim of this thesis was to study some of the problems associated with the 
classification and quantification of 5a-reductase activity. As mentioned in the 
introduction, some of the discrepancies between previous reports might be attributed 
to the different methods of quantification. Isozymes can be quantified on the mRNA, 
protein and on the enzymatic activity level. If measured on the activity level, 
isozymes can be compared at their optimal pH or at neutral pH. 
We adhered to the supposition to measure both isozymes at neutral pH. To be able to 
distinguish between two isozymes at the same pH, we applied a wide range of 
testosterone concentrations and plotted the estimated initial velocities according to 
Eadie-Scatchard. As can be seen in figures 3.2, 3.3 and 4.2, a smaller testosterone 
concentration range could result in a straight line when plotting according to 
Lineweaver-Burke or Eadie-Scatchard. Plotting the wide range of substrate 
concentrations we applied according to Lineweaver-Burke could also results in an 
oversight of the presence of two isozymes. We quantified enzymatic activity both by 
their Vmax, and by their efficiency ratio Vmax/Km. The Vmax of an enzyme describes 
the maximum velocity the enzyme can achieve at high, saturating substrate 
130 
GENERAL DISCUSSION 
concentrations. However, as the testosterone tissu lar concentrations in vivo are much 
lower than the Km of 5a-reductase, the efficiency ratio Vmax/Km might be a better 
quantification parameter. According to this latter parameter, results presented in this 
thesis suggest that the type I isozyme hardly contributes to DHT formation in rat 
epididymis and human prostate, at least in vitro. On the other hand, the in vivo 
situation might still be quite different. In figure 7.1 several speculative mechanisms are 
depicted whereby the low affinity of the type I 5a-reductase isozyme does not 
preclude DHT formation by this subtype at physiological substrate concentrations. 
The first mechanisms involve active transport of testosterone into the cell. This can be 
effectuated by a Sex Hormone Binding Globulin (SHBG) or Androgen Binding Protein 
active 
transport of 
Τ by 
membrane 
AR 
2 
nucleus 
cooperative 
binding of 2 
AR to RED 
accumulation 
of Τ In nucleus 3 
by AR 
{ T i n 
J membrane • 
two 
) · dimension 
\ 
active 
transport of Τ 
by SHBG/ABP 
receptor 
5alpha-REDUCTASE 
Figure 7.1: several speculative mechanisms whereby the substrate concentration could be raised and 
the contribution of 5or-reductase type I to DHT formation augmented. Ь The SHBG/ABP receptor or 
2: membrane-associated androgen receptor (AR) actively transports testosterone (T) into the cell, thus 
raising the intracellular Τ concentration. 3: The AR binds to 5a-reductase, thereby delivering substrate 
directly to the enzyme. 4: The AR accumulates Τ in the nucleus, thereby raising the substrate 
concentration in the microenvironment of the enzyme. 5: Τ enters the membrane (endoplasmatic 
reticulum (er) or nuclear envelope), thereby limiting the compartment of interaction to two dimensions. 
For references, see text. 
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(ABP) receptor (figure 7.1, J_), either of which has been detected on rat epididymis 
epithelial cells [27, 39] and in human prostate [47], and has been shown to be 
internalized in epididymal cells [34, 38]. The metabolism of testosterone by human 
prostatic slices is reportedly different when SHBG instead of albumin is added to the 
medium [75]. Chronic infusion of SHBG in rats, although leading to a marked 
decrease in free testosterone, does not influence testosterone action in these animals 
[21]. The SHBG receptors are only expressed in androgen-dependent tissues [28]. All 
this suggests a role for the SHBG receptor in active cellular androgen uptake, 
additional to diffusion. However, some reports indicate that the SHBG/ABP receptor is 
also involved in intracellular signalling [88]. Binding proteins with characteristics 
similar to the classical androgen receptor have been detected on rat liver and prostate 
cell membranes [58], which might also mediate active androgen uptake in these 
tissues (figure 7.1, 2)· In this respect, the report on the cooperative binding of the 
androgen receptor with 5o-reductase [56] is also interesting (figure 7.1, 3J. This might 
represent a mechanism of active transport of substrate directly to the enzyme. 
Furthermore, the internalization of the testosterone-androgen receptor complex into 
the nucleus [37, 85] would lead to an active transport of substrate to the 
microenvironment of the enzyme (figure 7.1, 4). This compartmentalization wil l lead 
to a higher reaction rate. Our results on the nuclear localization of the type I isozyme 
in the rat prostate (chapter 5) are in line with such a hypothesis. The final mechanism 
whereby the reaction rate of the enzyme can be increased, is by restricting the 
diffusion of reactants to the two dimensions of a membrane (figure 7.1, 5J [1/ 6]. The 
highly hydrophobic 5a-reductase isozymes are unequivocally membrane-bound [15, 
26, 30, 45, 57, 67, 70, 77, 78, 94]. As discussed in section 7.1, the hydrophobicity of 
the steroid binding domain of 5a-reductase and the correlation between substrate 
polarity and apparent affinity for the enzyme suggest the substrate must enter the 
membrane in order to bind to 5o-reductase. Therefore, the mechanism whereby the 
substrate concentration is relatively raised due to the restriction of the compartment of 
substrate-enzyme interaction to the two dimensions of a membrane (either the nuclear 
envelope or the endoplasmatic reticulum) seems conceivable. The aforementioned 
mechanisms would subsequently render the premise [ S ] < < Km, and thus the 
justification of the use of the Vmax/Km ratio [59, 112] as a method of quantification 
invalid. Thereby, the low affinity of the type I isozyme for testosterone would be 
overcome and this subtype would be able to significantly contribute to DHT 
formation. 
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Furthermore, as mentioned earlier, enzyme quantification is usually performed at 
optimal conditions, including optimal substrate and cofactor concentrations. In vivo, 
the situation may be quite different. For instance, citrate metabolism generates ATP, 
which reportedly augments 5a-reductase activity [65], but also NAD(P)H. Citrate is 
found in prostatic epithelium and is in fact a major secretory component of the 
prostatic epithelium [16]. Citrate concentrations are low in prostatic carcinoma and 
elevated in BPH [16, 17]. The extensive formation of citrate in the human prostate 
thus most probably influences the in vivo concentrations of cofactors in a cell. The 
intracellular concentrations of NAD(P)(H) has a tremendous influence on DHT 
formation and degradation as reported in chapter 6 for HSOR activities. For a correct 
interpretation of data obtained in vitro, these considerations should be kept in mind. 
7.2 POSSIBLE INVOLVEMENT OF TYPE I 5o-REDUCTASE ACTIVITY IN 
HYPERPLASIA OF THE HUMAN PROSTATE 
Benign Prostatic Hyperplasia (BPH) develops after the fourth decade of life and leads 
to urinary obstruction symptoms in 30-40% of all men after sixty years of age [23, 44]. 
The incidence of histopathological BPH is 50% at sixty and almost 100% at eighty 
years of age. Eventually, one in four men wil l have to be treated for symptoms of BPH 
[4]. This usually required —until recently—transurethral resection of the prostate (TURP) 
to relieve symptoms. The morbidity of this procedure is 15 to 18% [44]. Therefore a 
substantial amount of research has focused on the pharmacological treatment of BPH. 
For some time now it has been appreciated that growth of the prostate is controlled 
by androgens and it has been proposed that an elevation of tissular DHT 
concentration plays a role in the pathogenesis of BPH [101]. As 5o-reductase is the 
enzyme responsible for the formation of DHT, research has focused on the 
pharmacological attenuation of 5a-reductase activity for the treatment of patients with 
BPH. Of the two isozymes of 5a-reductase, it was the type II isoform that was 
implicated in the pathogenesis of BPH as this subtype is mainly expressed in androgen 
target tissues [62] and patients with type II 5a-reductase deficiency (male 
pseudohermaphroditism) have atrophic prostates [29, 50]. Therefore, a type II 5a-
reductase-specific inhibitor, finasteride (Proscar®), has been developed for the 
treatment of patients with BPH [35]. This inhibitor, however, only leads to reduction 
of urinary obstruction symptoms in a subset of patients [83, 106]. 
Recently, mRNA of the type I isozyme has been detected in both normal prostatic and 
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BPH tissue [9, 71], although this could not be confirmed [111] (section 1.7, tables 1.1 
and 1.2). The results reported in chapter 4 of this thesis provide, for the first time, 
evidence for the presence of type I 5a-reductase in the human hyperplastic prostate 
on the enzymatic activity level. A 6-times higher Vmax is found for the type I than for 
type II 5o-reductase activity in prostate homogenates. Type I 5ff-reductase, expressed 
in the liver of both rat and man, was originally considered primarily to participate in 
the metabolism and excretion of steroid hormones like testosterone (catabolic enzyme) 
[82]. The presence of type I 5a-reductase activity in the human prostate, reported in 
this thesis, indicates that this subtype might also play an anabolic role. This section 
wil l therefore address the possibility of type I 5o-reductase involvement in growth and 
maintenance of the human prostate, and, in addition to type II, in the pathogenesis of 
BPH. 
In order to discern the role of type I 5o-reductase in the human prostate, its specific 
localization has to be taken into account (table 1.2). The cell-type specific localization 
of the 5a-reductase subtypes has been investigated by several authors. On the mRNA 
level, detection of specific mRNA has as yet not been extended to cell-type specific 
localization [9]. However, the epithelium-derived prostatic cell-line DU-145 expresses 
type I specific mRNA [22], suggesting the type I would be localized in epithelium of 
the human prostate. Type I 5<r-reductase immunoreactivity has not been found in the 
human prostate [102, 103], although a rat type I antiserum did bind to a protein in 
nuclei of both stromal and epithelial cells of the human prostate [42]. Antibodies 
against the type II isoform have located 5cr-reductase in the basal epithelial cells of the 
human prostate [24], but also in stromal cells of this tissue [102, 103]. 
On the activity level, previous reports on isozyme specific expression in the human 
prostate have not been irrefutable. Several differences between stromal and epithelial 
5o-reductase in the human prostate have been described that might indicate a distinct 
localization of the isozymes. The affinity constants for testosterone vary, being higher 
in stroma (23 to 230 nM) than in epithelial cells (11 to 90 nM) [12, 49, 59, 90, 114], 
suggesting, although both are in the range of the type. II isozyme, a more stromal 
localization of the type I isozyme and a predominantly epithelial localization of the 
type II. The 5a-reductase activity found in epithelium is more sensitive to finasteride 
(Ki - 7 ± 3 nM, IC50 - 38 nM) than stromal activity (Ki - 31 ± 3 nM, 1C50 - 112 
nM) [61, 114], again suggesting a more stromal localization of the type I isozyme. The 
more acidic pH-optimum of epithelial 5a-reductase (pH 6.5) than that in stroma (pH 
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7.4) [49] seems to corroborate this finding. Furthermore, zinc, which has a triphasic 
effect on prostatic 5or-reductase activity [36, 40, 48, 63, 113] exerts a stronger 
inhibitory effect on stromal 5o-reductase than on epithelial enzymatic activity [49]. As 
only the type I isozyme is inhibited by zinc [107], a more stromal localization of the 
type I isozyme activity is again suggested. The aforementioned isozyme characteristics 
do not unequivocally demonstrate a dissimilar cell-type specific localization of the 
isozymes. This, however, might be attributed to either the incomplete separation of 
stromal and epithelial prostate fractions and/or to the use of a substrate range 
inappropriate for detecting type I 5o-reductase isozyme activity. Summarizing, these 
data from literature seem to corroborate our finding of the presence of type I 5a-
reductase enzymatic activity in the human prostate. Furthermore, these data suggest a 
predominantly stromal localization of type I 5o-reductase activity, and a more 
epithelial localization of type II activity. 
Whether the type I isozyme is capable of generating significant amounts of DHT, 
considering its low affinity for T, has been discussed in section 7.1.4. Furthermore, 
reports comparing epithelial and stromal cells of human prostate in 5a-reductase 
capacity have shown either an equal 5o-reductase activity [5, 4 1 , 96], or a higher 
amount of activity (Vmax) in stroma [12, 18, 60, 61]. As stromal 5o-reduction of Τ 
seems to be effectuated preferentially by the type I isozyme (see above), this would 
suggest this subtype is indeed capable of generating appreciable amounts of DHT. 
Remarkably, in rat prostate, epithelial 5a-reductase is more active than stromal 
enzyme activity [86, 87]. In this tissue, contrary to the situation in the human prostate, 
the type I isozyme is located in the epithelium, as established by mRNA 
measurements and immunohistochemistry [7]. Thus, again, the cell-type that expresses 
type I 5ff-reductase seems most active in generating DHT. 
DHT, formed by 5a-reductase, wil l bind to the androgen receptor (AR) to exert 
androgenic effects [14, 84, 85]. Therefore, to ascertain the role of the 5a-reductase 
isozymes, the cell-type localization of the AR is vital. During embryogenesis, a 
functional AR in stroma, but not in epithelium, is essential for normal prostatic 
development [19, 20]. Indeed, AR is found prenatally in stroma, and not in epithelium 
of rat prostate [108]. In contrast, in adulthood the AR is expressed mainly in glandular 
epithelial cells [53], but also in stroma of rat [13, 55, 60] and human prostate [62, 
104]. Remarkably, castration or 5o-reductase inhibition only leads to atrophy and 
apoptosis of epithelial cells [89, 9 1 , 99]. Thus the stromal cells do not require 
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androgen for growth and maintenance. Currently it is presumed that DHT binds to the 
AR in stroma, thereby instructing this cell-type to produce paracrine factors that 
induce epithelial morphogenesis [20, 52] or that DHT produced in stroma binds to the 
epithelial AR [106]. Either mechanism would suggest a role for the type I isozyme in 
DHT formation in stromal cells to influence epithelial cell morphogenesis. 
Finally, the human prostate can be subdivided in several zones [73, 74]. Prostate 
cancer mainly originates from glandular epithelial cells [52] in the peripheral zone of 
the human prostate [106]. BPH is initially confined to either the transition or 
periurethral zone [73, 106]. The BPH nodules that arise in the transition zone tend to 
be more epithelial, whereas nodules in the periurethral zone initially are stromal 
[106]. Thus, it seems possible that BPH is a heterogeneous disease, originating either 
from stromal cells or from epithelial cells. As the type II inhibitor finasteride only 
leads to relieve of urinary obstruction symptoms in a subset of patients [83, 106], one 
has to consider the possibility that two forms of hyperplastic growth exist, one in 
which the type II 5a-reductase is involved, and another which might be associated 
with altered type I activity. 
Prostate biopsies from patients with symptomatic BPH contain more stromal elements 
than those of patients with BPH but without urinary obstruction symptoms [97]. There 
is a lack of correlation between prostate size and urinary obstruction symptoms in 
patients with BPH. This could depend on the type of hyperplastic growth, as stroma 
mainly consists of smooth muscle cells. Growth of these contractile smooth muscle 
cells could more easily lead to obstruction symptoms than would epithelial 
hyperplastic growth. Type I 5a-reductase enzymatic activity in the human prostate 
described in this thesis seems to significantly contribute to the amplification of the 
anabolic effects of testosterone in stromal cells. Establishment of the role of type I 5a-
reductase in BPH is thus essential to evaluate the necessity of (supplementary) type I 
inhibition in the treatment of patients with this neoplasia. Already a specific human 
type I inhibitor (LY191704) is available [43], while more type I inhibitors are being 
developed [33, 68]. In light of the results presented in this thesis, and the reports 
discussed in this paragraph, it seems attractive to test these inhibitors, alone or in 
combination with type II inhibitors, for their efficacy in treatment of patients with 
BPH. 
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CHAPTER 8 
SUMMARY AND CONCLUSIONS 
This thesis focuses on the measurement of the enzymatic activities of the two known 
isozymes of 5o-reductase, type I and type II. The product of 5a-reduction of 
testosterone, DHT, has been implicated in a wide variety of physiological mechanisms 
and in the pathogenesis of several diseases and disorders as benign prostatic 
hyperplasia (BPH), and possibly prostatic carcinoma, acne, hirsutism and alopecia. 
Measurements of the enzymatic activities of 5a-reductase are hampered by the kinetic 
peculiarities of mainly the type II isozyme and by the lack of an assay that can 
distinguish between both isozymes. The aim of the experiments described in this 
thesis is to set up a valid assay for both isozyme activities, and to subsequently 
quantify their activities in rat prostate and epididymis and in the human prostate. The 
intracellular localization of their activities are assessed in the rat prostate to get more 
insight into the role of the 5a-reductase isozymes. Finally, enzymes that degrade DHT 
(as HSOR) are studied, to get an impression of the degradation, in addition to the 
formation of this steroid hormone. 
In chapter 2, several of the kinetic peculiarities of the isozymes are studied in 
homogenates of the rat prostate and epididymis. The enzymatic activity of both type I 
and type II 5a-reductase appears unstable during homogenization, which impedes 
correct kinetic evaluation of the isozymes. Prebinding the enzyme before 
homogen ization with its cofactor, NADPH, preserves much of the activity. 
Furthermore, at acidic pH, the time course of 5a-reduction of testosterone is non-
linear in these tissues, showing an initial burst, which hampers the estimation of initial 
velocities in a single time point measurement. This initial burst is shown to result from 
the sudden shift in pH in the microenvironment of the enzyme at the start of the 
incubation. The homogenate is prepared in a buffer of neutral pH, whereas the assay 
is performed at acidic pH. When the enzyme preparation is brought to acidic pH 
beforehand, the initial burst in activity is abolished. Subsequently, 5o-reductase 
activity is studied over a pH-range of 4.5 to 8.0. Especially at acidic pH, the kinetic 
characteristics Vmax (maximum velocity, an indication of the amount of enzyme) and 
Km (apparent affinity constant of the enzyme for its substrate) vary manifold. Minor 
changes in experimental pH will have a substantial influence on kinetic parameters 
and thereby on enzyme velocities. This could explain the variation in these 
143 
CHAPTER 8 
parameters reported in literature and discrepancies in described effects on enzymatic 
activities. 
Although the type II 5o-reductase isozyme is optimally active at acidic pH in vitro, 
previous work of other authors have shown that both isozymes probably operate at 
neutral pH in vivo. In chapter 3, 5ff-reductase enzymatic activities are studied at 
neutral pH in the rat prostate and epididymis. Eadie-Scatchard plots of initial velocities 
against a wide range of testosterone concentrations are non-linear in these tissues. 
These non-linear plots can indicate cooperativity in the enzymatic reaction, or the 
expression of isozymes. So far, the presence of two isozymes has been described on 
the mRNA-, protein- and enzymatic activity level in rat prostate. In the rat epididymis, 
the type I isozyme has only been found on the mRNA and protein level. Applying the 
assay established and described in chapter 3, both isozyme activities are quantified at 
neutral pH. In the rat prostate, a 50-times higher Vmax is found for the type I isozyme 
than for the type II at neutral pH. In the rat epididymis type I 5a-reductase activity is 
established for the first time. The maximum velocities of both isozymes are 
approximately equal in this tissue. 
As the type I isozyme has a relatively low affinity for steroid hormones, other authors 
have proposed the Vmax/Km ratio to quantify enzymatic activities. This ratio is a 
measure for enzymatic activity at low substrate concentrations. Using the Vmax/Km 
ratio as method of enzymatic activity quantification, the type I isozyme contributes to 
25% of the total potential in vivo activity in the rat prostate. The Vmax/Km ratio of the 
type I isozyme in the rat epididymis suggests that this subtype hardly contributes to 
DHT formation in this tissue. The highly segmental expression of the type Ι 5σ-
reductase isozyme in the rat epididymis, however, could still implicate this subtype in 
DHT formation. 
In chapter 4, the same assay is used to quantify isozyme activities in homogenates of 
the human hyperplastic prostate. The type II isozyme is implicated in the pathogenesis 
of prostatic hyperplasia, which eventually necessitates transurethral resection in 25 % 
of all men. Furthermore, type II inhibitors have been developed for the 
pharmacological treatment of BPH. Verifying the presence of type I 5a-reductase in 
this tissue might be important to establish optimal pharmacological treatment of 
patients with BPH. Results described in this chapter indicate, for the first time, type I 
5a-reductase isozyme activity in the human prostate. The maximum velocity of this 
type I activity is 6-times higher than that of the type II isozyme. However, if isozyme 
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activities are quantified by their Vmax/Km ratio, this method would indicate that the 
type I hardly contributes to DHT formation in the human prostate. Future research wil l 
have to focus on the validity of Vmax or Vmax/Km ratio as a method of enzyme 
activity quantification. 
So far, the type I 5a-reductase isozyme has been considered to exert catabolic effects, 
being mainly engaged in the degradation of steroid hormones, whereas the type II was 
considered anabolic, serving to amplify the androgenic effects of testosterone. To get 
more insight into the role of the isozymes in androgenic action, the subcellular 
distribution of the 5a-reductase isozyme activities is studied in chapter 5. Surprisingly, 
the type I isozyme appears predominantly nuclear bound, whereas the type II isozyme 
is mainly detected in the microsomal fraction. This would strongly suggest that the 
type I isozyme is implicated in the amplification of androgenic action of testosterone 
in this tissue. The proposed catabolic role of this isozyme does therefore not seem to 
concur with its subcellular localization and ample expression in the rat prostate. 
The tissular DHT concentration is the result of a balance between several enzymatic 
activities. The degradational product Adiol can also be back-oxidized to DHT. To get 
more insight into the formation and degradation of DHT in vivo, the metabolism of 
DHT is studied in homogenates of rat prostate and epididymis (chapter 6). The 3σ-
HSOR-mediated reduction to Adiol is the major degradational route of DHT in vitro. 
At cofactor concentrations reportedly present in vivo, i.e. [NADPH] > > [NADP+] and 
[NAD+] > > [NADH], tissular DHT concentrations wil l be maintained in both these 
tissues. The established enzymatic activities suggest a potentially important function of 
the cofactors in the regulation of tissular DHT concentration. 
The results described in this thesis shed more light on the kinetic peculiarities of the 
isozymes of 5a-reductase. The method described for the measurement of isozyme 
activities at neutral pH is capable of detecting both isozymes in androgen target 
tissues, i.e. the rat prostate, epididymis and the human prostate. The expression of 
type I 5a-reductase in the human prostate, described in this thesis, warrants further 
research into the role of this isozyme in the pathogenesis of benign prostatic 
hyperplasia. 
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CHAPTER 9 
SAMENVATTING EN CONCLUSIES 
In dit proefschrift staat de meting van de enzymatische activiteit van de twee bekende 
isozymen van 5o-reductase, type I en type II, centraal. Het produkt van 5a-reductie 
van testosteron, DHT, wordt van belang geacht bij een veelvoud aan fysiologische 
processen, maar ook bij het ontstaan van verschillende ziektebeelden en 
aandoeningen, als prostaat-hyperplasie en mogelijk ook prostaat-carcinoom, acne, 
hirsutisme en alopecia. Experimenten waarin men de enzymatische activiteit van 5σ-
reductase wil meten worden gehinderd door de bijzondere kinetische eigenschappen 
van voornamelijk het type II isozym, maar vooral ook door het feit dat er tot nu toe 
geen enzymatische activiteits-metingen beschikbaar zijn waarmee beide isozymen 
kunnen worden onderscheiden. Het doel van het onderzoek beschreven in dit 
proefschrift is een valide meting op te zetten voor beide 5a-reductase isozym-
activiteiten, waarmee hun activiteiten in de prostaat en de epididymis van de rat en in 
de humane prostaat kunnen worden gekwantificeerd. Om meer duidelijkheid te 
krijgen over de functies van de 5o-reductase isozymen, is ook hun intracellulaire 
lokalisatie bepaald in de prostaat van de rat. Tenslotte zijn de enzymen die DHT 
afbreken (HSOR) bestudeerd om, naast over de aanmaak, ook over de afbraak van dit 
hormoon een indruk te krijgen. 
In hoofdstuk 2 zijn enkele van de kinetische eigenschappen van de isozymen 
bestudeerd in homogenaten van de prostaat en de epididymis van de rat. De 
enzymatische activiteit van zowel het type I als het type II 5a-reductase blijkt tijdens 
homogeniseren van het te onderzoeken weefsel niet stabiel te zijn, hetgeen een 
correcte evaluatie van de verkregen kinetische gegevens onmogelijk maakt. Uit ons 
onderzoek is gebleken dat na toevoeging van de cofactor NADPH vóór het 
homogeniseren echter een groot deel van de enzymatische activiteit behouden blijft. 
Bovendien blijkt dat bij een lage pH de 5o-reductie van testosteron niet lineair met de 
tijd is in deze weefsels. In het begin van de meting vindt een bijzonder snelle 
enzymatische omzetting plaats, gevolgd door een periode met minder enzymatische 
activiteit. Het bepalen van enzymatische snelheden door middel van een enkel 
meetpunt is daardoor niet valide. De oorzaak blijkt te zijn gelegen in een plotselinge 
verandering van de pH bij de start van de enzymatische meting. Het weefsel-
homogenaat wordt namelijk bereid in een buffer met neutrale pH, terwijl de reactie 
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wordt gemeten bij lage pH. Door het enzym preparaat vóór de start van de incubatie 
op gewenste pH te brengen, wordt de 5o-reductie van testosteron wel lineair met de 
tijd. Vervolgens is de 5o-reductase activiteit gemeten over een pH bereik van 4.5 tot 
8.0. Vooral bij lage pH blijken de kinetische parameters Vmax (maximale snelheid, 
een maat voor de hoeveelheid enzym) en Km (de affiniteits-constante van het enzym 
voor een substraat) sterk te variëren. Kleine experimentele pH-verschillen hebben 
grote verschillen in kinetische parameters en dus ook in enzymatische activiteit tot 
gevolg. Dit zou een mogelijke verklaring kunnen zijn voor de grote variatie in deze 
parameters gerapporteerd in de literatuur en voor de discrepanties in beschreven 
effecten op enzym activiteiten. 
Hoewel het type II isozym in vitro een optimale activiteit vertoont bij lage pH, blijkt 
uit in de literatuur beschreven onderzoek dat beide isozymen in vivo waarschijnlijk 
toch bij neutrale pH werken. In hoofdstuk 3 is de activiteit van beide 5a-reductase 
isozymen in de prostaat en epididymis van de rat bestudeerd bij pH 7.0. In deze 
weefsels blijken zogenaamde Eadie-Scatchard plots, waarbij de activiteit uitgezet 
wordt tegen een uitgebreide reeks van testosteron concentraties, niet lineair te zijn. 
Een niet-lineaire Eadie-Scatchard plot duidt ofwel op coöperativiteit in de 
enzymatische reactie, of op de aanwezigheid van isozymen. In de ratte-prostaat zijn 
twee isozymen beschreven op zowel mRNA, eiwit als op enzymatisch activiteits 
niveau. In de ratte-epididymis echter is het type I alleen op mRNA en eiwit niveau 
aangetoond. Uit de bovengenoemde Eadie-Scatchard plots blijkt dat het type I, bij 
neutrale pH, een 50 maal hogere Vmax heeft dan het type II in de prostaat. In de 
epididymis wordt met deze methode voor het eerst type I enzymatische activiteit 
aangetoond. In dit weefsel is de Vmax voor beide isozymen gelijk. 
Omdat het type I 5a-reductase een lage affiniteit heeft voor steroïd-hormonen, is 
eerder door andere auteurs de Vmax/Km ratio voorgesteld om enzymatische 
activiteiten te kwantificeren. Deze ratio is per definitie een maat voor enzymatische 
activiteit bij relatief lage substraat concentraties. De Vmax/Km ratio geeft aan dat het 
type I voor 25% verantwoordelijk is voor de vorming van DHT in de prostaat van de 
rat, maar nauwelijks bijdraagt aan de vorming van DHT in de epididymis. Echter, de 
sterk gelokaliseerde expressie van dit subtype in een specifiek segment van de ratte-
epididymis zou wellicht toch kunnen leiden tot een significante bijdrage van dit type I 
5cr-reductase aan de omzetting van testosteron naar DHT. 
In hoofdstuk 4 is van de ontwikkelde meting gebruik gemaakt om de enzymatische 
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activiteit in homogenaten van de humane hyperplastische prostaat op isozym niveau 
te bepalen. Type II 5o-reductase speelt mogelijk een rol bij het ontstaan van 
hyperplasie van de prostaat, welke bij 25 % van alle mannen een operatieve 
behandeling noodzakelijk maakt. Daarnaast zijn type II 5a-reductase remmers 
ontwikkeld om deze hyperplasie medicamenteus te kunnen behandelen. Tot nu toe is 
aanwezigheid van het type I enzym in dit weefsel alleen op mRNA niveau 
beschreven. Kennis van de eventuele aanwezigheid van type I 5o-reductase kan van 
belang zijn bij het vaststellen van een optimale medicamenteuze behandeling van 
prostaat hyperplasie. In dit proefschrift wordt de aanwezigheid van type I 5o-reductase 
enzymatische activiteit in de humane prostaat voor het eerst aangetoond. De Vmax 
van type I 5a-reductase in dit weefsel is zelfs 6 maal zo hoog als dat van het type II. 
Wanneer de isozymen worden gekwantificeerd volgens hun Vmax/Km ratio, dan lijkt 
type I nauwelijks bij te dragen aan vorming van DHT in de humane prostaat. Verder 
onderzoek zal moeten aangeven of de Vmax of de Vmax/Km ratio een valide methode 
voor de kwantificering van enzymatische activiteiten is. 
Tot nu toe werd de functie van het type I 5o-reductase isozym als catabool 
beschouwd, betrokken bij de afbraak van Steroiden, en dat van het type II isozym als 
anabool, betrokken bij het versterken van de androgene effecten van testosteron. Om 
een beter inzicht te verkrijgen in de functies van beide 5a-reductase isozymen m.b.t. 
androgene effecten, is in hoofdstuk 5 de subcellulaire lokalisatie van isozym 
activiteiten in de ratte-prostaat bepaald. Opvallend is dat het type I 5a-reductase 
voornamelijk in de kern gelokaliseerd blijkt te zijn, terwijl het type II meer 
microsomaal wordt gevonden. Dit zou betekenen dat het type I wel degelijk een rol 
speelt bij de versterking van de androgene effecten van testosteron op dit weefsel. De 
veronderstelde catabole functie van dit isozym lijkt derhalve niet overeen te komen 
met zijn subcellulaire lokalisatie en aanzienlijke expressie in de prostaat van de rat. 
De weefsel-DHT concentratie wordt bepaald door de balans tussen diverse 
enzymatische activiteiten. Het belangrijkste afbraak produkt van DHT, Adiol kan ook 
weer terug worden geoxideerd tot DHT. Om een betere indruk te krijgen van de 
vorming en afbraak van DHT in vivo is het metabolisme van DHT bestudeerd in 
homogenaten van ratte-prostaat en -epididymis (hoofdstuk 6). De door het enzym 3σ-
HSOR gemediëerde omzetting tot Adiol is de belangrijkste route van DHT afbraak, 
althans zeker in vitro. Bij in vivo geldende cofactor concentraties, waarbij [NADPH] 
> > [NADP+] en [NAD+] > > [NADH], zullen de gevonden enzym-activiteiten 
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resulteren ¡π een netto aanmaak van DHT. De gemeten enzymatische activiteiten 
duiden op een mogelijk belangrijke functie van de betrokken cofactoren in de 
regulatie van de weefsel DHT-concentratie. 
De resultaten beschreven in dit proefschrift geven meer duidelijkheid over de 
kinetische eigenschappen van de 5a-reductase isozymen. De beschreven methode 
voor de meting van isozym-activiteiten bij neutrale pH, stelt ons in staat om beide 
isozymen te detecteren in androgeen-doelwitorganen, namelijk de ratte-prostaat, 
-epididymis en humane prostaat. Gezien de aanwezigheid van type I 5o-reductase in 
de humane prostaat, zoals beschreven in dit proefschrift, dient de rol van dit type 5a-
reductase bij het ontstaan van prostaat-hyperplasie verder te worden onderzocht. 
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The two isozymes of steroid 5 α-reductase mediate in the conversion 
of testosterone to the potent androgen dihydrotestosterone. 
Distortion of 5cx-reductase activity is considered implicated in the 
pathogenesis of a variety of androgen-dependent diseases like 
Benign Prostatic Hyperplasia. 
This thesis addresses the assessment of 5 α-reductase isozyme 
activities in rat and human androgen target tissues. The obtained 
results warrant a réévaluation of the proposed dissimilar roles of 
the 5 α-reductase isozymes type I and Π in androgen metabolism as 
catabolic and anabolic respectively. 
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